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Colorectal cancer is the most common gastrointestinal cancer in the Western world. In
1995, 8000 new colorectal cancer patients were registered in The Netherlands, of whom
about 25% had rectal carcinoma.1 One of the main problems in the treatment of rectal
cancer is the development of local recurrences, of which the reported incidences vary
widely.2,3 Local recurrences cause severe disabling symptoms, are difficult to treat, and
usually kill the patient.4 Recurrences of rectal cancer are often confined to the pelvis without
distant metastases, and are considered loco-regional failures.5,6 Most of them become overt
within two years of operation.
Traditional surgical treatment
The surgical principles in the treatment of colorectal cancer were formulated for the first
time by Lord Moynihan in 1908.7 Early in this century the local recurrence rate following
surgery for rectal cancer was nearly 100%. Miles described a combined radical abdominal
and perineal approach8 to remove the pelvic mesocolon and the “zone of upward spread” to
solve this problem. For a long time Miles operation was the “gold standard” for treatment of
rectal cancer, even for tumours above 15 cm from the anal verge.
Since Miles described his abdominoperineal resection (APR) technique, various
modifications9,10 have been proposed to improve patient prognosis. Turnbull9 described a
technique in which lymphovascular isolation and ligation was performed prior to mobilisation
of the segment of tumour bearing colon, which was called the “no-touch” isolation technique.
In subgroup analysis the concept showed to be of statistically significant benefit only when
microscopic vascular invasion was present in the tumour.11 En bloc resection of lymph
nodes at the origin of the inferior mesenteric artery from the aorta, often called “high”
ligation, was assumed in the 1960s to give a survival benefit.10 Two more recent comparative
studies have failed however, to show a survival benefit for “high” versus “low” ligation.12,13
Improvement of quality of life after surgery was obtained due to the introduction of
mechanical stapling devices14 together with the observation that the safe distal margin is at
2 cm from the primary tumour.15,16 The combination of these two factors made lower
resection with reconstruction possible, guaranteeing an anatomically and functionally intact
anal sphincter, instead of the much more mutilating abdominoperineal resection with implicit
definite colostomies. Developments of new approaches also included the construction of
coloanal anastomoses.17 This technique has acceptable functional results and complication
rates and therefore has become a viable alternative to the APR in the treatment of low rectal
cancer. In addition, significant functional improvement, particularly in the first 12 to 24
months after surgery, can be achieved with the use of a colonic J-pouch.18
Apart from these surgical technicalities, the availability of blood transfusion and major
improvements in anaesthesia, perioperative care management and control of infectious
complications, have also enabled surgeons to resect the tumour and reconstruct the continuity
of the bowel, rather than to only construct a colostomy and to leave the tumour in situ.19
Nevertheless, despite the aforementioned developments, one of the problems in the
treatment of rectal cancer surgery has remained the inability of surgeons to optimise local
tumour control. The basic conventional procedure involving blunt dissection, often resulted
in incomplete removal of mesorectal tissue with high local recurrence rates.2,20,21 Table 1
shows local recurrence after “curative” surgery” in conventional surgery series; local
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recurrence rates from 12% up to 38% have been reported. In addition, damage to the
autonomous pelvic nerve plexus with the consequence of a high incidence of sexual22,23 and
bladder dysfunction24 was very likely in conventional surgery with great impact on quality
of life after surgery.











Rao ‘8125 204 44 21.6
Rich '8326 142 43 30.3
Pahlman ’8427 197 74 37.6
Phillips '8421 848 124 14.6
Philipsen '8428 382 105 27.5 27% received preop RT
McDermott '8529 934 193 20.7
Pescatori ‘8730 162 19 11.7
Athlin ‘8831 99 37 37.4 unknown no. of pts
received postop RT/CT
Rinnert-Gongora ‘8932 258 53 20.5
Zirngibl '9033 1153 265 23.0
Akyol ‘9134 294 49 16.7
Stipa ‘9135 235 42 17.9
Norstein '9336 275 81 29.5
Adam '9437 141 32 22.7 6% received postop RT
Nymann ‘9538 175 37 21.1
Damhuis ‘9739 902 162 18.0 8% received postop RT
Mollen ‘9740 232 42 18.1 27% received postop RT
Kapiteijn '9820 668 150 22.5 36% received postop RT
Variability in outcomes
Inter-institution and inter-surgeon variabilities in colorectal cancer surgery have been shown
in several studies with conventional surgery. This applies to immediate results, such as
surgical morbidity and mortality,41-45 as well as long-term results, such as local recurrence
and survival.20,21,41,46-49 An explanation of inter-institution and inter-surgeon variation in outcome
remains a delicate matter. The different patient and tumour-related factors have to be
considered as well as the surgical technique itself; anaesthesia, pre- and postoperative care
(including management of post-surgical complications and further follow-up), additional
non-surgical treatment modalities, diagnosis, and management of recurrences.
Table 2 shows an overview of studies which have investigated the influence of hospital-
and surgeon-related factors in rectal cancer according to short- and long-term outcomes.
This table is a shorter version of the table in a paper by Kapiteijn et al. in which a complete
overview of published studies on influence of hospital- and surgeon-related factors in
colorectal cancer is given.50
With regard to short-term end-points, there are indications that higher volume and
specialisation or teaching status are related to better outcomes.20,21,42-45,48,51-54 Other studies
however, found no correlation between hospital- and/or surgeon-related factors and short-
term outcomes.43,55,56
Several studies have investigated the effect of hospital volume on long-term outcomes.
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However, findings in literature are controversial,20,46-48 with also one report suggesting that
e.g. hospital volume predicts clinical outcome for colorectal cancer, but not in the absolute
magnitudes in comparison with the variation observed for higher-risk cancer surgeries.57-59
The influence of individual surgeon volume and specialisation on long-term outcomes
have also been investigated in several studies.21,41,48,49 Hermanek suggests that, in order to
maintain good quality of surgery, the minimum volume per surgeon should be about one or
two radical resections per month.60 In his study48 however, there was one particular high-
volume surgeon with very poor outcome, which makes his conclusion about the role of
volume controversial. In the study of Porter et al. it was shown that outcome is improved
both with colorectal surgical subspecialty training and a higher frequency of rectal cancer
surgery.49
When reviewing the data in the literature with respect to volume, it must be considered
that the definitions of high volume are different with varying cut-off points. This makes
comparison of the studies on hospital- and surgeon-related factors and outcome difficult,
also since data sources and statistical methods applied are different. Cut-off points should
be defined prospectively to avoid biases inherent in post-hoc analysis (in which cut-off
point can be selected to maximise volume-outcome associations).
In conclusion, it is evident from the data published that surgery is less than optimal as
reflected by some surgeons or in some hospitals. It is therefore important to give surgeons
the opportunity to undergo training and to adopt new and improved techniques. It seems
more difficult to find good arguments which support the hypothesis that treatment volume
or specialisation in certain centres are important factors. Rather, it could be that the relationship
between treatment volume and results is more a consequence of bad organisation or badly
trained surgeons than volume or specialisation itself.
Variability in definitions
Apart from variability in hospital and surgeon outcome, important factors responsible for
the large range of local failure rates are different definitions used for rectal cancer, curative
resection, local recurrence and the methods used for detecting such a local failure.70 A
study of Marsh et al.71 showed that for the same series of patients local recurrence rate
could be calculated as low as 4% or as high as 43% by exclusion or inclusion depending on
the used definition. Marsh et al. proposed in their paper that local recurrence after operation
for rectal carcinoma should be defined as any detectable local disease at follow-up, occurring
either alone or in conjunction with generalised recurrence, in all patients who have undergone
resection. Investigators publishing on rectal cancer treatment should clearly state crucial
definitions since it is obvious that the diversity in conducting and reporting surgical studies
in rectal cancer does little to facilitate interstudy comparison or the evaluation of novel
therapies.
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(Neo-)adjuvant therapy
In order to improve local control and survival after conventional surgery, additional
radiotherapy has been given. The results of studies using radiotherapy for rectal cancer,
suggest that preoperative radiotherapy is more effective than postoperative radiotherapy in
reducing local recurrence rates.72-74 Swedish trials showed improved local control and survival
with the short-term 5x5 Gy preoperative irradiation scheme.72,75 So far, chemotherapy alone
for rectal cancer has shown little or no effect in combination with conventional surgery on
disease-free and overall survival.76 Combinations of radiotherapy and chemotherapy have
also been given with improved outcomes, but sometimes at the expense of severe toxicity.77-
81
The studies so far published on adjuvant therapy have been carried out without an
adequate definition of the surgical procedure and without appropriate quality control. In
contrast with radiotherapy and chemotherapy, the quality of surgery has appeared difficult
to examine. Nevertheless, standardisation and quality control of surgery are prerequisites to
study the effect of (neo)adjuvant therapy reliably, also since the surgeon can be an important
factor in the accomplishment of tumour control (Table 2). In some trials, operation reports
were reviewed by a surgical board,79 but otherwise no meaningful quality control on surgery
was enhanced. Local recurrence rates in the “surgery alone” control groups of these trials
were often high; 20% or higher,40,75,77,78,82,83 representing non-standardised, conventional
surgical techniques.
In addition, in none of the studies were explicit details given of safety margins, excision
of mesorectum and lymph node dissection. Optimal quality control of the surgical procedure
must also include a standardised examination by pathologists. Quirke et al.84 described a
method of detection of mesorectal spread which required systematical examination of the
specimen, by serial sectioning of the whole tumour and the surrounding mesorectum in the
transverse plane. This method should be used to monitor differences in operative technique.
Furthermore, surgery can be documented photographically due to reproducible gross
specimen features.85
Lymph node dissection
In order to reduce local recurrence and hence improve survival more radical resections
have been devised. Extended lymphadenectomy, involving dissection of pelvic and aorto-
iliac lymph nodes without resection of organs other than the rectum, was described as early
as 1942.86 Most studies on extended pelvic lymphadenectomy (EPL)/D3 dissection however,
have been retrospective with historical controls as control group. Only one prospective trial
has been performed and this could not demonstrate an overall benefit, although in subgroup
analysis of mid-rectal Dukes’ C cancers this benefit was present.87 Partly because of the
wide variety in lymph node yield and salvage methods, and the differences in definition of
lymph node metastasis, there is still wide spread controversy on the extent of lymph node
dissection (LND) recommended for primary cancer of the rectum.
Furthermore, extended lymph node dissection carries a higher postoperative morbidity
which may be contributed to longer time of operation and increased blood loss. Another
strong argument against pelvic LND is the very high rate of bladder and sexual dysfunction88
as compared to conventional resections. The technique of nerve-sparing LND might decrease
these complications,89 but it requires a meticulous surgical technique and accurate knowledge
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of the anatomy of the pelvic autonomic nervous system and prolongs operation time even
more significantly.88
For the aforementioned reasons, extended lymph node dissection has not become standard
surgical practice in the Western world. In Japan however, extended lymph node dissection
is the standard surgical procedure since the mid seventies. A possible relevant factor in this
is that postoperative morbidity and mortality are minimal in Japanese patients, possibly
because of the low prevalence of obesity and atherosclerosis.
TME-surgery
The concept of Total mesorectal excision (TME) was introduced by Heald at the North
Hampshire Hospital in Basingstoke in 1979.90 By using sharp dissection under direct vision
a relatively bloodless plane is followed along the lipoma-like outer surface of the mesorectum.
The sharp technique used in TME ensures a specimen with intact mesorectum with negative
tumour margins in the majority of resectable (i.e. mobile) rectal cancers. Furthermore, the
sharp technique allows for preservation of the pelvic autonomic nerves, reducing sexual
and urinary dysfunction.
Heald’s first series of 112 curative anterior resections showed a cumulative risk of local
recurrence at 5 years of 2.7% and an overall corrected survival at 5 years of 87.5% with
tumour-free survival of 81.7%. These results were the best reported in rectal cancer treatment
up to then.91 However, many investigators doubted these findings with criticism focused on
patient case mix and analytical techniques,92 unclarified selection process93 and incorrect
use of definitions.71 In Enker’s personal series of 246 curable Dukes’ B and C cases only 18
tumours (7.3%) recurred locally, actuarial cancer specific 5-year survival was 74.2%.94
Aitken published a series of 64 curatively resected TME cases with at least 24 months
follow-up: only one patient (1.6%) developed a local recurrence.95
The acknowledgement of the important role of circumferential involvement in the
occurrence of local recurrences37,84,96-98 has led to the general introduction of TME-
surgery.63,99,100 In The Netherlands, Sweden and Norway, nation-wide projects have been
conducted in which surgeons were trained to perform a proper TME in an attempt to
improve their treatment results. Table 3 shows local recurrence rates after TME in several
studies, illustrating lower local recurrence rates with TME as compared to conventional
surgery (Table 1).
In addition to better results in terms of recurrence, the introduction of TME-surgery has
been shown to result in a reduction of abdominoperineal resections.99,101 However, higher
leak rates with TME-surgery as compared to conventional surgery have been reported.102,103
This increase can be partly explained by the removal of the pain-sensitive peritoneum,
which prevents early detection of anastomotic failure.104 The higher incidence of leakage
might also be caused by devascularisation of the anorectal stump during dissection of the
distal “tail” of the mesorectum in TME.103,105 Various other factors such as anastomotic
technique,106,107,108 method of preparation of the bowel,109 use of a diverting colostomy104
and the method of pelvic drainage110 have also been found to be related with leakage.
Since the introduction and application of TME-surgery has resulted in such low local
recurrence rates and improved survival, the question has yet to be answered as to whether
in combination with TME-surgery, adjuvant therapy is still capable of achieving any further
improvement in outcome.
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Heald '8691 112 3 2.7
Colombo ‘87111 89 10 11.2
Belli ‘88112 72 3 4.2
Kirwan ‘89113 67 3 4.5
Karanjia ‘90114 152 4 2.6
Cawthorn ‘9096 122 9 7.3
Dixon '91115 227 9 4.0
Moran ‘92116 55 4 7.3 only LAR
Tagliacozzo ‘92117 248 41 16.5
Jatzko ‘92118 187 25 13.4
MacFarlane '933 135 7 5.2
Enker '9594 246 18 7.3 70 pts had perioperative RT with
or without CT
Aitken ’9695 64 1 1.6
Eu ’97119 278 26 9.4
Carvalho ‘97120 51 1 1.9 adjuvant therapy was given in 33
pts
Hainsworth ‘97121 45 8 17.8
Arenas ’98122 64 4 3.1 42 pts received pre -or postop RT
Maas ‘00123 42 3 7.1
Martling et al. '0099 381 21 5.5 54% of the pts received 5x5 Gy
preop RT
Kapiteijn '0068 661 57 8.6
Tocchi '01124 53 5 9.4 only LAR
Recent developments in The Netherlands
In The Netherlands, standards of care for rectal cancer surgery have been subject of interest
for some years. The results of extended pelvic lymphadenectomy in Japan and the excellent
results of TME by Heald and Enker were welcomed with interest but also with scepticism;
could these results be repeated in all surgeon’s hands? Initially, attention was focused on the
Japanese style extended lymphadenectomy. In his thesis, Steup concluded that the value of
extended lymphadenectomy should be studied in a randomised controlled trial125 and a trial
was proposed to compare the D3 lymphadenectomy technique with TME. Many Dutch
surgeons however, feared a considerable morbidity with the Japanese D3 technique in
Dutch patients. A second and third proposal was to compare conventional surgery with
TME-surgery or compare in a two by two factorial design yes/no short-term preoperative
radiotherapy and conventional vs. TME-surgery. Both designs for trials however, would
allocate 25-30% of the patients to the inferior arm of conventional surgery without
preoperative radiotherapy. Literature data were so convincing with regard to the superiority
of the TME technique,3,94,95 that a majority of the Dutch surgeons had the opinion that it
would be unethical to randomise patients in such a design. Furthermore, there are potential
difficulties in a surgeon randomly applying different surgical techniques.126 Finally, the last
proposal was made for the TME-trial: compare TME-surgery with or without preoperative
radiotherapy.
Y. Moriya from the National Cancer Centre Hospital in Tokyo visited The Netherlands in
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1994-1995 to assess the feasibility of nerve preservation and pararectal resection comparable
to the TME-technique in a series of 47 Dutch patients.127 The nerve-preserving technique
yielded good results in terms of morbidity and functional outcome. Of the 42 curatively
operated patients, 3 (7.1%) developed a local recurrence. Sixty-seven percent were overall
free of recurrence after a median follow-up of 42 months. From these results it was concluded
that preservation of the pelvic autonomous nerve system does not compromise radicality in
mesorectal excision.123 This study comprised the pilot study of the TME-trial.
The TME-trial
A large prospective randomised trial (TME-trial) was started in 1996 under the auspices of
the Dutch ColoRectal Cancer Group (DCRCG) to document local control when standardised
TME is used and to answer the question whether 5x5 Gy preoperative radiotherapy75 is still
beneficial in TME treated patients.101 Eligibility criteria included histological confirmed
resectable primary adenocarcinoma of the rectum without evidence of distant metastases.
An extensive structure of workshops (run together with Heald, Enker and Moriya),
symposia and instruction videos helped to accomplish that TME was performed according
to strict quality demands. In addition, a monitoring committee of specially trained instructor-
surgeons was installed for on-site instructions. In each hospital, the first five TME procedures
had to be supervised by an instructor-surgeon.101 Special training courses were given to
pathologists for instruction of the protocol of Quirke et al.84 The results of histopathological
examination of the specimens were reviewed by a panel of supervising pathologists and a
quality manager.128 Eligibility, treatment and follow-up details were checked by the study-
coordinators. Fresh frozen and paraffin-embedded tissue samples were collected of each
patient for molecular biological research purposes.
The TME-trial was one of the first randomised trials with standardisation and quality
control of all participating disciplines. Both of these are prerequisites to study the effect of
(neo)adjuvant therapy reliably. In this thesis the set-up and results of the TME-trial are
extensively described.
PART II: MOLECULAR BIOLOGY
A genetic model for colorectal cancer
Colorectal cancer is one of the best-characterised cancers from the perspective of
understanding the genetic events which underlie the development of malignancy. The majority
of colorectal cancers develop from benign preneoplastic lesions, the adenomatous polyps
or adenomas. Progression from a benign adenoma to a malignant carcinoma passes through
a series of well-defined histological stages, which is referred to as the adenoma-carcinoma
sequence.129 The aetiology of colorectal cancer is multi-factorial, involving environmental
factors, genetic susceptibility and somatic changes during its initiation and progression.130
The genetic model for the progression of colorectal neoplasia is the molecular counterpart
of the morphological adenoma-carcinoma sequence. This model represents a simplified
picture of the complex process of tumour initiation and progression. Alterations in several
oncogenes (K-ras) and tumour suppressor genes (APC, DCC/DPC4, p53), as well as
epigenetic changes (methylation) are implicated in the stepwise development of colorectal
neoplasia (Figure 2). The accumulation of these changes is associated with a gradual increase
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in the size, disorganisation and malignancy of colorectal tumours.
APC
Inactivation of the Adenomatous Polyposis Coli gene (APC) on chromosome 5q has been
shown to be the underlying defect in familial adenomatous polyposis (FAP), in which germline
mutations in APC are found. However, inactivation of APC is also one of the earliest events
in the development of sporadic colorectal cancers with somatic mutations in the mutation
cluster region (MCR).131,132 In the majority of colorectal neoplasia, the APC gene is either
deleted or mutationally inactivated by the introduction of premature termination codons.
This inactivation is already observed in the smallest precursor lesions of adenomas, the
dysplastic aberrant crypt foci132,133 and therefore, APC is called the “gatekeeper” of colorectal
epithelial cell proliferation, as its inactivation is a rate-limiting event in the initiation of the
adenoma-carcinoma sequence.
APC has 3 binding sites which allows for interaction with ß-catenin, a well-known
adhesion and signaling molecule which is associated with E-cadherin in the formation of
epithelial cell-cell contacts. By the interaction with ß-catenin, APC is a key member of the
Wnt signal transduction pathway (Figure 1), which is recognised to function in critical
biological processes such as embryonic induction, the generation of cell polarity and the
specification of cell fate.134 In general, secreted Wnt/Wingless glycoproteins interact with
receptors of the frizzled gene family, thereby activating the cytoplasmatic phosphoprotein
dishevelled (dsh). Dsh inhibits the function of the serine/threonine kinase GSK3β. Inhibition
of GSK3β results in the accumulation of β-catenin in the cytoplasm and in its translocation
to the nucleus where it forms complexes with the TcF/Lef family of HMG transcription
factors.135 These complexes can activate target genes, of which c-myc136 and cyclin D1137
are examples. In the absence of the Wnt signal, GSK3β forms a complex together with
conductin, axin, APC and β-catenin promoting the rapid degradation of β-catenin.138 Hence,
loss of APC results in a critical loss over β-catenin control, leading to constitutive signaling
to the nucleus and activation of downstream target genes.
Figure 1. The Wnt signal transduction
pathway. APC acts as a negative regulator
of β-catenin accumulation and signaling.
In the absence of the Wnt signal, GSK-3β
forms a multiprotein complex with APC
and β-catenin, triggering β-catenin
degradation. In the presence of the Wnt
signal, Dsh is activated, which inhibits the
function of GSK-3β. APC remains
unphosphorylated and unable to
downregulate intracellular β-catenin,
leading to its translocation to the nucleus
where it can activate transcription of target
genes, including c-myc and cyclin D1.135
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Further clonal expansion of benign tumour cells is driven by mutations at the K-ras proto-
oncogene on chromosome 12p. K-ras mutations are frequent in colorectal cancer and usually
involve missense mutations of codon 12 and 13.139 These mutations result in an increase of
the GTPase activity of the ras protein, which is part of a signal transduction pathway. The
ras signaling pathway relays signals from the cell surface to the nucleus and has an important
role in the control of cell proliferation. Consecutive activation of ras in the pathway has
been shown to lead to oncogenesis.
DCC/DPC4
Alterations in the Deleted in Colorectal Cancer (DCC) and/or Deleted in Pancreatic Cancer
4 (DPC4, both on chromosome 18) and p53 (on chromosome 17) tumour suppressor
genes occur during the later stages of tumourigenesis, and result in the progression from
the benign to the malignant state of colorectal neoplasia. The DCC gene was originally
identified due to its high frequency of deletion in colorectal cancer and was mapped to
chromosome 18q.140 Frequent loss of heterosygosity at the DCC locus and loss of DCC
expression have been observed in colorectal cancers.140,141 However, although the DCC
gene might play some role in progression of colorectal cancers, the frequency of loss of
heterozygosity (LOH) on 18q in some tumours does not correlate simply with the low
frequency of mutations on the DCC gene.142 The DCP4/SMAD4 gene, lying in close proximity
to the DCC gene at 18q21.1, was recently identified as a candidate suppressor for a
predisposing gene for Juvenile Polyposis Syndrome (JPS).143 This gene functions as a
cytoplasmic mediator in the signaling pathway of transforming growth factor (TGF)-β.
Inactivation of both alleles of the DPC4/SMAD4 gene was also demonstrated to occur in a
substantial proportion of sporadic colorectal cancers.144 Loss of DCC and DPC4 has been
observed to occur independently from each other.145
p53
Mutations of the p53 tumour suppressor gene on chromosome 17p are the most frequently
found genetic alterations in human cancer.146 LOH of the p53 region is observed in more
than 75% of colorectal tumours, and usually correlates with point mutation of the remaining
allele.147,148 p53 has been named the “guardian of the genome” because of its capacity to
monitor the integrity of the DNA.149 The function of p53 is to maintain genetic stability of
cells by eliminating cells with damaged DNA and by facilitating the repair of such damage.150
Therefore, it has an important role in several apoptotic pathways. Elimination of p53 tumour-
suppressor activity by mutations in the gene will lead to escape of neoplastic cells with
DNA alterations from p53 induced growth arrest, that would normally be followed by
either DNA repair or apoptosis (programmed cell death).151
DNA repair genes
Apart from alterations in the aforementioned genes, inactivation of genes which control the
rate of mutations (DNA repair genes) is also observed in colorectal cancer. A link between
DNA repair deficiency and colorectal cancer is seen in Hereditary Non-Polyposis Colorectal
Cancer (HNPCC). Individuals with HNPCC carry germline mutations in DNA-mismatch
repair genes (most frequently in hMLH1 and hMSH2), and exhibit microsatellite instability
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(MSI) in their colorectal tumours.152 A target often hit in these tumours is TGF-β-RII. The
TGF-β/SMAD signaling pathway is involved in a variety of biological functions; i.e. cellular
differentiation, embryonal morphology and in immunological defense. Finally, TGF-β/SMAD
signaling usually inhibits growth in epithelial tissue.153
Proliferation/apoptosis
Dividing normal cell populations maintain the balance between cell proliferation and cell
loss. This is important for maintaining a constant number of cells within a tissue. If there is
increased proliferation, decreased apoptosis or both, uncontrolled growth occurs and this
may result in tumour formation.154 Amongst the cell proliferation markers are Ki-67 and
PCNA.155 An important apoptotic gene other than p53 is Bcl-2. Overexpression of Bcl-2
protects cells against induction of apoptosis by a variety of stimuli, including irradiation and
most clinically used chemotherapeutic drugs.156 Bcl-2 is the founding member of a family
of proteins that can either repress (e.g. Bcl-2, Bcl-Xl, Bcl-W) or promote apoptosis (e.g.
Bax, Bak, Bcl-Xs).157
Cell adhesion
In the progression of colorectal cancers (i.e. invasion and metastasis), microenvironmental
interactions are important. Loss of cell adhesion leads to a reorganisation of epithelial cells
to make invasion and metastasis possible.158 E-cadherin is a cellular adhesion molecule,
which has an important role regulating cell differentiation and establishing surface-membrane
polarity. When E-cadherin is lost, epithelial cells dedifferentiate, cell adhesion and polarity
are lost and the cells become invasive.159,160 In cell-cell adhesion, E-cadherin is associated
with the actin cytoskeleton via cytoplasmic proteins, including α-, β-, and γ-catenins,
which together form the cadherin/catenin complex.161 The epithelial cell adhesion molecule
(EpCAM) is a homophylic cell adhesion molecule, which is thought to be important for cell
segregation. EpCAM has attracted attention as a potential tumour marker, because it is
expressed in a vast majority of carcinomas.162 EpCAM has been shown to affect in vitro
expression of the intercellular adhesions mediated by cadherins.163
Angiogenesis
Angiogenesis is mediated by multiple molecules that are released by both tumour cells and
host cells including endothelial cells, epithelial cells, mesothelial cells and leucocytes. Among
these molecules are members of the Fibroblast Growth Factor (FGF) family, vascular
endothelial growth factor (VEGF), platelet derived growth factor (PDGF), TGF-β and
others.164,165 Angiogenesis is essential in tissue development, reproduction and wound
healing.166 In addition, angiogenesis has been described as vital for tumour growth and
expansion; influx of new blood vessels may facilitate dissemination to distant sites.167,168
Other genes
Numerous other genes have been identified to play a role in the tumourigenesis of colorectal
tumours. For a full understanding of the process of normal cells becoming malignant tumours,
all the genetic pathways and mechanisms need to be identified. A complete genetic pathway
would include all the genes involved, whether mutated or functionally altered without
mutation, and the order in which they become involved from the first change through to
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metastasis in different tissues. In addition, a full description of all modifier genes and the
impact of their alleles on progression along the genetic pathways is desirable. These will
form the basis of eventually achieving complete understanding of all the functional effects
and interactions of these genes to reveal exactly how a tumour evolves.
Genomic instability
Within the adenoma-carcinoma sequence, two mechanisms of genomic instability have
been identified (Figure 2). Genomic instability is considered to play a crucial role in leading
to the accumulation of alterations in oncogenes and tumour suppressor genes necessary for
malignant transformation.
The first form of genomic instability is known as chromosomal instability (CIN). Due to
loss or gain of genetic material at a specific chromosomal region on one or both alleles of
the tumour cells, these cells show an altered ratio of both alleles when compared with
corresponding normal tissue. CIN is characterised by gross chromosomal segregation
abnormalities and is commonly detected as aneuploidy.169 The majority (85-90%) of sporadic
colorectal carcinomas is associated with chromosomal instability.129 Despite the fact that
CIN is a relatively common phenotype, its mechanistic basis has mainly been unclear.
Molecular mechanisms thought to be involved are p53-inactivation,150 changes in mitotic
checkpoint genes (Bub1),170 failure of DNA-damage checkpoints (ATM)171 and the JC-
virus.172 Recently it was demonstrated that loss of APC sequences that lie C-terminal to the
β-catenin regulatory domain contributes to CIN in colorectal cancer, which was independent
of its role in signal transduction. Loss of APC function therefore probably initiates
tumourigenesis by constitutively activating Wnt signaling and probably elicits CIN in later
stages of malignant progression with the cooperation of other acquired mutations.173
Another form of genomic instability in colorectal tumours is Microsatellite Instability
(MSI). MSI, characterised by an altered number of repeat units that constitute DNA
microsatellite repeats in tumour DNA,174,175 has been identified in the majority of hereditary
non-polyposis colorectal cancers and is caused by germline mutations in human DNA
mismatch repair genes.130 MSI also occurs in 10-15% of sporadic colorectal tumours,177
mainly by somatic inactivation of hMLH1.176 MSI reflects the failure to repair replication
errors within repeat sequences contained in genes relevant for growth control and
differentiation.178
MSI-positive colorectal carcinomas have specific clinical and pathological manifestations
as compared to MSI-stable cancers, such as right-sided predominance, occurrence in young
patients, tumour multiplicity, mucinous histopathological type, prominent lymphoid
inflammatory response and diploid DNA content.175,179-183 Furthermore, MSI-positive cancers
appear to show a molecular genetic spectrum that is distinct from CIN-tumours. The genes
that are most frequently affected in CIN-tumours are APC, K-ras and p53. Mutations in
these genes seem to occur with reduced frequency in MSI tumours,184,185 but other studies
have found APC, K-ras and p53 alterations at frequencies similar to MSI-stable
cancers.175,186,187 In MSI-tumours, mutations within small repeated sequences are usually
found in genes such as TGF-β-RII, Bax and insulin-like growth factor receptor II (IGF-
RII).184,188,189 However, TGF-β-RII mutations are also present in 15% of MSI-stable colorectal
cancer cell lines, although these are not frameshifts of the (A)10 tract typically mutated in
tumours with MSI.190
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Figure 2. Alterations in several oncogenes and tumour suppressor genes according to two major
mechanisms of genomic instability: microsatellite instability (MSI) and chromosomal instability
(CIN). N=normal, Ad=adenoma, Ca=carcinoma.
In conclusion, at least two different molecular pathways are involved in the development
of colorectal cancer: the APC/β-catenin (Wnt) mutational pathway, usually associated with
CIN, and DNA mismatch repair (MMR) pathway, associated with MSI with often inactivation
of TGF-β-RII.191 These routes are not totally independent, but show crosstalk with mutations
in certain genes (APC,186 TGF-β-RII190 and axin192) in both pathways. The APC and MMR
pathways show mutations in different parts of cell regulation mechanisms, but these may




































Colon vs. rectal tumours
First, it is important to mention that colon vs. rectal cancers can also be defined as right-
sided vs. left-sided or proximal vs. distal colorectum. The rectum is regarded as the left-
sided or distal colorectum.
Tumours located in the distal colorectum have been proposed to arise and progress by
pathways distinct from those originating in the proximal colon. Distal tumours display a
higher frequency of 17p193 and 18q194 allelic loss, p53 accumulation,195 c-myc expression196
and aneuploidy.197 Right-sided tumours are more often mucinous,198 diploid197 and of the
MSI-phenotype.179 Furthermore, clinical behaviour has appeared different in that in rectal
cancer local recurrence has been the major problem and in colon cancer distant metastasis.
However, through the recent introduction of a better surgical technique (TME) for rectal
cancer, this difference in clinical behaviour may disappear. Nevertheless, it is still reasonable
to suggest that the molecular basis differs between the colon and rectum.
Cellular responses to ionising radiation damage
Ionising radiation, as an effective physical agent for cancer therapy, targets primarily DNA
molecules and produces an array of lesions that include single-strand breaks, base alterations
and double-strand breaks. These lesions are repaired by distinct DNA repair mechanisms,
each covering a specific spectrum of damage. In addition to repair pathways, DNA lesions
are also recognised by components of the DNA damage cell cycle checkpoint pathways.
The function of p53 in normal cells is to respond to DNA damage by ionising radiation
by either causing cell cycle arrest or by forcing damaged cells to go into apoptosis. The
stability of the p53 protein is regulated by binding to MDM2, a protein that degrades p53
and consequently inactivates the transcriptional function of p53.199,200,201 Mutations in p53
prevent degradation by MDM2, allowing stabilisation and detection of the protein by
immunohistochemistry.
The induction of the CDK inhibitor p21waf1 after ionising radiation leads to a G1 growth
arrest, thus allowing the cell to repair the damage.202 Apart from induction by wild type p53,
activation of the p21waf1 gene can also occur through mechanisms independent of p53.203
TGF-β, the BRCA1 gene products and Nerve Growth Factor (NGF) are examples of factors
that promote p21waf1 transcription by p53-independent mechanisms.204-206 In addition to a
role in the repair process, p21waf1 has an important function during differentiation of cells.207
Role of molecular investigations in rectal cancer treatment
Investigations of the genetic pathways involved in rectal cancer give insight in the
mechanisms of development of these tumours and may provide new therapeutic targets. In
addition, biological parameters that identify a higher degree of aggressiveness, independent
of known clinicopathological features of colorectal carcinoma may help to improve treatment
strategies. However, to be able to investigate genetic pathways and prognostic markers in
rectal carcinoma, standardised treatment is a prerequisite, since treatment-related variation
of outcome should be ruled out.
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OUTLINE OF THIS THESIS
In this thesis, we have studied clinical and molecular aspects of rectal carcinoma. Most
results reported in this thesis are based on the prospective randomised TME-trial, a large
trial investigating the role of short-term preoperative radiotherapy in combination with
standardised TME-surgery. The first part of this thesis focuses on advances in the treatment
of rectal cancer, while the second part involves new insights in molecular biology of rectal
carcinomas. We investigated both aspects of rectal cancer since investigation of molecular
parameters can provide a better understanding of clinical outcome.
PART I: ADVANCES IN TREATMENT
The basic conventional procedure involving blunt dissection, often resulted in incomplete
removal of mesorectal tissue with high local recurrence rates. Chapter 2 describes a
retrospective analysis of local recurrence rate in a regional cancer centre in the west
Netherlands of rectal cancer patients diagnosed between 1988 and 1992. In this study, we
evaluated patients who were treated with conventional surgery.
In Europe, TME has become the preferred standard of operative management for rectal
cancers. Current clinical trials examining the role of adjuvant therapy in patients who are
undergoing standardised operations are now setting the standard of care in several European
countries. Chapter 3 provides an overview of present European trials in which TME-
surgery is intentionally performed.
The TME-trial was set up to document local control when standardised TME is used
and to answer the question whether short-term preoperative radiotherapy is still beneficial
in TME treated patients. However, when investigating (neo)adjuvant therapies, side effects
must be weighed against potential benefits with regard to recurrence and survival. In Ch pter
4, short-term results of the combination of preoperative radiotherapy and TME-surgery are
presented.
Before the start of the TME-trial there were doubts whether the excellent results of
specialised surgeons performing TME-surgery could be repeated in a large multicentre trial.
Chapter 5 compares outcomes of rectal cancer patients in a former randomised trial, the
Cancer Recurrence And Blood transfusion (CRAB)-trial in which conventional surgery was
applied, with the TME-trial, in which standardised TME-surgery was introduced under
extensive quality-control. Furthermore, the influence of hospital volume and specialisation
was investigated
In Chapter 6, the main objective of the TME-trial, the role of preoperative radiotherapy
in combination with TME-surgery, is analysed. Both short-term preoperative radiotherapy
and TME have independently demonstrated to improve local control in rectal cancer, but
the combination of these treatment modalities was never investigated.
PART II: NEW INSIGHTS IN MOLECULAR BIOLOGY
Several studies have suggested that the development of colon and rectal cancers may involve
different mechanisms. In Chapter 7 we investigated different genes involved in oncogenesis
of colon and rectal cancers, and analysed their prognostic value. Cases were obtained from
consecutive series of colon carcinomas and standardised treated rectal tumours from the
pilot study of the TME-trial. Mutation analysis was performed for p53 and APC. hMLH1,
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Colorectal cancer is the most common gastrointestinal cancer in the Western world. In
1992, 7700 new colorectal cancer patients were registered in The Netherlands, of whom
about 35% had rectal carcinoma.1 One of the major problems in the treatment of rectal
cancer is the appearance of local recurrences. These cause severely disabling symptoms,
are difficult to treat and usually have a fatal outcome.2 Most of them become overt within 2
years of surgery.
Surgery is still the primary therapy for rectal cancer. In the literature, the reported local
recurrence (LR) incidence after curative resection varies widely, between 5% and 45%.3,4
The inter- and intra-institutional local recurrence rates vary to the same extent.5 This
emphasizes the importance of varying levels of surgical skill in the genesis of local failures.
Conventional non-standardised surgery of rectal cancer consists of a partial blunt
dissection, directed “cone-wise” towards the rectal wall through the mesorectum. A high
incidence of local recurrence is associated with this procedure. Surgeons specialised in
rectal surgery have results of improved local control (5-8%) and survival in their series
with standardised surgery. In the Western world the concept of circumferential or total
mesorectal excision (TME) is advocated.6,7 In Japan the extended lateral pelvic lymph node
dissection is routinely conducted in a standardised procedure.8
Important factors of local recurrence and survival in rectal cancer are Dukes’ Astler-
Coller stage9-11 and lateral margin involvement.12,13 Other important factors include tumour
grade,14 fixation,15,16 level of the tumour in the rectum,17,18 blood19 and lymphatic20 vessel
invasion and inadvertent perforation of the tumour during resection.9,21,22 Sex23 and age24-26
are patient-related prognostic features. Prognostic factors can be used to assign patients
with unfavourable prognosis to the most suitable adjuvant protocol to improve outcome.
In different studies, the benefit of radiotherapy (RT) in the treatment of rectal cancer
has been demonstrated. Both pre- and postoperative radiotherapy have been shown to improve
local control and disease-free survival.27-29 In a large, prospective Swedish trial it was shown
that preoperative hypofractioned radiotherapy results in better local control than postoperative
radiotherapy.30 Recently, results of the Swedish Rectal Cancer Trial showed reduced rates
of local recurrence and also improved survival with the preoperative short-term 5x5 Gy
regimen.31 Shorter overall treatment time and better treatment compliance are probably the
most important reasons for better results of short-term preoperative radiotherapy compared
to postoperative radiotherapy.
A population-based retrospective study in patients with primary rectal cancer was set
up by the Tumour Study Group Gastroenterology of the Comprehensive Cancer Centre
West (CCCW). The objectives were to compile an inventory of overall local recurrence rate
after non-standardised conventional surgery for rectal cancer and inter-institutional recurrence
rate variability, and to investigate correlations between patient- and tumour-related factors
and recurrence rate. In this study radiotherapy was given postoperatively according to
CCCW guidelines. We also investigated compliance to these guidelines and whether violation
of the protocol had consequences for local recurrence rate. Patients in this study were
treated during the period 1988-1992 in 12 hospitals.
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METHODS
The medical records of 1105 patients with rectal cancer diagnosed between January 1988
and December 1992 were reviewed. Basic data were obtained from the population-based
registry of the CCCW, which derives its data from clinical records in hospitals upon
notification of pathology laboratories and medical record administration. The minimum
follow-up date was set on 1 February, 1995, the follow-up period being 3-8 years.
Information on stage, type of surgery, local recurrence and survival was extracted from the
clinical records. Additional information on dates of recurrence or death was provided by
general practitioners.
Data from rectal endoscopy were used to determine the exact location of the tumour:   6
cm, 6.1-12 cm and 12.1-18 cm. The surgical procedure was considered to be curative
when the surgeon stated in his surgical report that local tumour resection had been
macroscopically radical without intraoperative detection of metastases. Extent of the tumour
was recorded according to the modified Astler and Coller classification.32 Tumours diagnosed
in 1988 were classified according to the extent of disease (EOD) system33 in the CCCW
registry. As a consequence this left us with B1/B2 and C1/C2 tumours which we could not
specify further. Tumour spill was defined as rupture of the tumour during resection. Surgical
margins were considered tumour-free when proximal and distal margins were microscopically
negative. Residual tumour (R1) was defined as either tumour spill or positive surgical margins.
Local recurrence was defined as tumour growth in the pelvis. This definition also included
anastomotic recurrences and perineal wound recurrences in abdominoperineal resection
(APR) patients. Distant metastases were defined as recurrence of tumour growth outside
the pelvis. This definition also included “recurrence” at the side of the stoma or in para-
aortic lymph nodes.
Indications for postoperative radiotherapy were Dukes’ Astler-Coller B2 and C tumours,
positive surgical margins, or tumour spill, according to the guidelines of the CCCW. Patients
with an indication for radiotherapy received a dose between 50 and 60 Gy in fractions of
1.8-2.0 Gy, five fractions per week, depending on the institute. Treatment was ideally
started within 6 weeks.
Hospitals were analysed separately, but also by volume category. The average number
of patients per hospital was 56. The categories of low- and high-volume were determined
by dividing the 12 hospitals into two volume-groups: hospitals with a number of patients
lower than or equal to the average number of patients per hospital,  56, were classified as
low-volume hospitals, and hospitals with a number of patients higher than the average
number of patients,>56, were classified as high-volume hospitals.
Statistical methods
Univariate analysis of local recurrence rates was performed using Chi-square tests. Odds
ratios and 95% confidence intervals (CI) represent the relative risk compared to a reference
category.
Logistic regression analysis was used for multivariate evaluation of prognostic factors
including age (groups of <65, 65-75, >75 years), gender, location of the tumour (cm), type
of surgery, intraoperative tumour spill, surgical margins, residual tumour, Dukes’ Astler-
Coller stage, adjuvant radiotherapy, adjuvant chemotherapy, hospital, and the low- and high-





variables and their predictive value was assessed using the P-value of the log-likelihood.
Only variables which significantly improved the fit of the model (P<0.10) were included in
the final model.
Survival rates were calculated using the Kaplan-Meier method and differences between
groups were assessed with the log-rank test.
RESULTS
Of 1105 cases, 437 were ineligible. 205 (19%) cases were excluded because of missing
medical records, no carcinoma, or incorrect registration; 107 (10%) because of no
laparotomy; 75 (7%) because of a non-curative resection; and 50 (5%) were lost to follow-
up. The median age of the 1105 patients was 68.6 years (range 24.4-98.5). The baseline
characteristics of these patients are shown in Table 1. For our final analysis, 668 curative
resection cases were left. Median follow-up of these patients was 4.6 years.
Local recurrence rate
The overall local recurrence rate was 22.5% (150/668). Sixty-six percent (99/150) of the
local recurrences were diagnosed within 2 years and 88% (132/150) within 3 years.
In the univariate analysis, tumour location (P=0.001), intraoperative tumour spill
(P=0.002), positive surgical margins (P=0.001), residual tumour (P<0.001), Dukes’ Astler-
Coller stage (P<0.001), and adjuvant radiotherapy (P=0.03) were significant prognostic
factors for the risk of local recurrence. These results are shown in Table 2. The local
recurrence rate was highest (29%) for patients with a tumour in the most distal part of the
rectum (0-6 cm). Patients with intraoperative tumour spill had a higher local recurrence
rate than patients without tumour spill, 47% vs. 21%, although tumour spill was reported in
only 34 (5%) of the patients. Local recurrence rate was significantly higher in patients with
tumours with positive surgical margins than for patients with negative surgical margins,
56% vs. 22%, although only 16 (2%) patients had tumours with positive margins. Obviously,
residual tumour (R1), defined as either tumour spill or positive surgical margins, was also a
significant factor. The local recurrence rate was highest for patients with a Dukes’ C
tumour. It is surprising however, that patients with C1 tumours had a higher recurrence
rate than patients with C2 tumours, 40% vs. 32%. Patients who had received postoperative
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radiotherapy had a significantly higher local recurrence rate than patients who had not
received radiotherapy, 27% vs. 20%.
In the multivariate analysis tumour location (P<0.001), residual tumour (P=0.001) and
Dukes’ Astler-Coller stage (P<0.001) were significantly related to local recurrence. Figures
1 and 2 show local recurrence risks for the R0 and R1 groups by Dukes’ Astler-Coller
stage and tumour location as obtained from the logistic regression model. The risks shown
in these figures are not the fractions by subgroup. The risks probably correspond with
these fractions, but in the logistic regression model risks can also be calculated in almost
empty subgroups. Patients with C1 tumours, tumours at 0-6 cm from the anal verge and
R1 status had the highest risk for local recurrence.
Local recurrence rates varied from 9% to 36% between the 12 hospitals (Table 2).
However, these differences were not statistically significant on univariate or multivariate
analysis. There was also no significant difference in local recurrence rate between the low-
and high-volume hospital groups; low-volume hospital LR rate, 22%, vs. high-volume hospital
LR rate, 23%. Figure 3 shows the 95% confidence intervals of the local recurrence rates of
the 12 hospitals in the univariate analysis, ranged according to volume. The lowest and
highest recurrence rates are observed in hospitals with low numbers of patients. High-
volume hospitals have average recurrence rates.
Recurrence-free and overall survival
In studying the time to local recurrence one should note that patients who die before local
recurrence will not experience a recurrence. Therefore, using the Kaplan-Meier method
with death as a censoring variable is not appropriate because such an analysis assumes
that patients can still experience a recurrence after death! A correct analysis will set the
time to local recurrence at a very high value (e.g. 4000 days) for patients who die before
recurrence. The resulting Kaplan-Meier is shown in figure 4 and estimates the chance of
ever having experienced recurrence at about 24%. This is very close to the observed overall
local recurrence rate we found (22.5%). Figure 4 also shows that there is hardly any
censoring due to short follow-up before the Kaplan-Meier curve reaches its plateau.
Figure 1. Risk of local recurrence by Dukes’
Astler-Coller stage and tumour location for
the R0-group as obtained from the logistic
regression model. Distance from anal verge:
     , 0-6 cm; · · ·, 6.1-12 cm; - · -, 12.1-18 cm,
- - -, unknown.
Figure 2. Risk of local recurrence by Dukes’
Astler-Coller stage and tumour location for
the R1-group as obtained from the logistic
regression model. Legend as for figure 1.
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Table 2. Local recurrence rate (LR) for rectal cancer patients (668), univariate analysis.
n (%) LR % LR P Odds ratio (95% CI)
Age (years)
    -<65
    -65-75
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*   abdominoperineal resection.
** low anterior resection.
The P-values given are the P-values of the chi-square test in the 2xk table. Odds ratios are given for
the prognostic factors showing a significant effect. The most favourable group is chosen as baseline.
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Therefore, we can safely assume that the patients censored after 1000 days will only rarely
have experienced recurrence. Moreover, it can be concluded that actual experienced local
recurrence can be safely taken as our outcome variable (as there are only a few patients
with early censoring that might have had a recurrence later on).
The outcome “observed local recurrence” was analysed by logistic regression. To
investigate the influence of local recurrence on overall survival we applied Cox regression
with the factors from the univariate and multivariate analysis and occurrence of LR as time-
dependent covariate. Age, Dukes’ Astler-Coller stage, type of surgery and sex were
determinants for overall survival. The appearance of a local recurrence influenced overall
survival after diagnosis of the recurrence and made the chance of dying 10 times greater
than no appearance of local recurrence (data not shown).
The median overall survival in patients with local recurrence was 265 days after diagnosis
of the recurrence. Overall survival was 40% for the whole group of patients at the end of
the follow-up period (1 February 1995). Cancer-free survival was 60% for the whole
group (data not shown).
Compliance to guidelines for postoperative radiotherapy
Adjuvant radiotherapy was given to 239 patients (36%, Table 2). Twenty-three patients
(3%) received adjuvant chemotherapy. Of these patients, 12 also received radiotherapy
while 11 did not (data not shown). The chemotherapy was administered within a clinical
trial similar to that published by Moertel et al.34
In Table 3 the compliance to the guidelines for radiotherapy is shown. According to the
guidelines, 432 patients should have received radiotherapy. However, only 214 patients
(50%) actually received radiotherapy. Eight (5%) of 163 patients who should n t have
received radiotherapy, did so. In the patient group with an indication for radiotherapy, there
was no significant difference in local recurrence rate between patients treated according to
the guidelines and those not treated according to the guidelines: 29% vs. 27%. These results









Figure 3. 95% CI intervals of the local
recurrence rates of the 12 hospitals, ranged
according to volume (univariate analysis).
Figure 4. Recurrence-free survival. Kaplan-Meier curve in which
the time to local recurrence is set at 4000 days for the patients who
have died before recurrence. The possibility of experiencing a
recurrence is estimated at about 24%.




This population-based study showed an overall local recurrence rate of 22.5% in patients
with primary rectal cancer after non-standardised surgical treatment with or without adjuvant
treatment. Independent prognostic factors for the risk of local recurrence were Dukes’
Astler-Coller stage, distance from the anal verge and residual tumour. Although there was
great variability (9-36%) between local recurrence rates between hospitals, no significant
differences in recurrence rates between the separate hospitals or between low- and high-
volume hospitals were found. Postoperative radiotherapy guidelines were available in this
study. The compliance to these guidelines was only 50%. However, no significant difference
in recurrence rate was found between patients treated according to the guidelines and those
not treated according to the guidelines.
We performed this population-based study with data collected retrospectively from rectal
cancer patients diagnosed between 1988 and 1992 from 12 hospitals in the west Netherlands.
The greatest advantage of a population-based study is that analysis is based on an unselected
group of patients from oncological centres and peripheral hospitals. This is in contrast with
most trials in which, due to the use of inclusion and exclusion criteria, selection or centralisation
of treatment inevitably takes place. The minimum follow-up was 3 years. This period seems
long enough since most recurrences are diagnosed within 2-3 years. In our study, 88% of
the local recurrences were diagnosed within 3 years.
The overall local recurrence rate of 22.5% is not at variance with other studies in which
non-standardised conventional surgery was performed.26,35 However, standardised TME
surgery has been shown to result in much lower recurrence rates and improved survival.6,7
In The Netherlands, TME surgery was introduced a few years ago to improve the results of
treatment of primary rectal cancer.
Prognostic factors can be used in selecting patients with tumours with an unfavourable
prognosis to be assigned to the most suitable adjuvant protocol to improve outcome. We
found a higher local recurrence rate for patients with Dukes’ C tumours as compared to
Dukes’ B tumours. Other authors9-11 have found that patients with Dukes’ B and C tumours
have a higher rate of recurrence and a poorer outlook than those with Dukes’ A lesions. In
our study it was notable that patients with C1 tumours showed a higher recurrence rate
Table 3. Compliance to guidelines for postoperative radiotherapy.
RT given (222) RT not given (373)
guideline: RT (432) 214 (50%) 218 (50%)
guideline: no RT (163) 8     (5%) 155 (95%)
unknown: 73*
* unknown: guidelines were unknown in 73 cases because of unknown
   Dukes’ Astler-Coller stage and Dukes’ B1/B2 tumours.
Table 4. Local recurrence rates by guideline and radiotherapy group.
RT given RT not given
guideline: RT 63/214 (29%) 58/218 (27%)
guideline: no RT 0/0       (0%) 18/155 (12%)
unknown: 73
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than patients with C2 tumours. This finding can most probably be explained by the fact that
the number of C1 tumours was very small. Another explanation is that the C1 group might
have been mixed with C2 tumours which were staged as C1 tumours.
We found the highest recurrence rate in patients with tumours located between 0 and 6
cm from the anal verge. The prognostic significance of the tumour level in the rectum
seems to be generally accepted; tumours arising at distances of under 6 cm from the anal
verge have also been found to be associated with an increased local recurrence rate in other
studies.17,18
Furthermore, residual tumour was an independent prognostic factor for the risk of local
recurrence, while tumour spill and positive surgical margins appeared to be significant in
the univariate analysis only. Ranbarger et al.,36 Slanetz et al.37 and Zirngibl et al.,21 also
showed in their studies that intraoperative spillage of tumour cells significantly increases
the local recurrence rate. Tumour involvement of bowel mucosa at resection margins can
also predict a possible anastomotic recurrence. However, most recurrences in the operating
field are extraluminal and relate to lateral tumour spread. These local recurrences can only
be predicted in less than half of the cases by pathological examination in current use in
which only proximal and distal margins are investigated. Quirke et al. clearly demonstrated
that a different method of pathological preparation and examination, which can reveal lateral
margin involvement, is able to predict a local recurrence in 85% of the cases.12,13 In our
study circumferential margins were not routinely investigated.
Hospital was not a significant prognostic factor in our analysis. No significant differences
in local recurrence rate were found between the separate hospitals or between low- and
high-volume hospitals. However, the variability of local recurrence rate was large between
the hospitals: 9% to 36%. The explanation for the non-significance of this variance might
be that the lowest and highest recurrence rates were seen in hospitals with low numbers of
patients.
Inter-institution and inter-surgeon variabilities have been shown in other studies. This
applies to immediate results, such as surgical mortality and morbidity,5,38-40 as well as long-
term results, such as local recurrence5,9,41 and survival.5,41 Philips et al.9 found that local
recurrence rate varied from 5% to 20% between the 20 individual surgeons participating in
the Large Bowel Cancer Project. Similarly, McArdle et al.42 nd McArdle and Hole5 noted
recurrence rates ranging from 0% to 21% between the individual surgeons participating in
their study. Controversy exists about case volume in itself being important for achieving
good results in cancer surgery. It is becoming increasingly clear that specialist interest is
also important.43 The specialist will be familiar with the relevant anatomy and techniques so
that good results will be achieved, even though relatively small numbers of patients may be
treated. It seems that a certain volume is necessary for good long-term results, but above
this level inter-surgeon variability in long-term outcome cannot be correlated with surgeon
volume.44 However, in a recent study of Porter et al.,45 it was shown that outcome is
improved both with colorectal surgical subspecialty training and a higher frequency of
rectal cancer surgery.
Radiotherapy was a significant prognostic factor in the univariate analysis for the risk of
local recurrence. Patients who received radiotherapy did worse than patients who did not
receive radiotherapy. A likely explanation for this finding might be that the patients who
received radiotherapy were those whose tumours had the worst behaviour. Apparently,
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clinicians were able to select those patients with the highest risk of local recurrence.
The compliance to the guidelines for postoperative radiotherapy was only 50%.
Surprisingly, no difference in local recurrence rate was found between patients treated
according to the guidelines and those not treated according to the guidelines in the group
which should have received radiotherapy. However, it cannot be concluded from this finding
that postoperative radiotherapy does not play a role in the prevention of local recurrence.
The patients who did not receive radiotherapy, despite the fact that they were entitled to it
according to the guidelines, might have done better if they had received radiotherapy, and
the local recurrence rate in the group of patients who received radiotherapy might have
been higher if these patients had not received any further treatment.
In the Uppsala trial it was shown that a short course of preoperative radiotherapy resulted
in better local control compared to postoperative radiotherapy.46 One explanation for the
success of the preoperative radiotherapy is that a radiobiological high dose is given in a
short overall time followed by immediate surgery. In our study and in most postoperative
radiotherapy studies, treatment ideally starts within 6 weeks and lasts for 5-6 weeks. This
long overall treatment time might lead to regrowth of residual tumour. Another explanation
for the better results of short-term preoperative radiotherapy is better compliance for
preoperative radiotherapy compared to that of postoperative radiotherapy. In the Uppsala
trial, 16% of the patients who should have been referred to postoperative irradiation did not
receive radiotherapy, usually due to problems with postoperative recovery. The non-
compliance for the preoperative short-term radiotherapy scheme was only 0.5%.46 Within
our study, we will investigate the reasons for violations to the postoperative radiotherapy
protocol in an additional medical record check.
The objective of this study was to complete an inventory of local recurrence rate after
curative non-standardised surgery for rectal cancer. This study was set up prior to the
initiation of a nation-wide trial. Since January 1996, surgeons, radiotherapists, and pathologists
have been involved in a prospective randomised trial “Total mesorectal exision (TME) with
or without preoperative radiotherapy in the treatment of primary rectal cancer”.47 In this
trial, surgery, radiotherapy, and pathology are standardised. At present, 1278 patients have
been randomised from a large number of hospitals in The Netherlands and several hospitals
in other countries. This trial will hopefully result in a low local recurrence rate and provide
an answer to the question of whether preoperative short-term radiotherapy is still beneficial
in the treatment of primary rectal cancer when standardised TME-surgery and pathology
are applied.
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Until a few years ago, results after curative surgery for rectal cancer were not optimal,
reflected in high local failure rates.1-3 The basic conventional procedure involving blunt
dissection, has been shown to result in an incomplete removal of mesorectal tissue, with a
high risk for local failure and damage to the autonomous pelvic nerve plexus, resulting in a
high incidence of sexual4,5 and bladder dysfunction.6 Lack of improvement in the surgical
results of rectal cancer has prompted many investigators to seek different adjuvant therapy
approaches in conjunction with surgery.
In several studies, the benefit of radiotherapy (RT) in the treatment of rectal cancer has
been suggested. In a large prospective Swedish trial it was shown that preoperative
hypofractioned radiotherapy results in better local control than postoperative radiotherapy.13
The role of chemoradiotherapy or chemotherapy (CT) as sole treatment still has to be
determined. The Netherlands Adjuvant Colorectal Cancer Project (NACCP) did not show
an effect of chemotherapy in rectal cancer.14 In the United States the opinion is that all
patients with a Dukes’ B or C lesion should have postoperative chemoradiotherapy.15
Chemo(radio)therapy is not routine in Europe and is still considered investigational therapy
in rectal cancer.
Improvement in survival with radiotherapy alone was not demonstrated until the Swedish
Rectal Cancer Trial (SRCT).7 This was the first randomised study to demonstrate a significant
survival benefit in patients receiving preoperative radiation (compared with surgery alone).
In recent years, local control and survival have been further improved by the introduction
of total mesorectal excision (TME) surgery, as first described by Heald.8-10 With this technique,
less morbidity4,11,12 and a reduction in abdominoperineal resections have also been reported.10
A major problem of published studies on adjuvant therapy in the treatment of primary
rectal cancer is that surgery has not been standardised in these studies. Moreover, the
surgeon remains an important factor in the accomplishment of tumour control and reduction
of morbidity.16-18 Therefore, the effect of adjuvant therapy can only be studied when strict
standardised and quality-controlled surgery is performed.
Optimal quality control of the surgical procedure must also include a standardised
examination by pathologists.19-20 Detection of mesorectal spread requires systematic
examination of the specimen, by serial sectioning of the whole tumour and the surrounding
mesorectum in the transverse plane. This method can be used to monitor differences in
operative technique. Furthermore, standardised surgery can be documented photographically,
due to reproducible gross specimen features.21
In Europe, TME has become the preferred standard of operative management for rectal
cancers.22 Current clinical trials examining the role of adjuvant therapy in patients who are
undergoing standardised operations are now setting the standard of surgical care in several
European countries. We studied European trials in which TME-surgery is intentionally
performed. Trials were classified in neoadjuvant and adjuvant trials. Furthermore a subdivision
was made according to short- and long-term radiotherapy. Most of these trials are still in
progress and have short follow-ups, so definitive results cannot be presented yet, apart
from feasibility and interim analyses.
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NEOADJUVANT TRIALS, SHORT-TERM PREOPERATIVE RADIOTHERAPY
TME-trial, Dutch ColoRectal Cancer Group (DCRCG)
In this trial, patients with resectable rectal cancer underwent standardised TME surgery
alone, or patients received preoperative radiotherapy (5x5 Gy) followed within 10 days
after the start of radiotherapy by TME.23 Table 1 shows the characteristics of this trial and
the other trials described.
TME was performed according to strict and controllable quality demands. An extensive
structure of workshops, symposia, and instruction videos helped to accomplish this goal.
In addition, a monitoring committee of specially trained instructor-surgeons was formed
for on-site instructions to optimise quality. R.J. Heald, W.E. Enker and Y. Moriya were
involved as operating surgeons in different hospitals in The Netherlands and as instructors
at several workshops about the trial. Pathological examination was done according to the
protocol of Quirke.19,20 Special training courses were given to pathologists. A pathology
review panel and a trained quality manager guaranteed quality control.
Taking into account an ineligibility rate and an R1-resection percentage of 25%, it was
calculated that 1400 Dutch patients had to be randomised in order to detect a difference of
5% in local recurrence rate (LR) between the R0-patients in the TME alone group (LR
10%) and R0-patients in the RT-group (LR 5%).
From January 1996 until January 2000, 1861 patients were randomised; 1530 patients
from 84 Dutch hospitals and 331 patients from 24 hospitals in other countries (mainly
Sweden). The European Organisation for Research and Treatment of Cancer (EORTC)
participated in the TME-trial under trialnumber 40971, in order to assure quality control of
surgery for the EORTC-GastroIntestinal (GI) group.
Of the patients randomised to receive preoperative radiotherapy, 87% received it at the
correct dose and were operated within 10 days after its inception. In total, 37% of the
operations were attended by instructor-surgeons; in the first quarter, most operations (89%)
were supervised by instructor-surgeons. Later on, this percentage decreased to 19% in the
last quarter of the trial. Only perioperative blood loss was significantly higher in irradiated
patients, and the perineal wound dehiscention rate was higher in irradiated abdominoperineal
resection (APR)-patients.24 The clinical leak rate was 12% in the low anterior resection
(LAR)-group, with no difference between the randomisation groups. In the LAR-group,
temporary stomas were constructed in 57% of the patients. The percentages for side-end
anastomosis and pouch construction were 60% and 28%, respectively. From this trial it
can be concluded that performing a large, multicentre trial with quality control of surgery is
feasible. The accrual of the trial has been very good, and short-term preoperative radiotherapy
was also demonstrated to be safe in combination with TME-surgery.
In a recent study by Nagtegaal et al.,25 it was shown that pathology data need to be
based on pathology reports and controlled by trained quality managers. A retrospective
comparison of pathology data case record forms with hospital pathology reports was
performed using the data from 300 patients from the TME-trial. Successive rounds of
quality control appeared to be required for accuracy and completeness of pathology data.
The overall local recurrence rate up to 1 July 2000 (median follow-up 20 months, range
0.3-48.5 months) was low: 7% in the operated-upon with curative intent group (R0+R1)
and 5% in the R0-group. The role of preoperative radiotherapy in combination with
standardised TME-surgery is not known yet, because follow-up has not been completed.
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Medical Research Council (MRC) CR07 trial
The aim of this trial is to address the following question in operable rectal cancer: Are local
recurrence-free rates and quality of life optimised by giving all patients short-course
preoperative radiotherapy, or is it preferable to give postoperative chemoradiotherapy only
to those at high risk of recurrence (i.e. with involved margins following surgery)?
Randomisation is done for preoperative radiotherapy of 5x5 Gy and selective postoperative
radiotherapy of 25x1.8 Gy; if randomised for this arm patients with involved circumferential
margins receive chemoradiotherapy. Adjuvant chemotherapy can be given as per local policy
to these patients, but also to other randomised patients.
Although the aim of the operation is to achieve complete local excision of the tumour,
the performance of a formal total mesorectal excision is left to the surgeon’s discretion. All
specimens are assessed by the local pathologist using the procedure of Quirke and Dixon19
and Quirke et al.20 Pathologists had to attend a training day, and a network of regional
pathologists (including P. Quirke) has been established to handle any queries, and to provide
further pathology training if required. A system of quality assurance was implemented to
ensure uniformity of pathological reporting.
The trial is designed to show that there is less than a 5% difference in local recurrence
rates at 2 years. This will require the randomisation of approximately 1800 patients.
The trial started in March 1998, and up to July 2000, 375 patients have been randomised
from 46 centres in the UK, including South Africa and New Zealand. From an interim-
analysis, it appeared that anastomotic leak rate is 10% in the LAR-group. Of the patients
randomised to receive preoperative radiotherapy, 88% received it at the correct dose. Over
80% of patients in the postoperative arm with involvement of the circumferential margin
received postoperative radiotherapy, 75% at the dose stated in the protocol.(newsletter
MRC CR07, Spring 2000)
Stockholm IV trial
The aim of this study is to compare preoperative radiotherapy treatment with “conventional”
fractionation (25x2 Gy) with treatment of 5x5 Gy, and to study a possible effect of different
time intervals between the end of radiotherapy and surgery in operable rectal cancer. The
main questions to be addressed are: A) Is preoperative radiotherapy given during 5 weeks
with a conventional fractionation (25x2 Gy) followed by surgery after 4-8 weeks (arm 1)
preferable to treatment with 5x5 Gy during one week followed by surgery within a week
(arm 2) or after 4-8 weeks (arm 3)? B) Are there any clinically significant differences in the
rate of local recurrence, survival time, postoperative morbidity and mortality, or late morbidity?
C) Is the need of a permanent stoma less if the surgery is delayed?
Some centres and some patients will likely not accept the first randomisation arm, due
to long treatment time. In these situations patients may be randomised only between the
second and third arms.
Specimen-oriented surgery with total or partial mesorectal excision according to Heald
is performed in the trial. In Sweden, introduction of TME was done on a general basis
several years ago.10,26 In addition, the protocol of Quirke was introduced and taught to
pathologists.10 In the Stockholm IV trial, the surgical specimen is judged according to this
protocol.
Total accrual will be 840 patients. When 300 patients have been included and followed
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for at least 2 years in the two-armed comparison, an interim analysis regarding cumulative
local recurrence will be undertaken.
This study started in 1999 and up to 1 July 2000, 50 patients have been randomised.
NEOADJUVANT TRIALS, LONG-TERM PREOPERATIVE RADIOTHERAPY
Chirurgische Arbeitsgemeinschaft fur Onkologie (CAO)/Arbeitsgemeinschaft
Radiologische Onkologie (ARO)/Arbeitsgemeinschaft Internistische Onkologie
(AIO), Rectal Cancer Study
In this trial, patients with advanced rectal cancer (uT3/4 or uN+ or Mason III/IV) are
randomly assigned to pre- or postoperative radiochemotherapy: 50.4 Gy are applied to the
pelvis. 5-fluorouracil (FU) is administered concomitantly as 120h-continuous infusion. Four
cycles of 5-FU maintenance chemotherapy are applied. Radiochemotherapy is identical in
both arms except for a small-volume boost of 5.40 Gy in the postoperative setting. The
time interval between radiochemotherapy and surgery is 4-6 weeks in both arms.
Techniques of surgery are standardised and total mesorectal excision is mandatory for
lesions in the lower and middle parts of the rectum. The pathology examination is done
according to standardised procedures that were established by P. Hermanek.
A decrease in local recurrence rate is expected from 15% to 5-10% in the arm with
preoperative radiochemotherapy vs. the arm with postoperative therapy. Furthermore a
survival advantage of 5-10% is expected, with no difference in, or even lower toxicity. In
total, 680 patients must be randomised in order to detect these differences.
Regular study meetings are held twice a year with review of patients charts including
surgery and pathology reports and data of radiochemotherapy, to ensure quality control.
This trial started in the summer of 1994, and up to 1 July 2000, 597 patients have been
recruited from 26 participating institutions. Accrual of the trial will probably close in December
2000, when more than 800 patients will have been randomised. From an interim-analysis it
was concluded that accrual of the trial is going well and that neoadjuvant radiochemotherapy
is tolerated excellently and bears no higher risk for peri- and postoperative morbidity.27
EORTC 22921
This trial is conducted by the EORTC Radiotherapy Group and evaluates in a four-arm
randomised study the effects of combining 5-FU/leucovorin (LV) with preoperative irradiation
(45 Gy) vs. radiotherapy alone (45 Gy), and of postoperative 5-FU/LV vs. no adjuvant
therapy in patients with resectable T3/4 adenocarcinoma of the rectum.
The surgical procedure should be performed as soon as possible 3-10 weeks after
preoperative treatment in both arms. It is advised to perform a total dissection of the
mesorectal fat in any case. In the trial pathological examination is not strictly performed
according to Quirke. However, on the pathology form information is asked about the status
and quality of the circumferential margin.
In a previous study of the EORTC-GI group using preoperative irradiation, the 5-year
survival was 52% in clinically selected patients. The minimal clinically significant survival
difference of interest is 10%. If it is assumed that 25% of the randomised patients will
become potentially ineligible, a total of 992 patients have to be entered.
Quality control procedures take place by means of audits of the Radiation Physics Quality




This trial started in April 1993 and up to 1 July 2000, the accrual was 759 patients.
ADJUVANT TRIALS
Study 92/157-004
Randomised phase III studies for a direct comparison of 5-FU/LV + monoclonal antibody
(mAb) 17-1A vs. 5-FU/LV in colon cancer are completed, but not yet analysed for outcome.
A comparable study for rectal cancer has not been conducted yet. Therefore, the 92/157-
004 study was set up by the Austrian cooperative group. The objective of this study is to
assess the efficacy of preoperative radiotherapy in combination with postoperative
chemotherapy or postoperative immuno-chemotherapy.
At first all patients were treated with 10x2.5 Gy (5 days of 2x2.5 Gy) preoperative
radiotherapy followed by surgery. The rationale for this scheme was the fear of side effects
with the larger single dose of 5 Gy. After surgery, Dukes’ B or C tumour patients were
randomised between 5FU/LV vs. 5-FU/LV/mAb 17-1A. This trial has in the meantime been
amended. Investigators are allowed to choose prolonged fractionation in order to permit
inclusion in the study of patients whose tumours at presentation are felt to be unresectable
(and those who have a bulky, but resectable tumours). Operable tumours at presentation
may receive either short or prolonged fractionation radiotherapy according to individual
practise.
In carcinoma of the middle or lower third of the rectum, the mesorectum should be
removed completely, laterally as well as caudally, up to the visceral pelvic fascia of the
pelvic floor. Pathological examination is done according to the protocol of Quirke.
The study is designed to detect a difference in 5 year survival from 70% for chemotherapy
alone, as compared to 80% for chemotherapy plus mAb 17-1A. Total accrual is calculated
to be 700 patients, with 350 patients per arm.
This trial started in July 1997 and accrual up to 1 July 2000 was 278 patients.
PROCTOR-trial, Dutch ColoRectal Cancer Group (DCRCG)
The successor to the TME-trial is the PROCTOR-trial (Preoperative Radiotherapy and/Or
adjuvant Chemotherapy combined with Tme-surgery in Operable Rectal cancer). In this
trial, the role of adjuvant chemotherapy (5FU/LV) is investigated in combination with
standardised TME-surgery and pathology. Randomisation for preoperative short-term
radiotherapy is continued in the PROCTOR-trial, but hospitals can also choose for an own
policy of yes/no preoperative radiotherapy, until the outcome of the TME-trial is known.
After surgery and pathological examination, TNM-stage II or III, R0 patients are randomised
for chemotherapy with 5FU/LV or observation. The setup for this trial is the same as that
for the TME-trial.
The overall survival in the arm treated without chemotherapy is expected to be
approximately 60%. Assuming an improvement in overall survival from 60% to 70% in the
arm with chemotherapy, 500 R0, TNM-stage II or III patients are needed per arm.
The PROCTOR-trial has been accruing patients since April 2000; up to 1 July 2000,
eight patients have been randomised.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The outcome after surgery for rectal cancer differs markedly between patients series,
regarding both local recurrence rates and survival. A high incidence of local recurrence is
associated with conventional, nonstandardised procedures.1-3 To improve the results of
surgery, various additional treatments, such as radiotherapy, chemotherapy, and
immunotherapy, have been tested.
The Swedish Rectal Cancer Trial was the first trial to show that better local control
achieved with preoperative radiotherapy resulted in improved survival.7 The results found
in this trial confirmed the studies from P. Hermanek, which showed a clear correlation
between survival and local recurrence rate.18 This can be explained by the fact that the
disease recurs locally first and then disseminates to other organs in 20-30% of all patients
with a recurrent rectal cancer.
In recent years local control and survival have been further improved by the introduction
of the TME-technique, as first described by Heald.8-10 TME is accomplished by precise
sharp dissection within the true pelvis around the integral mesentery under direct vision,
enveloping the entire mid-rectum, with preservation of the hypogastric plexus.
The studies published so far on adjuvant therapy have been carried out without any
adequate definition of the surgical procedure and without appropriate quality control. In
none of the cases were explicit details given of the procedure applied, together with the
criteria to be met with respect to safety margins, excision of mesorectum and lymph node
dissection. Local recurrence rates in the “surgery alone” control groups of former trials
were often high; 20% or more.7,29-33 Therefore, it is necessary to determine whether a
further improvement can be obtained by adjuvant therapy, given the currently achievable
global local recurrence rates of less than 10% by standardised TME-surgery alone. If optimal
TME-surgery can be widely implemented, outcome improvement could, by the calculations
of Hermanek, be four times as great as that achievable by adjuvant therapy, and at a fraction
of the cost.
In this work an overview is given on European trials in which TME-surgery is intentionally
performed. Most of these trials are still in progress and have too short a follow-up, so
definitive results, apart from feasibility and interim-analyses, cannot be presented yet. In all
trials described, TME-surgery is indicated, or at least advised, in low or middle rectal
cancers. However, the extent of surgical quality control differs between the trials. In Sweden
and The Netherlands, nation-wide projects have been conducted in which surgeons were
trained to perform a proper TME in an attempt to improve their treatment results. The study
of Martling et al.10 showed that local recurrence rate decreased by more than 50% as a
result of a surgical teaching initiative in the county of Stockholm. The effect of the
introduction of TME-surgery with quality control on outcome of rectal cancer was also
investigated in The Netherlands. We compared results from Dutch patients in the TME-trial
with results from a former randomised trial (CRAB-trial), in which conventional surgery
was performed without quality control. It was found that the introduction of TME-surgery
with quality control led to a substantial decrease in local recurrence rate and cancer death in
The Netherlands.(paper submitted)
Besides better local control and survival, sharp TME-dissection has been associated
with a higher incidence of sphincter preservation and pelvic autonomic and plexus
preservation, avoiding both colostomy and impotence, as well as blood transfusions.4,11,12
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The proportion of abdominoperineal resections has come down from 35% or more1,34,35 to
30% or less in recent years.10,23 However, one adverse effect of the higher rate of sphincter-
preserving procedures may be a higher rate of anastomotic leakage.36 Hi her leak rates with
TME-surgery as compared to conventional surgery, have been reported.9,37 Several
conventional surgery studies report overall anastomotic leak rates between 0% and
17.4%.35,38,39 The clinical leak rate of 12% in the Dutch TME-trial and 10% in the MRC
CR07 trial are quite high, but within this range. Perhaps the construction of a high number
of temporary colostomies and side to end anastomoses or pouches, have prevented increased
clinical leak rates.40-42
Due to the extreme disability caused by local failure, a gain in local pelvic control per-se
is generally accepted as a main objective of any adjuvant treatment.15 In terms of tumour
biology, preoperative radiotherapy is preferred to postoperative radiotherapy because the
tumour cells before the operation have a higher oxygen saturation and are therefore more
sensitive to irradiation. Furthermore, preoperative radiotherapy devitalises tumour cells that
may be dispersed in the course of the operation. Preoperative radiotherapy over several
weeks results in “down-staging” in many cases, i.e. the size of the primary tumour is
reduced, the possibility of lymph node metastases is reduced, and in isolated cases complete
remission occurs.29,43 The timing dose and fractionation of preoperative radiotherapy in
combination with TME-surgery are currently under investigation in the Stockholm IV trial.
One advantage of postoperative radiotherapy is that it allows the exclusion of patients
with tumours in stages Dukes’ A or D. To be effective, postoperative radiotherapy should
begin within 4-6 weeks of the operation to prevent tumour cell proliferation in the
postoperative fibrous, hypoxic tissues. However, at this point many patients have not yet
recovered from the operation and therefore, there is often a delay before they receive the
adjuvant radiotherapy.13,44 In the MRC CR07 trial, the compliance of patients in the
postoperative radiotherapy arm was lower than in the preoperative short-term radiotherapy
arm. Therefore, higher compliance rates of the short-term preoperative radiotherapy regimen
(compared to the postoperative radiotherapy plan), as shown in the Dutch TME and MRC
CR07 trials, could explain the better results.
The probability of resistant cell lines may be smaller when irradiation is combined with
chemotherapy and when these are given earlier in the disease, i.e. sooner in the treatment
plan. Concurrent 5FU may have a sensitising effect on the radiotherapy. However, the role
of chemoradiotherapy in the treatment of primary rectal cancer still has to be determined.
In the United States the opinion is that all patients with a Dukes’ B or C lesion should have
postoperative chemoradiotherapy.15 Chemoradiotherapy is not routine in Europe and is still
considered investigational therapy in rectal cancer. The CAO/ARO/AIO and EORTC 22921
trials are ongoing to determine the role of chemoradiotherapy in combination with TME-
surgery.
In the Dutch NACCP-study, chemotherapy as sole treatment showed no effect in
combination with conventional surgery in the prevention of distant recurrences and
improvement of survival.14 This may in part be explained by the high rate of local recurrence,
which might have masked the beneficial effect of chemotherapy. The role of chemotherapy
has never been tested in combination with standardised TME-surgery, but is now under
investigation in the PROCTOR-trial. The efficacy of preoperative radiotherapy in combination
with postoperative chemotherapy or postoperative immuno-chemotherapy is currently being
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investigated in the Austrian 92/157-004 study.
For optimal quality control of the surgical procedure standardised examination by
pathologists is important.19,20 In all trials, the circumferential margin was included for
investigation. However, the protocol of Quirke was not used in all trials. In the Dutch, MRC
CR07 and Swedish trials, this protocol has been used in combination with extensive
pathological quality control.
The Dutch TME trial is one of the first trials in which the effect of adjuvant therapy in
combination with TME surgery was evaluated. Standardisation of surgery, radiotherapy,
and pathology were achieved. The accrual progressed swiftly and the trial was shown to be
quite feasible. The design of the TME-trial has already resulted in a large reduction of the
number of local recurrences. The first results on the role of preoperative radiotherapy in
combination with standardised TME-surgery are presented at a large congress in April
2001 in The Netherlands (www.colorectal2001.com). Results of the other European TME-
trials will take longer.
An effort will be made to achieve further standardisation and quality assurance of
diagnostics in the PROCTOR-trial. Based on the data of the TME-trial, 20% of the cases
with primary rectal cancer underwent an irradical resection either defined as an R1
(microscopic tumour left behind) or R2 (macroscopic tumour left behind) resection. Better
selection of patients for preoperative radiotherapy in case of a locally advanced tumour or
palliative procedures in patients with disseminated disease can be achieved by preoperative
staging of rectal cancer with the routine use of a spiral computed tomography scan.
CONCLUSIONS
During the past decade, it has been clearly demonstrated that adjuvant treatment has the
potential of improving not only prognosis in terms of local recurrence, but also in terms of
overall survival. However, the question has yet to be answered as to whether in combination
with TME-surgery, adjuvant therapy is capable of achieving any further improvement in
outcome. In Europe, mesorectal excision, with its persistent decline in local recurrence
rates, has become the new standard of operative management for rectal cancers, replacing
conventional resection technique.22 Current clinical trials examining the role of adjuvant
therapy in patients who are undergoing standardised operations, are now setting the standard
of care in several European countries.
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In the treatment of rectal cancer local recurrences are a major problem and the rate varies
between 15% and 45%.1-4 Local recurrences cause severe disabling symptoms and are
difficult to treat. In order to reduce local recurrence rates after curative surgery, additional
radiotherapy has been given either preoperatively5-14 or postoperatively.4,15-18 In a large Swedish
trial short term, preoperative radiotherapy resulted in better local control than postoperative
radiotherapy (13% vs. 22% local recurrences).5 All trials with short-term preoperative
radiotherapy show lower local recurrence rates in the radiotherapy arm.7,12,13,19 Results of
the Swedish Rectal Cancer Trial (SRCT) even showed an improved overall survival with
the short term 5x5 Gy regimen compared to surgery alone, with 58% 5-years survival in
the irradiated group versus 48% in the non-irradiated group.14 However, this beneficial
effect of preoperative radiotherapy was observed in combination with conventional surgery.
This conventional procedure implies partially blunt dissection of the rectum along the
presacral fascia, resulting in incomplete removal of mesorectal tissue. This possible residue
of tumour cells was a logical rationale behind application of radiotherapy. The
acknowledgement of the important role of circumferential margin involvement in the
appearance of local recurrences in rectal cancer has led to the general introduction of total
mesorectal excision (TME) surgery, as advocated by Heald20 an  Enker.21 The main principle
of this technique is to achieve a radical resection by sharp dissection within the true pelvis
around the intact mesorectum under direct vision, thus enveloping the entire midrectum
with the tumour. This technique has shown to reduce the number of local recurrences
significantly in retrospective series.22 A second beneficial effect of TME surgery is the
possibility to preserve the autonomic pelvic nerve plexus, resulting in less bladder dysfunction
and less sexual morbidity.23,24
To answer the question whether preoperative radiotherapy is still beneficial in TME
treated patients a randomised, prospective international multicentre trial was conducted
under the auspices of the Dutch ColoRectal Cancer Group (DCRCG) to compare the effect
of preoperative, hypofractionated radiotherapy combined with TME surgery with TME
surgery alone.25 Any benefit regarding a reduced local recurrence rate and possible improved
survival must be weighed against potential adverse effects in both the short- and the long-
term. Several trials with preoperative, short-term radiotherapy have shown that preoperative
5x5 Gy followed by surgery within one week is a safe procedure.12,26-28 In these studies
however, the preoperative radiotherapy was combined with conventional surgery.
The present study was undertaken to assess the side effects of short-term, preoperative
radiotherapy in rectal cancer patients operated with the TME surgical technique and to
study the influence of 5x5 Gy on surgical parameters, postoperative morbidity and mortality
in patients randomised in the TME trial.
METHODS
Study population
From January 1996 until December 1999, 1861 patients were randomised to preoperative
radiotherapy followed by standardised TME surgery or to TME surgery only in a large
international multicentre trial.
Patients entering the trial were required to have biopsy confirmation of a rectal
adenocarcinoma, resectable tumours as judged by clinical examination, tumours with the
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inferior margin within 15 cm of the anal verge and no hereditary colorectal cancer syndrome.
Distant metastases had to be excluded by chest X-ray and ultrasound or CT scan of the
liver. Patients in whom previously a malignancy was diagnosed were not included in the
study. The World Health Organisation (WHO) performance score had to be less than or
equal to two. The patient had to give written or oral informed consent, depending on local
hospital regulations.
Stratification took place for institute of surgery and expected type of resection, i.e.
Abdomino Perineal Resection (APR) or Low Anterior Resection (LAR). Balanced
randomisation lists with a block size of six were used for central randomisation at the
Datacentre in Leiden.
The majority of the included patients (1530) were from the Netherlands; the other 331
patients were included by Swedish, other European and Canadian co-investigators. For the
final analysis of the trial, all patients will be analysed. Since the Dutch follow-up has been
extremely thorough, data about the Dutch patients considering treatment characteristics,
toxicity, complications and mortality are very complete and checked by the study
coordinators. We therefore only included the Dutch patients in the current analysis.
Preoperative radiotherapy
Patients assigned to preoperative radiotherapy received a total dose of 25 Gy in 5 fractions
over 5-7 days. The prescribed dose was specified according to ICRU 50 guidelines.29 Th
clinical target volume included the primary tumour and the mesentery with vascular supply
containing the perirectal, presacral and the internal iliac nodes (up to the S1/S2 junction).
The recommended upper border was at the level of the promontory. The perineum was
included if an APR was planned, whereas the lower border was 3 cm above the anal verge
if the planned operation was a LAR. The treatment was delivered with three portals or with
a four-portal “box” technique, depending on the institutes’ preference.
Shielding of the lordotic area at the dorsum of the sacrum was recommended. The
protocol recommended a treatment time from Monday till Friday, with surgery on the
following Monday, Tuesday or Wednesday. In case treatment started on other days and
was interrupted during the weekend, the time between the first radiotherapy fraction and
the day of surgery was not to exceed 10 days.
In case of resection margins smaller than 1 mm or tumour spill during operation,
postoperative radiotherapy was mandatory for the TME only patients.
Treatment details were reported on a radiotherapy form and checked by a radiation
oncologist for inconsistencies.
Surgery
All patients underwent surgery according to the Total Mesorectal Excision principle, as
advocated by Heald.20 An extensive structure of workshops, symposia and instruction videos
ensured the instruction of this novel technique. In addition, a committee of instructor surgeons
was formed to optimise quality. In each participating hospital the first five TME procedures
had to be supervised by an instructor surgeon.
A surgery- as well as a post-surgery form, on which all operation characteristics, operative
and postoperative complications were recorded, was completed by the operating surgeon.
These forms were compared with the operation report and discharge letter by the surgical
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trial coordinator and checked for inconsistencies. Additional information was requested
when data were not clear or incomplete.
Pathology procedures
Standardised routine pathology examination was performed as described by Quirke et al.30
Pathologic information on the resected tumour was recorded by pathologists from the
referral hospital on a pathology case record form for all patients. A pathology quality manager
and a pathology review committee were installed to ensure constant quality of all pathology
data and procedures.31 Tumour staging was performed using the TNM classification.32
Side effects and complications
Radiation oncologists were asked to score acute side effects within 3 months from the start
of radiotherapy according to the Radiation Therapy Oncology Group (RTOG) scoring
system.33  In general, grade 0 represents no complaints, whereas grade 5 is any toxicity
leading to death. The RTOG system has no scoring system for acute neurological symptoms.
Since acute plexopathy was observed in the SRCT,34 we introduced a scoring system for
neurological complaints, with the following categories for painful buttocks or legs: 0: no
complaints, 1: mild or intermittent pain not requiring intervention, 2: moderate constant pain
requiring narcotics or adjustment of the treatment, 3: intractable severe pain or treatment
interruption. This scoring system was introduced in 1997, a year after the start of the trial,
explaining the missing data for patients randomised in 1996.
For the postoperative complications, all complications during the first admission were
taken into account and the following definitions were used.
Anastomotic leaks included those clinically apparent or after suspicion determined on a
contrast-enema. An abscess around the anastomosis was recorded as leakage. Since it is
very difficult to discriminate between perineal dehiscence or perineal wound infection these
complications were recorded as perineal wound complication. Rare complications were
classified as other. Two categories were used: moderate consisting of complications that
needed non-invasive treatment or se ious defined as complications that required reintervention
or caused a prolonged hospital stay.
Hospital death was defined as any death occurring during first admission, whereas
postoperative mortality was defined as any death occurring during the first 30 days after
the operation.
A reintervention was defined as any surgical procedure that took place in the operating
room after the initial operation during the first admission. Only the first reintervention was
taken into analysis. Elective procedures like removal of gauzes left behind during the initial
operation for bleeding or opening/closure of stoma were not considered as a reintervention.
Re-resections for positive margins were not considered as reinterventions.
Data collection and statistics
All case record forms were sent to the central data office in Leiden. After several checking
rounds, the data were entered in a database and analysed with SPSS statistical software
(version 9.0 for Windows, SPSS, Chicago).
Mann-Whitney tests were used to compare quantitative and ordered variables and Student’s
t-tests were used to analyse differences in normally distributed data between the two groups.
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Of the 1530 Dutch patients included in the trial, 116 turned out to be ineligible. Reasons for
ineligibility are recorded in Table 1. In some institutes, a CT-scan for treatment planning of
the radiotherapy was performed, leading to detection of metastasis or irresectability.
Consequently, more TME only patients turned out to be irresectable or metastasized during
the operation. Thus, 1414 patients remained evaluable: 695 in the radiotherapy group and
719 in the surgery alone group. Table 2 shows well balanced clinical and tumour
characteristics over both treatment arms. There was also no difference in the distribution in
TNM stages or in the percentage of patients with a positive circumferential margin.
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In the radiotherapy group, the following minor protocol violations occurred. Treatment
was not completed in 14 patients. The interval between the first day of radiotherapy and the
day of surgery exceeded 10 days in 11% of the patients (range 11-60). In 85 patients (12%)
the upper border of the treatment field was at the level of S1/S2 and in 6 patients the upper
border was at the level of L4 or L5 instead of the promontory. In 40 patients undergoing an
APR, the perineum was not included in the treatment field. All patients with minor protocol
violations were included in the analyses.
Radiotherapy was given with 3 portal fields in 75% of the patients and with four portal
fields in 25% of the patients. Fifty-three percent of the patients were treated in supine
position. Of the 322 patients treated in prone position, 92 (29%) were treated on a belly
board. The dorsal sacrum and lordotic curve was shielded in 90% of all patients.
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7% of the patients there was a grade 2 or 3 complication.
Acute transient neurological complaints were recorded in 53 patients, of which 35 had
grade 1, not requiring any intervention. In 2 patients the shielding was adjusted and the
upper border was lowered in 3 patients. In 13 patients treatment was interrupted due to
serious pain in the gluteal region or legs. Remarkably, of these 13 patients, 6 patients were
treated in one radiation institute. No relation with number of portals, upper border, treatment
position or shielding could be found. Due to the fact that the neurotoxicity score was
introduced in 1997, data about neurotoxicity are missing in 178 patients.
In four (<1%) patients other grade 3 toxicity was reported, leading to postponement of
the operation in two patients with thrombo-embolic complications. One patient required a
catheter due to urinary retention after the radiotherapy. The last patient had anal blood loss
2 months after radiotherapy and proctoscopy confirmed a proctitis.
The median interval between randomisation and surgery was 21 days in the radiotherapy
group and 14 days in the surgery group, indicating that postponement of surgery did not
occur more often in the radiotherapy group, since it was anticipated that radiotherapy
increased the treatment time by a maximum of 10 days.
Toxicity
During radiotherapy, any kind of side effect was reported in 26% of all irradiated patients
(Table 3). Nineteen percent was grade 1 toxicity, representing only minor complaints. In
<
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Operation time in minutes, blood loss in ml and hospital stay in days.
Surgery
Surgical characteristics
To evaluate whether preoperative radiotherapy influences operation procedures, surgery
characteristics are compared in Table 4. There was no significant difference in median
operation time or median hospital stay between both treatment arms. Total blood loss was
slightly increased (100 ml) in the irradiated (RT+) group (P<0.001). Subset analysis revealed
that the difference in median blood loss was mainly present in the LAR patients: 1025 ml in
the RT+ group vs. 800 ml in the non-irradiated (RT-) group (P<0.001), whereas median
blood loss in the APR patients was not significantly different over the treatment arms.
Of the patients planned to undergo a LAR operation, 9% in the RT+ group and 7% of the
patients in the RT- group underwent an APR. In APR patients, conversion to a sphincter
saving procedure took place in 20% of the irradiated patients and in 19% of the TME alone
group. A pouch reconstruction was done in 28% of the irradiated patients undergoing a
Table 3. Number of patients with radiotherapy toxicity.
RTOG grading
0 1 2 3
Skin 685 8 2 0
Gastrointestinal 605 75 14 1
Genitourinary 676 16 2 1
Neurological 464 35 5 13








LAR vs. 29% of the non-irradiated patients.
More RT+ patients received a temporary diverting stoma at the time of TME surgery
than RT- patients did (64% vs. 57%, P=0.05). Postoperatively, slightly more RT- patients
required a stoma due to complications, resulting in a not significantly different overall number
of temporary stomas in both groups (68% vs. 63%, P=0.2), as is shown in Figure 1.
Complications
There was no difference in the percentage of patients with complications during the operation.
Bleeding during operation occurred in 13% of the patients in both groups. In 8% of the
irradiated patients and in 7% of the non-irradiated patients, an unintended organ injury
occurred.
All reported postoperative complications are listed in Table 5. For most complications
there was no difference between the two treatment arms. The overall postoperative
complication rate was 48% in the irradiated group vs. 41% in the non-irradiated group
(P=0.008). This difference was mainly attributable to the difference in perineal wound
healing.
In APR patients, perineal wound complications were significantly increased in the
irradiated patients (29% vs. 18%, P=0.008), whereas there was no difference in the abdominal
wound complications. Application of an omentoplasty did not lead to a reduction in perineal
complications. In 40 irradiated APR patients the perineum was not included in the treatment
field. Seven of these patients (18%) had perineal problems, vs. 54 (31%) of the 174 patients
in which the perineum was included in the treatment field.
The percentage of LAR patients showing clinical leakage postoperatively was 11% (n=105)
and was not statistically different for irradiated and non-irradiated patients (11% vs. 12%).
Leakage was less common in patients with a diverting stoma (8% vs. 16%, P=0.001). In
patients with an end-end anastomosis leakage occurred in 16% of the LAR patients, whereas
only 9% of the patients with a pouch reconstruction experienced anastomotic failure. In
patients with a side-end anastomosis this percentage was 12%. There was no influence of
the distance of the tumour from the anal verge or age on the occurrence of leakage. Twenty
percent of the patients with leakage were treated conservatively, whereas 80% required a
surgical reintervention.
In total, 201 patients (14%) underwent one or more reinterventions with 103 patients in
the RT+ group and 98 in the RT- group. Indications for reinterventions are listed in Table 6.
No difference between the number of reinterventions in the LAR or APR patients was
observed.
Twenty-eight patients (4%) died in hospital in the RT+ group vs. 24 (3.3%) in the RT-
group (P=0.49). Postoperative mortality (<30 days) was 3.5% in the RT+ group vs. 2.6%
in the RT- group (P=0.38). There was a strong correlation between age and hospital death
(P<0.001, Figure 2). Causes of hospital death are given in Table 7. In the RT+ group 10
patients died of cardiac problems versus 3 patients in the RT- group (P=0.04). Anastomotic
leakage contributed to postoperative mortality in 12 patients (23% of all in-hospital mortalities).
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1   #
27
Any complication 336 48 297 41  *
#   P<0.05
*   P<0.01
** The numbers and percentages of the separate complications do not summate "any complication"
since some patients had more than one complication. They were registered for each separate
complication, but for "any complication" they were counted as one.
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Table 6. Indications reintervention.
RT+TME TME Total
Anastomotic leakage 23 31 54
Abscess 27 13 40
Bleeding 11 16 27
Abdominal dehiscence 8 13 21
Perineal complications 4 2 6
Complications stoma 3 4 7
Other complications surgery 6 6 12
Peritonitis or sepsis 7 2 9
Ileus 11 9 20
Other 3 2 5
Total 103 98 201
Table 7. Causes of hospital mortality.
RT+TME TME Total
Abscess 1 1 2
Anastomotic leakage 4 8 12
Bleeding 1 1 2
Perforation bowel 3 1 4
Complications mechanic ileus - 3 3
Necrosis bowel 2 2 4
Sepsis 1 2 3
ARDS 1 - 1
Cardiac 10 3 13
Pulmonary embolism 2 2 4
Pneumonia 3 1 4
Total 28 24 52
Figure 1. Percentage of LAR patients
with a diverting stoma per randomi-
sation group (P=0.12).
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DISCUSSION
The results of this study indicate that short-term, preoperative radiotherapy does not
complicate TME surgery, although there is a slight increase in complications in the
preoperatively irradiated patients.
Acute side effects of preoperative, hypofractionated radiotherapy include nausea, diarrhoea
and skin erythema. These side effects develop to some degree in most patients, but usually
resolve within a few weeks. In this trial, few early side effects for radiotherapy were
reported. This may be attributed to the fact that most patients were operated in the week
after radiotherapy and not seen by the radiation oncologist until several weeks after the
operation. By this time, most side effects will have resided.
Lumbosacral plexopathy was a major cause of concern in the Swedish Rectal Cancer
Trial (SRCT) since six patients developed long-standing pain and/or neurological symptoms
at the level of the lower lumbar plexus.34 These six patients all complained about pain during
the radiotherapy. An extensive study on dose distribution showed that these patients might
have received a higher dose (112%) at the level of the lumbar vertebrae, when the dorsal
shields were inappropriately placed.
In our study, 53 patients had pain or a feeling of discomfort in the legs or in the gluteal
region, of which 18 needed medication or treatment interruption. In these patients, a careful
evaluation of the treatment fields and the dorsal shielding was done and adjustments were
made in 5 patients. As precaution, treatment was interrupted in 14 patients. So far, with a
median follow up of 25.4 months, there are no reports of longstanding pain or neurological
symptoms. This might be attributed to the fact that the upper border of the radiation field
was defined as L5/S1, as opposed to mid L4 in the Swedish trials. This prevents the irradiation
of the lower dorsal lumbar roots.
Although there was initial concern that irradiation would hamper the operation, this was
not reflected in the parameters of the surgical procedure. There was no increase in the
duration of the operation and although the difference in blood loss was significant, an
increase of 100 ml is not a serious clinical problem. Irradiation did not influence the choice
of the surgeon to perform a LAR or an APR procedure.
The relatively high incidence of postoperative complications in our trial (45%) might be
explained by the great effort taken to meticulously register all possible complications. Apart
from data from the case record forms as recorded by the surgeon, data from operation
notes and discharge letters were taken into account as well. Similar complication rates were
reported in a prospective comparison of conventional and TME surgery.35
The mortality rate in the Stockholm I trial with 5x5 Gy was 2% in the RT- group vs. 8%
in the RT+ group.27 In the Imperial Cancer Research Fund (ICRF) trial where patients were
treated with 3x5 Gy, these percentages were 7% vs. 12%, respectively.7 The difference
could mainly be contributed to an increase in cardiovascular deaths, particularly in patients
aged over 75 years. Therefore, patients elder than 80 years were excluded from the Stockholm
II trial and the SRCT. The explanation for the increased mortality rates in the Stockholm I
trial and the ICRF trial is possibly the suboptimal treatment technique. In these trials, the
treatment was given by two opposed fields, which increases the volume treated with 25 Gy
considerably. Later trials therefore requested a three or four portal technique in order to
reduce the treated volume. In the SRCT 48 patients were treated with a two-portal technique
and those patients showed a higher mortality rate than the patients treated with three or four
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portals.26 In the Stockholm II trial there was no longer a difference in mortality within 30
days between the two treatment arms: 2% in the irradiated group vs. 1% in the non-irradiated
group. In-hospital mortality rates in the SRCT were 4% in the RT+ vs. 3% in the RT- group.
The in-hospital mortality rate in our trial showed no difference between the treatment arms
and was 4% in the RT+ group vs. 3.3% in the RT- group. This can be considered as a
satisfying result, taking into account that patients above the age of 80 were included in our
trial. Our results demonstrate that the introduction of TME surgery after preoperative
radiotherapy does not lead to an increase in the postoperative mortality rate, as long as at
least three portals are used for the radiotherapy.
The two major causes of postoperative mortality in our trial were cardiovascular problems
and complications due to anastomotic failure in LAR patients. Anastomotic leakage is a
major clinical problem in rectal or anal anastomoses. The reported clinical leakage rate after
anterior resection varies from 3% to 11%.36-39 Karanjia et al. showed that a diverting colostomy
is an important measure in reducing the complications of anastomotic leakage.37 After TME
surgery, an increase in serious anastomotic leakage has been reported as compared to
conventional surgery.35,40 This increase can be partly explained by the removal of the pain-
sensitive peritoneum, which prevents early detection of anastomotic failure.37 In our study,
the number of patients with clinical anastomotic leakage was 105 (11%). This is consistent
with other reports in which TME surgery was applied. It is particularly reassuring since
this trial was a large multicentre study, whereas most other reports concern single institution
experience. No difference in clinical leakage rate between the RT+ and RT- patients was
observed, which is in agreement with previous reports about preoperative radiotherapy.11,12,27,28
Since patients with a diverting colostomy developed fewer leaks, we recommend a diversion
in case there is any doubt about the quality of the anastomosis.
Increase in perineal dehiscence after preoperative RT has been observed by several
authors, both after short-term as well as after long-term preoperative radiotherapy. Although
results are difficult to compare, due to various definitions of perineal dehiscence, a twofold
increase is generally reported after RT.11,12,26-28 In our study, 100 patients suffered from
perineal complications with 18% in the RT- group vs. 29% in the RT+ patients. When the
perineum was not included in the target volume, there was no increase of perineal
complications as compared to the non-irradiated patients. However, avoidance of irradiation
of the perineum is not desirable in APR patients since this might lead to an increase in local
recurrences.
In conclusion, our results show that although application of short term, preoperative
radiotherapy in combination with TME surgery leads to an increase in overall postoperative
complication rate when compared to TME surgery alone, the number of complications
leading to reintervention or even mortality are similar in both treatment arms. Although
follow-up is too short to comment on the occurrence of late side effects, long term results
from the SRCT give no reasons for concern so far. Therefore, preoperative hypofractionated
RT is to be considered a safe procedure also in patients treated with TME surgery, despite
a slight increase in complications when compared to TME surgery only.
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Impact of surgical training on recurrence and survival in
rectal cancer
Analysis of rectal cancer patients from two prospective,
randomised trials in The Netherlands
E. Kapiteijn1, H. Putter2, C.J.H. van de Velde1 and cooperative investigators of the Dutch
ColoRectal Cancer Group (DCRCG)






In The Netherlands, 8000 new colorectal cancer patients were registered in 1995, of whom
about 25% had rectal carcinoma.1 A major problem in the treatment of rectal carcinoma is
local recurrence. In literature, the reported local recurrence incidence after curative resection
varies widely with high incidences of local recurrence with conventional, often bluntly
dissectioning, non-standardised procedures.2-4 In recent years local control and survival
have improved by the introduction of total mesorectal excision (TME) surgery.2,5-8 TME is
accomplished by precise sharp dissection within the true pelvis around the integral mesentery
under direct vision, enveloping the entire mid-rectum, with preservation of the hypogastric
plexus. With the TME-technique, also a reduction in abdominoperineal resections has been
achieved.7
Inter-institution and inter-surgeon variabilities in colorectal cancer surgery have been
shown in several studies. This applies to immediate results, such as surgical morbidity and
mortality,9-13 as well as long-term results, such as local recurrence and survival.4,9,14-18
Obviously, surgical technique is a critical factor for immediate outcome, as well as good
postoperative care. Disease-free and overall survival can be influenced by tumour-related
factors (stage, lateral margin involvement), treatment related factors (surgical technique,
adjuvant therapy) and patient-related factors (gender, age). The treating institution as well
as the individual surgeon can be further prognostic factors.
The Dutch ColoRectal Cancer Group (DCRCG) was installed to conduct trials in order
to improve outcome of colorectal cancer treatment in The Netherlands. In the Cancer
Recurrence And Blood transfusion (CRAB)-trial, colorectal cancer patients were randomised
between transfusion of leukocyte-depleted or buffy-coat-depleted blood between 1987 and
1990.19 In this trial, conventional surgery was performed without quality control. The
randomised TME-trial investigated the role of preoperative short-term radiotherapy in
combination with standardised TME-surgery in rectal cancer patients and was conducted
between 1996 and 1999. In the trial, TME-surgery was introduced on a nation-wide basis
and performed according to strict and controllable quality demands.
The aim of this paper was to assess the effect of the introduction of TME-surgery on
outcome of rectal cancer in The Netherlands. Therefore, we compared results from the
TME-trial with outcomes from the CRAB-trial. Furthermore the influence of hospital volume
was investigated in both trials. The role of specialisation was analysed by comparing outcomes




Between June 1987 and December 1990, colorectal cancer patients were randomised between
transfusion of leukocyte-depleted or buffy-coat-depleted blood and received blood transfusion
upon indication in the CRAB-trial. Eligibility criteria were: histologically or radiologically
proven, primary adenocarcinoma of the colorectum without clinical evidence of distant
metastases. In total, 1108 colorectal cancer patients were randomised from 16 Dutch
hospitals. Colorectal cancer recurrence rates were not influenced by blood transfusion;
however, blood transfusion resulted in more infections and affected overall survival by an
association with non-cancer death.19
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Rectal cancer affected 331 patients. A rectal tumour was defined as a tumour with an
inferior margin within 15 cm of the anal verge (as measured preoperatively during withdrawal
of a flexible endoscope). The CRAB rectal cancer patients had conventional, non-standardised
surgery without quality control. The procedure was considered to be curative when a
macroscopically local radical resection was performed in the absence of intraoperative
metastases. Of the 331 rectal cancer patients, 281 patients were eligible and curatively
operated. The pathology of the carcinomas was classified according to the TNM system.20
Patients received preoperative radiotherapy of 30 Gy in 10 days in case of large tumours
(T3-T4) in a few hospitals. Indications for postoperative radiotherapy of 45-60 Gy were
tumour spill during operation or Dukes’ Astler-Coller B2 and C tumours and positive margins.
Median follow-up of living patients in the CRAB-trial was 78 months (range 34-114).
The TME-trial
A phase III trial “Total mesorectal excision with or without short-term preoperative
radiotherapy in the treatment of primary rectal cancer” was conducted from January 1996
until December 1999. This trial evaluated the effect of 5x5 Gy preoperative radiotherapy in
combination with standardised TME-surgery and pathology.21 Patients were randomised by
Dutch, Swedish, other European and Canadian participants; however, this paper only
concerns Dutch patients. Clinically operable patients with a histologically proven, primary
adenocarcinoma of the rectum without evidence of distant metastases were eligible. In
total, 1530 patients were randomised from 84 Dutch Hospitals. The trial was shown to be
feasible; the only significant differences between irradiated and non-irradiated patients
concerned more blood loss and a higher perineal wound complication rate in abdominoperineal
resection (APR) patients in the radiotherapy group.21,22
The height of the tumour was defined preoperatively by its inferior margin as measured
at withdrawal of a flexible scope. An extensive structure of workshops, symposia, and
instruction videos helped to accomplish that TME was performed according to strict quality
demands. In addition, a monitoring committee of specially trained instructor surgeons was
formed for on-site instructions. TME was taught to surgeons who generally deal with
rectal cancer (1-3 surgeons per hospital surgical unit). In each participating hospital the
first five TME ‘s had to be supervised by an instructor surgeon. A curative resection was
defined as a macroscopically radical local tumour resection without intraoperative detection
of metastases. Of the 1530 patients, 1352 patients were eligible and curatively operated.
Pathological examination was performed according to the protocol of Quirke23 with
special attention for circumferential margin involvement, and the carcinomas were classified
according to the TNM system.20 Patients randomised for preoperative radiotherapy received
5x5 Gy. In patients having TME alone, postoperative irradiation of 50-60 Gy was mandatory
in case of tumour spill during surgery or tumour infiltration within 1 mm from the
circumferential resection margin. Median follow-up of living patients in the TME-trial was




We compared patients who were eligible and curatively operated by abdominal surgery to
enable homogeneity between the trials. Furthermore patients who had preoperative
radiotherapy were excluded from the analysis because the outcome of the TME-trial (=the
role of preoperative radiotherapy in combination with standardised TME-surgery) was not
known at the time of this analysis.
Of the 281 eligible rectal cancer patients curatively operated in the CRAB-trial, 9 patients
were excluded who received preoperative radiotherapy and 3 patients who underwent
polypectomy. In the TME-trial, 691 preoperatively irradiated patients were excluded. The
analysed numbers of eligible, curatively operated and preoperatively non-irradiated patients
were 269 patients in the CRAB-trial and 661 patients in the TME-trial.
Analysed short-term outcomes in both trials were operation time, blood loss during
operation, hospital stay, leakage, wound infection and 30-day mortality. The breakdown of
anastomotic integrity was defined on clinical grounds. Wound infection was defined as
either abdominal or perineal wound infection. Deaths within 30 days after surgery were
those which occurred postoperatively either in- or outside the hospital.
Long-term outcomes included local and distant recurrence and overall survival. Local
recurrence was defined as the presence of any anastomotic, pelvic, or perineal tumour, as
proven by histology or radiology. Distant recurrence involved evidence of tumour in any
other area than the pelvis. Overall survival concerned deaths of any cause, with and without
tumour, as event. To ensure valid comparisons, we analysed only events occurring within
2 years of surgery in both trials.
Hospital volume was determined per trial and based on the number of included eligible,
curatively operated, preoperatively non-irradiated patients treated in a certain hospital.
Furthermore the role of specialisation was analysed by comparing hospitals with instructor-
surgeons vs. hospitals without instructor-surgeons only in the TME-trial.
Statistics
Chi-square tests were used to compare proportions. Mann-Whitney tests were used to
compare quantitative and ordinal variables. Multivariate analyses of determinants of short-
term outcomes, including type of surgery (conventional (CRAB-trial) vs. TME (TME-
trial)), were done with the linear and logistic regression models. For long-term outcomes,
multivariate analyses were performed with the Cox proportional hazards model. Interaction-
terms of factors with type of surgery were included in the regression models to correct for
differences in the effect of factors between the trials. The effect of e.g. postoperative
radiotherapy (RT) in each trial might have been different since the indications for RT were
different between the trials.
Hospital volume was analysed as a continuous variable. For analysis of hospital volume
and specialisation all individual risks for an hospital with regard to short-term outcomes
were summated; the deviation of the expectation was calculated by subtracting the expected
complication rate (based on clinicopathological characteristics) from the observed rate.
The deviation was divided by the number of individuals for the hospital to obtain the crude
hospital effect. For long-term outcomes crude estimations of the hospital effects were
obtained by calculating the ratio of residual (observed minus expected=O-E) number of
deaths (or recurrence of disease) to expected (=E, based on clinicopathological
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Table 1. Eligible, curatively operated, preoperatively non-irradiated patients;
clinicopathological characteristics, univariate analysis, n (%).
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35   (5)
<0.001
* The inferior margin of the tumour was unknown in 59 patients in the CRAB-trial
   and in 3 patients in the TME-trial.
† Because of rounding, percentages may not total be 100.
characteristics) number of deaths (or recurrence of disease). An (O-E)/E ratio greater than
(less than) zero was an indication that an hospital was experiencing more (fewer) events
than would have been expected after adjustment for the burden of illness in that hospital
patient population. Subsequently, the crude estimates and standard errors of both short-
and long-term outcomes were used to analyse the effects of hospital volume and specialisation
by means of linear regression. By application of the empirical Bayes method,24 a more
realistic view on the results of especially, hospitals with low numbers of patients, was
obtained.
RESULTS
Clinicopathological characteristics (Table 1)
In the CRAB-trial significantly more female patients (P=0.002) and older patients (P=0.03)
were treated. More patients had postoperative radiotherapy (P<0.001) in the CRAB-trial,
while postoperative chemotherapy was more often applied in the TME-trial (P<0.001).
Tumour location, type of resection and TNM-stage did not differ between the trial-groups.
The variables in this table and their interactions with type of surgery were used in the





































11    (6)
n=432
51   (12)
0.046
Wound infection (abdominal or perineal)
-yes 21    (8) 61  (9)
0.49
Mortality < 30 days
-yes 12  (4) 16 (2)
0.10
*   Type of surgery was not an independent predictor for any of the short-term outcomes,
     including leakage.
** Postoperative deaths were included for analysis of hospital stay.
Short-term outcomes (Table 2)
Operation time, blood loss during operation and hospital stay did not differ significantly
between the two trials, although the difference in blood loss was of borderline-significance
(median 900 vs. 1000 ml, P=0.06). Clinical leakage was reported significantly more often in
the TME-trial (P=0.046), despite a higher number of temporary stomas in LAR-patients in
this trial (CRAB: 25% vs. TME: 55%, P<0.001). The rates for wound infection were 8%
and 9% and for 30-day mortality 4% and 2%, respectively in the CRAB vs. TME-trial; these
rates did not differ significantly between the trials. In the multivariate analysis, type of
surgery was not an independent predictor for leakage when corrected for case-mix.
Long-term outcomes (Table 3 and 4)
Local recurrence (P=0.002) and overall survival (P=0.002) at 2 years of surgery differed
significantly between the CRAB vs. TME-trial. No significant difference was found in
distant recurrence risk between the trials (P=0.86, Table 3). In the multivariate analysis
(Table 4), type of surgery was an independent predictor for local recurrence (hazard ratio
(HR) TME 0.017, 95% confidence interval (CI) 0.001-0.22, P=0.002, Figure 1), in addition
to TNM-stage (P=0.006). For distant recurrence (Figure 2), TNM-stage was the only
independent predictor (P<0.001). Type of surgery was also an independent predictor for
overall survival (HR TME 0.21, 95% CI 0.057-0.78, P=0.019, Figure 3), in addition to
TNM-stage and age. Interactions between factors and type of surgery were corrected for,
but not mentioned in Table 4 when a significant independent predictive value was found.
(9)
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Local recurrence risk after 24 months 16.3% 8.6% 0.002
Distant recurrence risk after 24 months 17.4% 17.1% 0.86
Overall survival after 24 months 77.0% 85.5% 0.002
In order to check whether there was a bias in the databases (data of the CRAB-trial were
more mature than those of the TME-trial due to longer follow-up), we repeated the multivariate
analysis for long-term outcomes separately for events occurring in the first year vs. those
in the first and second year. No major differences in size or direction of the Cox regression
coefficients were found between these analyses.
Table 4. Multivariate Cox regression model using the baseline characteristics of Table 1 as input
variables, including type of surgery, and long-term outcomes as outcome variables; only































































* Age was analysed as a binary variable; cut-off point was the median (66 yrs).
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Investigation of hospital volume and specialisation (Table 5)
Hospital volume did not have an effect on short-term outcomes in the CRAB- and TME-
trials. No effect of hospital specialisation was found either on short-term outcomes in the
TME-trial. For long-term outcomes however, higher hospital volume was significantly
associated with lower distant recurrence (P=0.006) and higher overall survival (P=0.011)
within 2 years in the CRAB-trial. The effect of hospital volume on local recurrence was of
borderline-significance (P=0.07) in the CRAB-trial. In the TME-trial, hospital volume did
not have an effect on local recurrence (P=0.57), distant recurrence (P=0.88) and overall
survival (P=0.65). Hospital specialisation was also not of significant value for long-term
outcomes in the TME-trial.
Figure 1. Kaplan Meier plot using local recurrence risk
as outcome variable, influence of type of surgery (Cox
model: HR TME  0.017, 95% CI 0.001-0.22, P=0.002).
Figure 3. Kaplan Meier plot using overall survival as
outcome variable, influence of type of surgery (Cox
model: HR TME 0.21, 95% CI 0.057-0.78, P=0.019).
Table 5. Multivariate Cox regression and empirical Bayes models; associations of hospital volume and
specialisation with long-term outcomes in the CRAB and TME-trials.*,**
Local recurrence risk Distant recurrence risk Overall survival
ß SE P ß SE P ß SE P
CRAB-trial
Hospital volume -0.046 0.022 0.07 -0.46 0.017 0.006 -0.037 0.014 0.011
TME-trial
Hospital volume -0.014 0.024 0.57 -0.0013 0.009 0.88  0.008 0.017 0.65
Hospital specialisation -0.49 0.35 0.17 -0.064 0.25 0.80 -0.093 0.26 0.72
*   ß=regression coefficient, SE=standard error.
** A negative ß means that lower volume or non-specialised hospitals did worse than higher volume or specialised
hospitals.
Figure 2. Kaplan Meier plot using distant recurrence
risk as outcome variable, influence of type of surgery

































































CRAB-tr ia l (n=269)
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DISCUSSION
The major problem in the treatment of rectal cancer is local recurrence. A high incidence of
local recurrence is associated with conventional, non-standardised surgical procedures.3,4
In recent years local control and survival have improved by the introduction of TME-
surgery.2,5-8 The aim of this study was to assess the effect of the introduction and training
of TME-surgery on outcome of rectal cancer by analysing data from two large, prospective
randomised trials performed in The Netherlands. In the CRAB-trial19 conventional surgery
was applied and in the TME-trial21 TME-surgery was introduced, quality-controlled by
specially trained instructor-surgeons.
This paper showed that introduction of TME has led to a substantial lower local recurrence
rate when analysing events within 2 years; 16.3% in the CRAB-trial vs. 8.6% in the TME-
trial. Type of surgery was an independent predictor for local recurrence in the multivariate
analysis. Before the start of the TME-trial there were doubts whether the excellent results
of specialised surgeons2,5,6 could be repeated in a large multicentre trial. With the low local
recurrence rate in the TME-trial, we conclude that good results can also be achieved in all
surgeons’ hands with thorough surgical instruction. It is remarkable that this result has
been achieved in a relatively short time (4 years) with a great number of surgeons participating
in the trial (n=213), especially since some surgeons performed only a restricted number of
TME-procedures. Our results are in concordance with the report of Martling et al.7 They
compared the Stockholm I and II randomised trials in which conventional surgery with or
without preoperative radiotherapy was performed, with the TME-project introducing the
concept of TME to surgeons in Stockholm, and found that 2-year local recurrence rates
had decreased from 14-15% to 6%.
Type of surgery also appeared to be an independent predictor for overall survival, with
a higher survival rate in the TME-trial. However, we have to be careful with this last
conclusion since follow-up of the TME-trial is not as mature as in the CRAB-trial. Type of
surgery was not associated with distant recurrence, which is in concordance with results
of Kockerling et al.25 Their and our data suggest that distant recurrence rate is independent
of the quality of surgery. This can most likely be explained by assuming that so-called
metachronous metastases were already present in the form of systemic minimal residual
disease at the time of primary surgery.
In addition to better results in terms of recurrence, the introduction of TME-surgery has
been reported to result in a reduction of abdominoperineal resections.7 H wever, we did not
find this reduction in our comparison of the 2 trials. In the univariate analysis, we found a
higher clinical leak rate in LAR-patients in the TME-trial, but this association was not significant
anymore when corrected for case-mix. Higher leak rates with TME-surgery as compared
to conventional surgery have been reported before.26,27 An additional analysis showed that
clinical leakage was related to postoperative mortality in both trials (P=0.024 and P=0.001
respectively), but no difference in 30-day mortality rate was found. This can be explained
by the great number of temporary stomas in the TME-trial (55%) which might have
prevented a higher mortality from leakage.28
The influence of hospital volume and specialisation was also investigated. Hospital volume
was analysed as a continuous variable; this approach has as advantage that when effects
are linear, differences come out more clearly than when choosing a cut-off point. In addition,
cut-off points are sometimes arbitrary; they should be defined prospectively to avoid biases
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inherent in post-hoc analysis (in which cut-off point can be selected to maximise volume-
outcome associations). Inter-institution and inter-surgeon variabilities in short-term outcomes
in colorectal cancer surgery have been shown in several studies.9-11,13 A study by Hannan et
al.12 showed that hospitals with volumes of 40 or fewer procedures for colectomies had
significantly higher standardised in-hospital mortality rates as compared to hospitals with
volumes higher than 40. No effect of hospital volume was found on short-term outcomes
in the CRAB- and TME-trials, nor was there any significant effect of hospital specialisation
in the TME-trial.
Several studies have investigated the effect of hospital volume on long-term outcomes.
However, findings in literature are controversial,4,14-16 with also one report suggesting that
hospital volume predicts clinical outcome for colorectal cancer, but not in the absolute
magnitudes in comparison with the variation observed for higher-risk cancer surgeries.29-31
In the CRAB-trial, hospital volume appeared to have a significant effect on distant recurrence
and overall survival. In the TME-trial hospital volume did not have an effect on any long-
term outcome. An explanation for the different findings in the CRAB- and TME-trials might
be that standardised TME-surgery with quality control was not performed in the CRAB-
trial, by which differences between hospitals came out to be significant. It is remarkable
however, that hospital volume in the CRAB-trial had mainly influence on distant recurrence
and not on local recurrence, although the association with local recurrence was of borderline-
significance. Perhaps differences in surgical factors related to distant metastasis (e.g. tumour
spill during surgery) might have influenced the association between hospital volume and
distant recurrence.
Several studies have investigated the influence of individual surgeon volume and
specialisation on outcomes.9,16-18 We could not analyse individual surgeon volume and
specialisation. In the CRAB-trial, no information was available on individual surgeons, while
in the TME-trial the effect of surgeon volume was not analysed since most operations were
performed by 2 surgeons, so individual surgeon analyses are difficult interpretable.
An advantage of analysing data of prospective trials, is that stringent follow-up, particularly
when chronic outcome is an end-point, is often present, whereas in retrospective analysis
these data are often absent. Nevertheless, some biases have to be ruled out concerning our
analyses. The CRAB- and TME-trials were performed during different time-periods with
different numbers of patients and follow-up periods. However, inclusion and classification
criteria were the same, data on outcome were collected in an equal uniform way, only
events within 2 years were analysed and we corrected for differences in clinicopathological
characteristics by means of multivariate analyses. Although we must admit that the data of
the CRAB-trial are more mature than those from the TME-trial, we consider minimal follow-
up time of 2 years sufficient since 55-80% of local recurrences present during the first 2
years with a peak at 6-12 months.17,32 In addition, no major differences in size or direction
of the Cox regression coefficients were found between the multivariate analysis for events
occurring in the first year vs. those in the first and second year. Besides surgical technique,
pathology data on circumferential margin involvement may also not be comparable between
the trials because pathology in the TME-trial specifically focused on this issue. Staging of
tumours however, was performed according to the same classification.20 Lastly, the question
can be raised whether our analysis represents developments in all parts of The Netherlands.
We think this is the case, since patients were randomised from hospitals throughout the
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whole country in both trials.
In general, it is thought that high volume and specialist care produces superior results to
low volume and non-specialist care, especially for those less frequent forms of cancer.
Centralisation in fewer hands seems also of importance in technically difficult operations,
like those for rectal cancer. The results of the CRAB-study support the idea of volume
being important in outcome in rectal cancer. However, limiting the performance of rectal
cancer surgery to those who work in specialised colorectal surgery centres or to only those
general surgeons who perform more than a certain volume threshold is impractical in view
of the prevalence of rectal cancer. The concentration process for patients with rectal
carcinomas can also be achieved within the individual clinic. This has been demonstrated in
the TME-trial, in which it is shown that training in TME-surgery to surgeons who diagnose
and treat rectal cancer (1-3 per hospital surgical unit), leads to improved outcome without
volume- or specialisation-related differences.
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Local recurrence is a serious problem in the treatment of rectal cancer, since it causes
disabling symptoms and is difficult to treat.1,2 There is a high incidence of local recurrence
(15 to 45%) after conventional surgery, in which blunt dissection of the rectal fascia often
fails to remove all the tissue that may bear tumour.3-5
In an attempt to improve local control and survival after conventional surgery, radiotherapy
has been given. The only randomised trial h t compared preoperative and postoperative
radiotherapy showed the superiority of preoperative radiotherapy for local control.6 The
Swedish Rectal Cancer Trial (SRCT) found that preoperative radiotherapy also improved
the rate of survival at five years.7 A recent meta-analysis8 concluded that the combination of
preoperative radiotherapy and surgery, as compared with surgery alone, significantly mproved
overall survival and cancer-specific survival.
The recognition that involvement of the circumferential margin by tumour cells is important
in local recurrences has led to the general use of total mesorectal excision,9-13 in which the
entire mesorectum is enveloped and resected by precise, sharp dissection. Improvements in
local control with this technique have been shown, mainly in retrospective series.9-12,14
In previous studies of radiotherapy for rectal cancer, surgery was not standardised.
Since surgical technique is a key factor in the success of tumour control,15-17 standardisation
and quality control with respect to surgery are indispensable for valuating the effects of
adjuvant therapy. Optimal quality must also include the use of standardised methods of
pathological examination.18 A prospective, randomised trial was organised by the Dutch
ColoRectal Cancer Group to investigate the efficacy of preoperative radiotherapy in
combination with standardised total mesorectal excision in patients with rectal cancer.19 In
this article, we present the results of the trial after a median follow-up of two years.
METHODS
Eligibility, randomisation and sample size
Patients were enrolled between January 1996 and December 1999. To be eligible, patients
had to have histologically confirmed a enocarcinoma of the rectum, without evidence of
distant metastases, and the inferior margin of the tumour had to be located not farther than
15 cm from the anal verge and below the level of S1–2. Patients with fixed tumours or
tumours that were treated by local (transanal) resection were excluded. Patients with previous
or coexisting cancer and those who had previously undergone large-bowel surgery,
chemotherapy or radiotherapy of the pelvis, were also excluded.
After informed consent had been obtained, we randomly assigned the patients to treatment
with preoperative radiation (5 Gy on each of five days) followed by total mesorectal excision
or to total mesorectal excision alone. Randomisation was performed at the central trial
office and was based on permuted blocks of ix, with stratification according to centre and
the expected type of operation (low anterior resection or abdominoperineal resection). The
trial was approved by the medical ethics committees of all the participating hospitals. The
trial design and the calculation of the sample size have been described in detail elsewhere.19
Follow-up
Clinical evaluation every three months during the first year afte  surgery and yearly thereafter
for at least two more years was mandatory and included yearly liver imaging and endoscopy.
Local control with preoperative radiotherapy and TME
91
Local recurrence was defined as evidence of a tumour within the lesser pelvis or the perineal
wound. Distant recurrence was defined as evidence of a tumour in any other area. Recurrence
at the colostomy site or in the inguinal region was also classified as distant recurrence.
Quality control
In The Netherlands, participating surgeons attended workshops and ymposiums, saw
instructional videotapes, and were monitored by specially trained instructor surgeons. At
each hospital, the first five total mesorectal excisions were supervised by an instructor
surgeon.19 Pathologists were trained to identify lateral spread of tumour according to the
protocol of Quirke et al.18 The results of histopathological examination of the sp cimens
were reviewed by a panel of supervising pathologists and a quality manager.20 Patients’
eligibility and treatment and the details of follow-up were checked by study coordinators.
Local and distant recurrences were confirmed radiologically or histologically and checked
by a radiation oncologist.
In Sweden, the technique of total mesorectal excision was introduced on a national basis
several years ago,12,13 as was the protocol f Quirke et al.18 The European Organisation for
Research and Treatment of Cancer participated in this trial under protocol 40971. Visits to
other participating hospitals and specialists were made before the start of the trial to ensure
the quality of treatment at those sites. For logistic reasons, no quality con rol with respect to
radiotherapy, surgery, or pathological examination was performed outside The Netherlands
during the trial.
Statistical analysis
Case-report forms were sent to the central trial office, where information on the forms was
entered into a data base and analysed with SPSS statistical software (version 9.0 for Windows,
SPSS, Chicago). Chi-square tests were used to compare proportions. Ma n-Whitney tests
were used to compare quantitative and or inal variables. Univariate analyses of survival
were carried out by the Kaplan-Meier method, and the evaluation of differences between the
two groups was performed with the log-rank test. The Cox proportional hazards model was
used to calculate hazard ratios and 95% confidence intervals in the univariate nd multivariate
analyses. A two-sided P value of 0.05 or less wa  considered to indicate statistical significance.
The starting point for the analyses of survival and recurrence was the day of surgery.
Data on patients who were alive or free of recurrence were censored at the time of the last
follow-up. The analysis of overall survival was performed on an intention-to-treat basis and
thus included all the eligible patients. The rate of local recurrence was calculated on the
basis of the number of eligible patients who underwent a macroscopically complete local
resection. The rate of distant recurrence was calculated on the basis of the number of
eligible patients who did not have distant metastasis at the time of surgery. The overall rate
of recurrence was calculated on the basis of the number of ligible patients who had
macroscopically complete local resection without distant metastasis. Analyses of





Patients with major or minor protocol violations, or both, were included in all the analyses.
Major violations: Of the 897 eligible patients assigned to undergo radiotherapy before
total mesorectal excision, 29 did not receive preoperative radiotherapy for the following
reasons: known metastases (8 patients), carcinoma in situ (1), sigmoid carcinoma (3), a
second cancer (1), withdrawal of informed consent (11), and physical limitations that made
radiotherapy impossible (5). Long-term preoperative radiotherapy was given to seven patients
for locally advanced tumours. One patient was unable to tolerate surgery and was treated
RESULTS
Patients
A total of 1861 patients were randomly assigned to one of the two treatment groups. There
were 1530 patients from 84 Dutch hospitals, 228 from 13 Swedish hospitals, and 103 from
11 other European and Canadian centres. Of these 1861 patients, a total of 56 were found to
be ineligible before randomisation, including 4 patients for whom there was no information
on eligibility. Our analysis therefore included 1805 eligible patients. Of these, 1653 patients
had a curative resection. Of the remaining 152 patients, 57 did not undergo a macroscopically
complete local resection, and 95 were found to have distant metastasis at surgery (Table 1).
The characteristics of the 1805 patients who were eligible for the study and the features of
their tumours were similar in the two treatment groups (Table 2). In 28 patients (2%), no
tumour was found in the resected specimen, despite a r operative biopsy that showed an
adenocarcinoma.
Table 1. Characteristics of the eligible and ineligible patients and rates of macroscopically
complete local resection, according to treatment group.*
All patients Treatment group




Randomly assigned to treatment 1861 (100) 924 (100) 937 (100)
Ineligible for participation
  No adenocarcinoma
  Fixed tumour
  Tumour treated by transanal resection
  Tumour location > 15 cm from anal verge
  Previous cancer
  Coexisting cancer
  Previous large-bowel surgery, pelvic
    radiotherapy, or chemotherapy





























  Incomplete local resection
    Without distant metastases
    With distant metastases
  Complete local resection
    With distant metastases



















* Percentages are based on the total numbers of patients randomly assigned to one of the two treatment
   groups.
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Distance of tumour from anal verge
  10.1-15 cm
  5.1-10 cm








































































* Characteristics were unknown in some cases because not all case-report forms were received.
   Because of rounding, not all percentages total 100. TNM denotes tumour-node-metastasis.
† A Hartmann resection is a low anterior resection without the construction of an anastomosis.
with long-term radiotherapy alone. Preoperative radiotherapy was discontinued in 14 patients,
mainly because of neurotoxicity.
Of the 908 eligible patients assigned to total mesorectal excision alone, 3 patients withdrew
their informed consent and requested ra iotherapy (5 Gy on each of five days), and 8
patients had advanced local tumours for which long-term preoperative radiotherapy w s
given.
Postoperative adjuvant therapy was not allowed in patients who had microscopically
tumour-free margins without spillage of tumour cells during the operation. Of 1759 eligible
patients with available information on margins and tumour spillage, 1351 (77%) had tumour-
free margins without tumour spillage. Eighty-five of these patients (38 in the group assigned
to radiotherapy and surgery and 47 in the group assigned to surgery alone) received adjuvant
therapy (chemotherapy, radiotherapy, or chemoradiotherapy), which was a major protocol
violation.
Minor violations: Of the 846 eligible patients randomly assigned to preoperative
radiotherapy who received the total dose of 25 Gy, the interval between the first day of
radiotherapy and the day of surgery xceeded 10 days in 110 patients (13%). In 127 of the
patients (15%), the upper border of the treatment field was at the level of S1–2 instead of at
the promontory, and in 161 of the patients undergoing an abdominoperineal resection (19%),




Postoperative morbidity and mortality
The median interval between randomisation and surgery was 21 days in the group assigned
to radiotherapy and surgery and 14 days in the group assigned to surgery alone. The
patients assigned to radiotherapy and surgery lost slightly more blood during the operation
than those assigned to surgery alone (median loss, 1000 vs. 900 ml, P<0.001), and of the
patients who had an abdominoperineal resection, those assigned to radiotherapy had more
perineal complications than those assigned to surgery alone (26% vs. 18%, P=0.05). No
other significant differences with respect to postoperative morbidity and mortality were
found between the two groups.
Follow-up
As of February 2001, surviving eligible patients without local recurrence had been followed
for a median of 24.9 months (range, 1.1 to 56.0). Of these patients, 87% were followed
for at least one year, 54% for at least two years, 24% for at least three years, and 5% for
at least four years. Rates of survival and recurrence are presented here at a follow-up f
two years. A reanalysis as of June 1, 2001, produced essentially the same results for all
the major end points of the study.
Events
As of February 2001, 365 (20%) of the 1805 eligible patients had died. Of the 365 deaths,
61 occurred postoperatively, 231 were related to rectal cancer (growth of the primary
tumour (in cases of macroscopically incomplete resection) or recurrence), and 70 were
not related to rectal cancer. In three patients, the cause of death was unknown.
Local recurrence occurred in 87 patients. Of these 87 patients, 45 (52%) had local
recurrence alone, 28 (32%) had both local and distant recurrences, and 14 (16%) had
local recurrence after distant metastasis was found at surgery (in 9 patients) or during
follow-up (in 5). A total of 227 patients were found to have only distant recurrence.
Overall survival
The rate of overall survival at two years was 82.0% in the group assigned to radiotherapy
before surgery and 81.8% in the group assigned to surgery alone (P=0.84, Figure 1). The
hazard ratio for death in the group assigned to surgery alone as compared with the group
assigned to preoperative radiotherapy was 1.02 (95% confidence interval (CI), 0.83 to
1.25).
Local recurrence
The rate of local recurrence at two years was 5.3% in the population of 1748 patients
who underwent a macroscopically complete local resection. The rates of local recurrence
at two years were 2.4% in the group assigned to radiotherapy before surgery and 8.2% in
the group assigned to surgery alone (P<0.001, Figure 2). According to a univariate analysis,
the hazard ratio for local recurrence in the group assigned to surgery alone as compared
with the group assigned to preoperative radiotherapy plus surgery was 3.42 (95% CI,
2.05 to 5.71).
In the univariate analyses, treatment-group assignment (P<0.001), the location of the
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tumour (distance of the tumour from the anal verge, P=0.003), and the tumour-node-
metastasis (TNM) stage (P<0.001) were significant predictors of the risk of local recurrence.
In the multivariate Cox regression a alysis (Table 3), the treatment-group assignment
(P<0.001), the tumour location (P=0.03), and the TNM stage (P<0.001) were independent
predictors of the risk of local recurrence, whereas the type of resection (P=0.90) had no
independent prognostic value with respect to this end point.
Univariate subgroup analyses showed that preoperative radiotherapy r duced the risk of
local recurrence significantly in patients who had tumours with an inferior margin less than
or equal to 5 cm (P=0.05) or 5.1 to 10 cm (P<0.001) from the anal verge (Table 4).
Radiotherapy had no significant effect on tumours located 10.1 to 15 cm from the anal
verge (P=0.17). For TNM stage II and III tumours, preoperative radiotherapy had a significant
beneficial effect (P=0.01 and P<0.001, respectively), which was not observed for TNM
stage I and IV tumours (P=0.15 and P=0.25, respectively). However, tests for interaction
among the tumour location, TNM stage, and treatment-group assignment in a multivariate
analysis showed no significant interaction between tumour location and treatment-group
assignment (P=0.08) or between the TNM stage and treatment-group assignment (P=0.61),
suggesting that the treatment effect did not differ among the subgroups analysed (data not
shown).
Distant recurrence
The rate of distant recurrence at two years was 14.8% in the group assigned to radiotherapy
and surgery and 16.8% in the group assigned to surgery alone (P=0.87). The hazard ratio
for distant recurrence in the surgery-only group as compared with the radiotherapy-plus-
surgery group was 1.02 (95% CI, 0.80 to 1.30).
Figure 2. Rates of local recurrence in the population of
1748 eligible patients who underwent macroscopically
complete local resection, according to treatment group.
At two years, the rate of local recurrence was 2.4% in the
group assigned to radiotherapy and surgery and 8.2% in
the group assigned to surgery alone (P<0.001).
873               691        407                 170                 30
875    688        406            173                 37
                  897               741      435          192                  41
                  908   744                454          207               42
No. at risk
Radiotherapy
  plus surgery
Surgery alone
Figure 1. Rates of overall survival in the population of
1805 eligible patients, according to treatment group.
At two years, the rate of overall survival was 82.0% in
the group assigned to radiotherapy and surgery and
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Table 3. Results of multivariate Cox regression analysis of local recurrence among the 1748





  Radiotherapy and surgery





Distance of tumour from anal verge
  10.1-15 cm
  5.1-10 cm





































* A variable was included in the multivariate analysis if the P-value in the univariate analysis was
   less than 0.10. Patients with missing data were excluded from the analysis of local recurrence.
   Twenty-eight patients without a tumour (TNM stage 0) were excluded from the multivariate
   analysis because they were not at risk for local recurrence. CI denotes confidence interval and
   TNM tumour-node-metastasis.
† A Hartmann resection is a low anterior resection without the construction of an anastomosis.
DISCUSSION
In this trial, we evaluated the efficacy of short-term preoperative radiotherapy combined
with standardised total mesorectal excision in patients with resectable rectal cancer. We
found that radiotherapy before total mesorectal excision can improve local control of disease.
Reported rates of local control after surgery for rectal cancer vary widely. In studies of
conventional, nonstandardised surgery, usually with a minimal follow-up of five years, rates
of local recurrence have been 15 to 45%.3-5 By contrast, surgeons who specialise in total
mesorectal excision report local-recurrence rat s of 7% or less.9-11 The low rate of local
recurrence in the group assigned to total mesorectal excision only in our study (8.2% at two
years) demonstrates that similar excellent r sults can be achieved by other surgeons at
multiple centres after they are trained in the procedure.
We found that preoperative radiotherapy further reduced the two-year rate of local
recurrence from 8.2% to 2.4%, an indication of the value of preoperative radiotherapy
when used in conjunction with standardised surgery. In the Swedish Rectal Cancer Trial
(SRCT), the reduction in the rate of local recurrence at five years from 27% in the surgery-
Overall recurrence
The overall rate of recurrence (the rate of local recurrence a d distant recurrence) at two
years was 16.1% in the group assigned to radiotherapy and surgery and 20.9% in the group
assigned to surgery alone (P=0.09). The hazard ratio for any recurrence in the surgery-only
group as compared with the radiotherapy-plus-surgery group was 1.21 (95% CI, 0.97 to
1.52).
<
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Table 4. Results of univariate log-rank analyses of two-year rates of local recurrence
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* Patients with missing data were excluded from the analysis of local recurrence. Twenty-eight patients
   without a tumour (TNM stage 0) were excluded from the multivariate analysis because they
   were not at risk for local recurrence. In a Cox proportional-hazards analysis of age (as a continuous
   variable), the hazard ratio for local recurrence at two years was 0.99 (95% CI, 0.95-1.04; P=0.77)
   in the group of 873 patients assigned to radiotherapy and surgery and 1.01 (95% CI, 0.99-1.04;
   P=0.21) in the group of 875 patients assigned to surgery alone. TNM denotes tumour-node-metastasis.
† A Hartmann resection is a low anterior resection without the construction of an anastomosis.
only group to 11% in the radiotherapy-plus-surgery group improved the ra e of overall
survival at this time point from 48% in the surgery-only group to 58% in the combined-
treatment group.7 An effect of preoperative radiotherapy on overall survival has not yet been
detected in our trial, probably because of the small number of local recurrences and the
short follow-up. However, we believe that a median follow-up time of 24.9 months is sufficient
to detect the effect of preoperative radiotherapy on local recurrences, 55% to 80% of
which occur during the first 2 years after surgery, with the peak rate at 6 to 12 months.4,21,22
The beneficial effect of preoperative radiotherapy in our trial was observed for all tumour
locations 15 cm or less from the anal verge and for all TNM stages. However, in a univariate
subgroup analysis, the effect was not significant in patients who had tumours with an
inferior margin more than 10 cm from the anal verge and in patients who had TNM stage I
or IV tumours. Nevertheless, multivariate tests indicated that the treatment eff c  probably
did not differ among subgroups defined according to tumour location, TNM stage, and
treatment assignment. Therefore, considering the difficulties involved in predicting the location
of tumours high above the anal verge and in determining the TNM stage preoperatively, the
decision not to irradiate before surgery should be carefully considered.
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for locally advanced tumours. To avoid short-term irradiation of such tumours, we advocate
accurate preoperative imaging (e.g. computed tomography or magnetic resonance imaging).
This lack of down-staging explains why short-term preoperative radiotherapy has no effect
on sphincter preservation, which is often an end-point in conventional trials of long-term
radiotherapy.
Concern has been expressed about the side effects of hypofractionated radiation.24 In
the Stockholm I trial25 and Imperial Cancer Research Fund trial,26 postoperative mortality
was higher among patients who received radiotherapy than among those who did not. In
both trials, a suboptimal irradiation technique increased th  treated volume considerably. In
the SRCT, postoperative mortality did not increase with radiation, pr vided that radiotherapy
was optimal.27 In our trial, there was no difference in in-hospital mortality between the two
groups. In the SRCT, however, there was more incontinence among patients who underwent
preoperative irradiation and subsequently underwent a sphincter-preserving surgery.28
In conclusion, total mesorectal excision can significantly decrease the risk of local
recurrence of resectable rectal cancer. This result was achieved in a large, multicentre trial
that included extensive instruction and quality control of the surgical technique. In this large
group of patients who underwent standardised surgery, short-term preoperative radiotherapy
further reduced the risk of local recurrence.
Supported by grants from the Dutch Cancer Society (CKVO 95-04), the Dutch National Health Council
(OWG 97/026), and the Swedish Cancer Society.
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Several studies have indicated that there are differences in the aetiology, clinical behaviour,
pathological features and genetic abnormalities in cancer of the right colon vs. the left
colorectum.1-5 This evidence supports the theory that the oncogenesis of left- and right-
sided colorectal cancers may involve, at least partially, different mechanisms.
By far the best chance for cure in patients with colorectal cancer is radical resection at
an early stage. The results of traditional rectal cancer surgery, however, are discouraging
with high percentages of local recurrence. Two important factors that have been reported
to improve outcome are standardised total mesorectal excision (TME)-surgery6 and short-
term preoperative radiotherapy.7 In contrast, the main problem for colon cancer patients is
the development of distant metastasis. Adjuvant chemotherapy has been shown to improve
survival in colon cancer patients.8 An important prognostic factor in colon cancer is TNM
staging, whereas in rectal cancer the surgeon9 and lateral margin involvement,10 in addition
to TNM-stage, are of important prognostic value.
Many studies have been performed in order to find biological parameters that identify a
higher degree of aggressiveness, independently of the known prognostic clinicopathological
features of colorectal carcinoma. Such knowledge may help to improve treatment strategies.
However, few studies have addressed possible biological differences between rectal and
colon cancer and if so, they have investigated only one parameter.11,12 To be able to investigate
prognostic markers in rectal carcinoma, standardised surgery is a prerequisite, since treatment-
related variation of outcome should be ruled out.
In this study, the aim was to investigate oncogenes and tumour suppressor genes involved
in the oncogenesis of colon and rectal cancers. Mutation and expression profiles were
investigated and related to tumour site and prognosis. Rectal cancer patients were treated
with standardised surgery performed by an experienced rectal cancer surgeon.
METHODS
Study populations
For this project, 35 colon cancer patients were analysed. These patients were operated on
at the Department of Surgery, Leiden University Medical Centre by different surgeons
between 1990 and 1994. Between November 1994 and February 1995, 42 rectal cancer
patients from 24 hospitals throughout the Netherlands were operated on by Y. Moriya (YM)
from the National Cancer Hospital, Tokyo, Japan.13 The surgical technique was focused on
nerve preservation and pararectal resection, similarly to the TME technique.6
All histopathological slides were reviewed by a senior pathologist (JHJMvK). WHO
classification, histological differentiation, growth pattern of the tumour margin
(circumscribed, diffuse), degree of the lymphoid reaction that surrounded the tumour (none/
few, extensive) and the numbers of eosinophil granulocytes (none/few, moderate, extensive)
were evaluated. The presence of lymphangio-invasive growth was also registered.
Mutation analysis of APC and p53
Fresh frozen tumour samples were investigated from 22 rectal and 8 colon cancer patients.
DNA was extracted from tumour tissue by standard procedures of phenol/chloroform
extraction and ethanol precipitation.
APC mutation analysis of the mutation cluster region (MCR) in the rectal cancers was
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performed using the protein truncation test (PTT) as described by van der Luijt and Meera
Khan.14
In the rectal cancers, p53 mutation analysis of exons 5-8 was performed using polymerase
chain reaction (PCR) followed by constant denaturant gel electrophoresis (CDGE) as
described by Börresen et al.15 The exon 5-8 regions of the amplified fragment were sequenced
to rule out the presence of mutations not detected by screening. The eight colon tumours
were also analysed for p53 mutations by CDGE,15 but no sequencing was performed.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue blocks were cut 4 µm thick and mounted on
APES pre-coated slides. After mounting they were kept in an oven at 37°C overnight.
Sections were deparaffinised in xylene and rehydrated. Endogenous peroxidase activity
was blocked with 1% hydrogen peroxide for 20 minutes. Antigen retrieval was performed
according to Table 1. Overnight incubation was done with the primary antibody in 1%
phosphate buffered saline/bovine serum albumin (1% PBS-BSA).
For p53 and Bcl-2, rabbit-anti-mouse (RAM) was applied as secondary antibody and
swine-anti-rabbit (SWAR) as tertiary antibody. For hMLH1, hMSH2, E-cadherin and ß-
catenin, the streptavidin-biotin complex (sABC) staining method was applied, after incubation
with biotinylated rabbit anti-mouse (RAM). Staining was performed with AEC (3-amino-9-
ethylcarbazol in dimethylformamide). Finally, the sections were counterstained with
haematoxylin. Incubation with PBS instead of the primary antibody served as a negative
control.
Table 1. Antibodies with their dilution and pre-treatment.
Antibody Dilution Pre-treatment
MLH1 (Oncogene research products) 1:50 boiling EDTA
MSH2 (Oncogene research products) 1:100 boiling EDTA
Bcl-2 (mAb clone 124, Boehringer Mannheim) 1:50 boiling citrate buffer
p53 (mAb NCL-p53-DO-7, Novocastra Laboratories Ltd.) 1:1000 boiling citrate buffer
E-cadherin (Anti-E-Cadherin clone HECD-1,
  Zymed Laboratories Inc.)
1:1000 boiling citrate buffer
â-catenin (Transduction laboratories) 1:24000 boiling citrate buffer
Analysis of staining patterns
The slides were assessed independently by three observers (EK, LCL and GJL). All sections
were reviewed by a pathologist experienced in the assessment of immunohistochemical
staining (JHJMvK) and discussed until agreement was reached.
For Bcl-2 staining, infiltrating lymphocytes were used as an internal positive control.16
Bcl-2 was scored as positive if Bcl-2 expression was seen in the cytoplasm of tumour cells,
regardless of the number of cells stained.
Nuclear p53 staining was scored in four categories; 0-25%, 26-50%, 51-75% and 76-
100%. Results were compared with p53 mutation analysis to define the immunohistochemical
cut-off point for p53 mutation.
Expression of membranous E-cadherin and ß-catenin was scored as loss/negative (0-
75% of the tumour cells positive) or no loss/positive (76-100% of the tumour cells positive).
Chapter 7
104
There were more male patients in the rectal group than the colon group (P=0.01), but no
other differences could be found between the series with regard to clinicopathological
characteristics. Median follow-up of the 77 colorectal cancer cases was 45 months. Disease-
free and overall survival were 48% and 56%, respectively, at four years.
Rectal cancer cases
Analysis of the MCR of APC by the PTT revealed 18 truncating mutations in 22 rectal
cancers (82%). No correlation could be found between nuclear ß-catenin expression and
APC mutation analysis (P=0.42, Table 3); there were nine nuclear ß-catenin negative tumours,
of which eight showed an APC truncating mutation and 12 nuclear ß-catenin positive tumours,
of which nine showed an APC mutation.
p53 mutation analysis showed mutations in 15 of 22 rectal cancers (68%); of these, 14
Normal colorectal tissue served as positive internal control. Apical E-cadherin17 and nuclear
ß-catenin18 were also scored. Any degree of apical E-cadherin or nuclear ß-catenin staining
was accepted as positive.
In order to check staining variability and intra-observer variation, 37 of the 77 ß-catenin
slides were stained and analysed a second time. Of 37 slides, only two (5%) were scored
differently from the initial scoring, implying good reproducibility of the staining technique
and assessment of staining patterns.
Statistics
Data were analysed using SPSS statistical software (version 9.0 for Windows, SPSS,
Chicago). Some clinicopathological variables were categorised in fewer categories to avoid
statistics with small numbers. Chi-square tests were applied to assess differences in the
distribution of parameters among groups. Mann-Whitney tests were used for comparison
of continuous variables. Univariate survival analyses were carried out by the Kaplan-Meier
method and differences between groups were compared with the log-rank test. For overall
survival, all deaths, irrespective of cause, were considered as events. For disease-free
survival, events were defined as recurrence of disease or death. Cases with macroscopically
incompletely resected tumour or metastases at operation were given a disease-free survival
of 0 months. The Cox proportional hazards model was used for multivariate analysis. A P-
value of 0.05 or less was considered statistically significant.
RESULTS
The rectal series consisted of 30 males and 12 females (Table 2). Median age of the 42
rectal cancer patients was 66.0 years (range 30-85 years). Median follow-up was 41 months
(range 32 to 48 months). Thirty-nine patients (93%) underwent a macroscopically curative
resection. Of these, nine (24%) developed distant recurrences in the follow-up and four
(10%) developed local recurrences without distant metastases. Disease-free and overall
survival were 50% and 66% at four years.
The colon series consisted of 15 males and 20 females. Median age of these patients
was 70.0 years (range 39-89 years). Median follow-up was 55 months (range 45 to 91
months). Twenty-seven patients (77%) underwent a curative resection. Of these, seven
(26%) developed distant recurrences in the follow-up while no local recurrences were
reported. Disease-free and overall survival were 49% and 49%, respectively, at four years.
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(93%), showed more than 25% p53 overexpression (one tumour with a p53 mutation was
not analysed for p53 immunohistochemistry). Of six tumours without a mutation, only one
showed more than 25% overexpression; the cut-off point of 25% was thus shown to be
both sensitive and specific for p53 mutation (P<0.001, Table 3).
No association was found between APC and p53 mutation rate (P=0.75); of the 18
tumours with an APC mutation, 12 tumours (67%) showed a p53 mutation; of the four
without an APC mutation, three (75%) showed a p53 mutation. APC mutation was not
associated with p53 immunohistochemistry either (P=0.69).
In the univariate analysis, no significant correlations were found between marker
expression and clinicopathological parameters. Our survival analysis, however, showed a
significant correlation between p53 overexpression and worse disease-free survival (P=0.008,
Figure 1). Analysis of local recurrence-free survival and distant recurrence-free survival
showed that p53 was prognostic for local (P=0.02), but not for distant recurrence (P=0.13).
Besides p53, advanced TNM stage was correlated with worse disease-free survival (P=0.03).
The Cox regression model showed that p53 expression (P=0.03) was an independent predictor
of disease-free survival, but not TNM stage (P=0.15).
Colon cancer cases
Table 3. Results of APC mutation analysis and ∃-catenin immunhistochemistry,









Codon From Base To Base
1 trunc - WT -
2 trunc + insertion +
3 trunc + 272 GTG TTG +
4 WT - exon 5 +
5 WT + 273 CGT TGT +
6 trunc - WT +
7 trunc - 248 CGG TGG +
8 trunc - 175 CGC CAC -
9 trunc + WT -
10 trunc - 282 CGG TGG +
11 trunc - WT -
12 trunc + 151 CCC ACC +
13 trunc ND 194 CTT CGT +
14 WT + WT -
15 trunc + 151 CCC TCC +
16 trunc + exon 5 ND
17 trunc - WT -
18 trunc + 282 CGG TGG +
19 trunc + 216 GTG ATG +
20 trunc + WT -
21 trunc - 248 CGG TGG +
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Colon cancer cases
In the colon tumours, no discrepancy was found between p53 mutation analysis and p53
immunohistochemistry. In four cases, a p53 mutation was found together with more than
25% p53 expression. The four cases without a mutation did not show more than 25% p53
expression.
In the univariate analysis, no significant correlations were found between marker
expression and clinicopathological parameters, nor did survival analysis show significant
correlations between p53 (Figure 2) or other marker expression and disease-free or overall
survival. Advanced TNM stage (P=0.0004) and male gender (P=0.03) were significantly
associated with worse disease-free survival.
Colorectal cases, colon vs. rectal tumours
In Table 4, the results of positive marker expression are shown. There are missing cases,
since some staining was not successful. All evaluated colon and rectal cases were positive
for hMLH1 and hMSH2. Positive membranous ß-catenin expression was found in 61% of
the cases. Rectal cancers showed nuclear ß-catenin expression significantly more often
than colon cancers (65% vs. 40%, P=0.04). In total, 22% of the tumours were positive for
Bcl-2. Rectal cancers showed positive p53 expression significantly more often than colon
cancers (64% vs. 29%, P=0.003). Fifty-eight percent of the tumours showed positive
membranous E-cadherin expression and 34% apical E-cadherin expression. No differences
were found in Bcl-2, E-cadherin and membranous ß-catenin expression between colon and
rectal cancers.
In the univariate analysis, no significant associations were found between marker
expression and clinicopathological parameters. Our survival analysis, however, showed a
significant correlation between p53 overexpression and worse disease-free survival (P=0.03,
Figure 3). Advanced TNM stage (P=0.0004) and age >65 years (P=0.03) were correlated
with worse disease-free survival. The Cox regression model showed that age (P=0.007)
was an independent predictor for disease-free survival, but not TNM stage (P=0.12) or p53
expression (P=0.09).













MLH1 66/66 (100) 31/31 (100) 35/35 (100) P=NA











Bcl-2 16/73 (22) 6/33   (18) 10/40 (25) P=0.48
















Colorectal cases, right- vs. left-sided tumours
In an additional analysis, descending colon tumours were analysed together with the rectal
tumour group, in order to investigate expression profiles in right- vs. left-sided tumours.
We found the same differences as in our analysis of colon vs. rectal cases. Right-sided
tumours showed significantly less nuclear ß-catenin (36% vs. 64%, P=0.025) and p53
overexpression (26% vs. 61%, P=0.004) than left-sided tumours. Furthermore, our survival
analysis showed a significant correlation between p53 expression and disease-free survival
(P=0.008) in the left-sided tumour group, but not in the right-sided group.
DISCUSSION
Tumours located in the distal colon have been proposed to arise and progress by pathways
distinct from those originating in the proximal colon. Distal tumours display a higher frequency
of 17p19 and 18q20 allelic loss, p53 accumulation,11 c-myc expression21 and aneuploidy.22
Right-sided tumours are more often mucinous,23 diploid22 and of the microsatellite instability
(MSI) phenotype.5 Furthermore, clinical behaviour is different, in that in rectal cancer local
recurrence is the major problem, whereas in colon cancer it is distant metastasis. It is
therefore reasonable to suggest that the aetiological factors and the molecular basis may
differ between the colon and rectal cancer.
We investigated markers that have a function in the oncogenesis of colorectal cancer. In
rectal cancer, the surgeon is an important factor in outcome9 and the role of prognostic
factors can only be studied when standardised surgery is performed. In our study, rectal
cancer patients were treated with standardised surgery performed by one experienced rectal
Figure 1. Kaplan Meier curve of 39 (out of 42) rectal
cancer patients with regard to negative and positive p53
immunohistochemical expression (P=0.008).
Figure 2. Kaplan Meier curve of 34 (out of 35) colon
cancer patients with regard to negative and positive
p53 immunohistochemical expression (P=0.37).
Figure 3. Kaplan Meier curve of 73 (out of 77)
colorectal cancer patients with regard to negative
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cancer surgeon. There was a significant difference only in gender; more male patients were
present in the rectal than the colon group, which agrees with a previous report.2
Expression of mismatch repair genes did not differ between colon and rectal cancers
and was positive in all cases. This implies that in our series, no HNPCC patients with
hMLH1 or hMSH2 mutations were present. HNPCC patients show MSI in 95% of their
colorectal tumours, but MSI has also been reported in 15-20% of sporadic colorectal tumours,
with a difference between colon (30% MSI) and rectal tumours (4% MSI).24 In another
series of 79 rectal tumours, we found MSI in only one tumour (1%), which also indicates
that MSI does not play a major role in the development of rectal cancers.(paper submitted)
Almost all of the mutations of APC, both germline and somatic, result in truncation of
the gene product.25 The somatic mutations exhibit a definite accumulation in an area termed
the MCR,25 so the protein truncation test of the MCR is an ideal procedure for APC mutation
analysis in sporadic colorectal tumours. In our rectal cancer series, we found truncating
APC mutations of the MCR in 18 of 22 (82%) cases. This mutation rate is comparable to
the APC mutation rates of sporadic colorectal cancers described in literature.25,26
Mutations of APC have been shown to result in the stabilisation or nuclear localisation
of ß-catenin, whilst ß-catenin mutations can also contribute to high/nuclear ß-catenin levels.27
Significantly more nuclear ß-catenin expression was found in rectal cancers than in colon
cancers (65% vs. 40%, P=0.04), but this was not associated with the presence of an APC
mutation. This could be due to other factors being capable of destabilisation or nuclear
localisation of ß-catenin. No association was found between APC and p53 mutation rate or
p53 immunohistochemistry. This seems to contradict the findings of Narayan and Jaiswal,
who support a model featuring a direct link between p53 and APC in response to a DNA
alkylating agent and suggest a novel role for p53 in a stress-response pathway involving
APC.28 However, in our study, no DNA-alkylating agents were given.
p53 mutations have been mainly found in the best conserved regions of the gene, exons
5-8, which harbour 95% of all mutations.29 We found p53 mutations in 15 of 22 (68%)
rectal and four of eight (50%) colon cases. The mutational spectrum of these mutations
was comparable with that described in literature.29,30 p53 mutation analysis and p53
immunohistochemistry corresponded very well, so our p53 immunohistochemistry results
are reliable. We found more p53 overexpression in rectal than colon tumours, indicating a
higher rate of p53 mutations in rectal cancer. This agrees with a previous report of Scott et
al.,4 but Zeng et al.31 and Yamaguchi et al.32 did not confirm our observation.
Several studies have shown that p53 overexpression, either in the nucleus or in the
cytoplasm, is related to unfavourable survival in patients with colorectal cancer,31,32 but
others have not found this relationship.4,16 We did not find a prognostic value for p53 expression
in the colon cancer group, but a significant relationship was found between positive p53
expression and shorter disease-free survival in the rectal cancer group and total colorectal
group. In the Cox regression model, p53 expression was found to be an independent predictor
for disease-free survival in the rectal cancer group, but not in the total colorectal group. It
is difficult to explain the higher rate of p53 mutations in rectal cancer than in colon cancer.
The different bacterial flora and longer transit time in the rectum might change the contact
between potential carcinogens or promoters in the faecal stream, which might lead to more
(exogenous) mutations of p53.
In conclusion, we investigated oncogenes and tumour suppressor genes in colon and
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rectal cancers. Rectal cancer patients were treated with standardised surgery to provide
optimal conditions for studying prognostic markers. Our results indicate that rectal cancer
may involve more nuclear ß-catenin in the APC/ß-catenin pathway than colon cancer, and/
or nuclear ß-catenin may have another role in rectal cancer independently of APC. The p53
pathway also seems to be more important in rectal cancer, in which p53 expression also has
independent prognostic value. This study shows that when prognostic markers are
investigated in larger series, differences in biological behaviour between colon and rectal
cancer should be considered.
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Diploid, microsatellite stable rectal carcinomas show
different molecular phenotypes
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In The Netherlands, approximately 25% of new cases of colorectal cancer comprise rectal
cancers. Tumours located in the distal colon have been proposed to arise and progress by
pathways distinct from those originating in the proximal colon. Distal tumours display a
higher frequency of 17p1 and 18q2 allelic loss, p53 accumulation,3 β-catenin expression,3 c-
myc expression4 and aneuploidy.5 Right-sided tumours are more often mucinous,6 diploid5
and of the MicroSatellite Instability (MSI) phenotype.7 Furthermore, clinical behaviour is
different. In rectal cancer local recurrence is the major problem and in colon cancer distant
metastasis.
The development of genetic instability is supposed to be an important event in the multi-
step evolution of colorectal cancer resulting in genetic alterations in both proto-oncogenes
and tumour suppressor genes.8,9 Two major mechanisms of genomic instability have been
identified. Chromosomal instability (CIN) is characterised by gross chromosomal segregation
abnormalities and is commonly detected as aneuploidy.10 Loss or gain of genetic material at
specific chromosomal regions may thereby result in altered allele ratios. The majority (85-
90%) of sporadic colorectal carcinomas arise through chromosomal instability.11
Alterations at DNA microsatellite repeat units in tumours, so-called microsatellite instability
(MSI), is a second form of genetic instability.12 MSI occurs in hereditary non-polyposis
colorectal cancers (HNPCC) and is caused by germline mutations in DNA mismatch repair
(MMR) genes.13 MSI also occurs in 10-15% of sporadic colorectal tumours,14 mainly by
somatic inactivation of hMLH1.15
In colorectal cancer, at least two different molecular pathways appear to be affected:
the APC/β-catenin (Wnt) pathway, often linked to CIN, and the DNA mismatch repair
(MMR) pathway, the latter often with inactivation of TGF-β-RII.16 These pathways are not
totally independent, but show cross talk and mutations in genes (APC,17 TGF-β-RII,18
axin19) of both pathways. We analysed MSI, loss of heterozygosity (LOH) and ploidy status
to study genetic instability of sporadic rectal cancer. Additional immunohistochemical, p53
mutational and expression array analyses were performed to provide a more detailed molecular
profile of cancers without evidence for genetic instability (diploid, MSI-stable). Cases were
obtained from a large, randomised trial investigating the role of preoperative radiotherapy in
combination with standardised Total Mesorectal Excision (TME)-surgery.20
METHODS
Tissue specimens
Formalin-fixed, paraffin-embedded tissue of resected rectal adenocarcinomas of 81 patients,
were obtained from a large prospective trial investigating the role of 5x5 Gy short-term
preoperative radiotherapy in the treatment of primary rectal cancer in combination with
total mesorectal excision (TME)-surgery (TME-trial). In total, 1530 patients were included
from 84 Dutch hospitals. In the trial, radiotherapy, surgery and pathology were standardised.20
The 81 patients were randomised in the trial during the first year; their samples were selected
from the 12 largest pathology laboratories to avoid too many different fixation methods.
MSI/LOH-analysis
Tumour and normal cell populations were microdissected separately with a needle under
microscopic observation from 10 serial paraffin sections (10 µm thick). For DNA-isolation,
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a method described by Isola et al.21 and Kersemaekers et al.22 was used.
MSI analysis was done for 12 different microsatellite loci distributed over 10 chromosomes
(BAT25, BAT26, D5S346, D2S123 and D17S250) and 2 alternative loci (BAT40, D13S175)
of the NCI workshop on MSI in colorectal cancer23 plus 5 additional loci (D3S2456, D8S1130,
D15S1232, D16S752, TP53). All primer sequences for microsatellite repeat markers can
be obtained from the Genome Database (http://www.gdb.org).
Fluorescent PCR and data analysis were performed essentially as described earlier.24-26
MSI was recorded when novel peaks or peaks shifts appeared in tumour DNA cases when
compared with matched DNA cases of normal cells. MSI-high tumours were defined as
having instability of two or more markers of the NCI reference panel or as having MSI in
>30% of all markers tested.23 MSI-low tumours were defined as having instability of one
marker of the reference panel. Cases showing no instability in any of the markers tested
were classified as MSI-stable. Loss of heterozygosity (LOH) was recorded when the ratio
of the peak heights of the tumour and normal alleles was <0.59 or >1.7. The tumour of a
patient was defined as LOH-positive if LOH was found in one of the possible 9 heterozygous
markers tested.
DNA ploidy analysis
The pepsin-digestion method of Hedley et al27 was used for nuclear isolation from 50 µm
paraffin sections. Propidium iodide was used as a DNA stain. DNA content was measured
on a FACSCalibur flow cytometer (Becton Dickinson, Mountainview, CA).28
Immunohistochemical analysis
The following markers were investigated: E-cadherin (Zymed Laboratories), α−, β− and γ-
catenin (Transduction laboratories), EpCAM (Centocor), p16 (Pharmingen), Cyclin D1
(Neomarkers), MDM2 (Neomarkers), p53 (Novocastra Laboratories), p21waf1 (Oncogene
research products), Ki-67 (Dako), Bcl-2 (Boehringer Mannheim), hMLH1 and hMSH2
(Oncogene research products) and hMSH6 (Transduction laboratories). For most antibodies,
the sections were first boiled in citrate buffer (pH 6.0) for 25 minutes. For hMLH1 and
hMSH2, paraffin sections were first boiled in EDTA. For EpCAM the sections were pretreated
with trypsin (0.1% trypsin with 0.1% calcium chloride), pH 7.4 at 37 °C for 20 minutes.
After overnight incubation with the primary antibody in 1% phosphate buffered saline/
bovine serum albumin (1% PBS-BSA), the secondary biotin-conjugated antibody and a
tertiary complex of streptavidin-avidin-biotin-conjugated to amino-9-ethyl-carbazole (AEC)
or 3’,3’-diaminobenzidine (DAB) were applied.
For each marker a scoring system was chosen after initial screening of the variation of
expression of each marker, or taking systems used in the literature or former studies of our
group into account.3,29-31 Membranous staining of E-cadherin, α-, γ-catenin and EpCAM,
was scored according to the following categories: severe loss (0-49%), moderate loss (50-
89%), loss only at the infiltrating front of the tumour (90-99%) and no loss (100%). β-
catenin was scored as membranous expression/no obvious nuclear expression, nuclear
expression in the infiltrating front of the tumour or nuclear expression all over the tumour.
p16, cyclin D1 and MDM2 were scored according to the following classification: no nuclear
staining/staining in a few nuclei, focal nuclear staining or >10% nuclear staining all over the
tumour. Nuclear p53, p21 and Ki-67 were scored as 0-25%, 26-75% or 76-100% expression.
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Bcl-2, hMLH1, hMSH2 and hMSH6 were scored according to the following categories: -
negative, +/- in case of faint or doubtful staining, or + positive.
p53 mutation analysis
Frozen tissue sections were stained with H&E and trimmed in order to select for tumour
tissue. DNA was extracted from 20 serial frozen tissue sections (20 µm thick) by way of
the Promega genomic DNA purification kit (Promega). The DNA yield was determined by
spectrophotometry and the DNA was analysed by p53 Genechip assay (Affymetrix) as
described by Wen et al.32 To account for any variations that occurred during the assay, each
sample batch was processed with human placental DNA as a wild-type control (Affymetrix).
Any sequence mismatch present in case DNA was identified by comparison to the control
placental DNA.
Gene array expression analysis
Frozen tissue sections were stained with H&E and trimmed in order to select for tumour
tissue. RNA was extracted from 20 serial frozen tissue sections (20 µm thick) by way of
Trizol reagent (Gibco BRL Life Technologies). 10.0-20.0 µg of total RNA was labelled and
hybridised to oligonucleotide arrays (Affymetrix, Oxford, UK), according to the
manufacturer’s recommendations, essentially as described earlier.33 Briefly, we used the
Affymetrix G110 array, which contains probe sets of 16-20 perfect match (PM) and mismatch
(MM) 25-mer oligonucleotide pairs representing 1700 genes. Absolute analysis and pair-
wise comparisons of arrays were made in the Microarray Analysis Suite (Affymetrix).
Absolute analysis yields Average Difference (AvgDiff) values representing the level of gene
expression calculated as the average difference between PM and MM hybridisation. In
addition, the Presence Call algorithm qualifies the signal as Present (P), Absent (A) or
Marginal (M) gene expression. In the comparison analysis, the Fold Change represents the
ratio of gene expression between two samples. T-test and self-organising map clustering
(16 nodes) were performed using the DataMining Tool software (Affymetrix).
hMSH2/hMSH6 mutation analysis
Genomic DNA isolation, polymerase chain reaction (PCR) amplification, denaturing gradient
gel electrophoresis (DGGE) mutation analysis, and nucleotide sequence determination were
performed in tumour DNA, as previously described.34,35 In short, the general strategy was
to amplify by the PCR each of the 16 hMSH2 exons and 10 hMSH6 exons, and to analyse
these products by GC-clamped DGGE. Exons exhibiting altered migration patterns were
sequenced to determine the molecular nature of the variant.
Data analysis
For statistical analysis of the data we used SPSS statistical software (version 9.0 for Windows,
SPSS, Chicago). Chi-square tests were used to compare proportions. Comparison of mean
values between groups were made using Student’s t-tests. A P-value of 0.05 or less was
considered statistically significant.
Cluster analysis of gene array expression analysis
We extracted tables (rows of genes, columns of individual array hybridisations) of scaled
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AvgDiff values for the tumours. Before clustering and display, the genes and arrays were
centred by subtracting the median of all values measured for that gene or array, and rows
and columns were normalised so their magnitudes were close to 1.0. We applied the Eisen
hierarchical clustering algorithm separately to the tumours and genes using the Pearson
correlation coefficient as the measure of similarity and average linkage clustering and displayed
the clusters by TreeView.36
RESULTS
Patient and tumour characteristics
The analysed series consisted of 42 irradiated and 39 non-irradiated patients. Mean age of
the patients was 62.5 years (range 29-84). The clinicopathological characteristics were
equally distributed among the randomisation groups, apart from a larger number of mucinous
tumours in the irradiated group (P=0.048), as was also shown for the whole trial population.37
Microsatellite instability
Screening of the 81 randomly selected rectal cancers, revealed only 1 tumour to be MSI-
high (1%) with instability in the mono- and dinucleotide markers D5S346, TP53, BAT25
and BAT26. Eighty tumours were MSI-stable. However, 11 of these tumours (14%) showed
MSI in the tetranucleotide markers; MSI was found in 2 tumours for D3S2456 (2%), in 5
tumours for D8S1130 (6%), in 1 tumour for D15S1232 (1%) and in 3 tumours for D16S752
(4%). These tumours were classified as MSI-stable since alterations in tetranucleotide markers
do not seem to have any biological relevance.38 In concordance with this, no significant
associations were found between tetranucleotide instability and clinicopathological
characteristics, irradiation or prognosis.
We examined an additional series of patients of the TME-trial for a possible association
of MSI status with particular subgroups of rectal cancer patients. In a subgroup of young
patients (# 45 years, n=22), all tumours were MSI-stable. However, 5 tumours showed
tetranucleotide instability (23%), which is not significantly more than in the random patient
group (14%, P=0.24, Table 1). In a patient group with synchronous tumours (more than
one carcinoma in the colorectum, n=10), 1 tumour showed tetranucleotide instability (10%)
and 9 tumours did not show instability at all (90%). The primary tumours of 8 patients who
developed local recurrences in the follow-up were all MSI-stable without tetranucleotide
instability (100%).
Loss of heterozygosity
The majority of tumours of the random patient group showed LOH with at least one marker
(60/81, 74%), while 21 showed no LOH (26%) in any of the 9 possible heterozygous
markers. The highest frequencies of LOH were detected at the TP53 (58%) and D5S346
(42%) loci. LOH for the other markers appeared as follows: D2S123 (9%), D3S2456
(19%), D8S1130 (36%), D13S175 (29%), D15S1232 (38%), D16S752 (16%) and D17S250
(23%). Of the 60 LOH-positive tumours, 53 were MSI-stable and 7 showed tetranucleotide
instability. Of the 21 LOH-negative tumours, 16 were MSI-stable, 4 tumours showed
tetranucleotide instability and one was MSI-high (Table 1). Comparison of tumour
characteristics of the LOH-negative vs. LOH-positive random groups demonstrated that





DNA ploidy status was investigated in 19 of the 21 LOH-negative tumours and in 16 of the
60 LOH-positive tumours as controls. Ten out of 19 LOH-negative tumours were diploid
(53%), while only 3 out of 16 LOH-positive tumours showed diploidy (19%, P=0.04, Table
2). The only MSI-high tumour was aneuploid. No significant associations were found
between ploidy status and clinicopathological characteristics, irradiation or prognosis.
As expected, the majority of LOH-positive tumours (81%) were DNA-aneuploid but
also 47% of the LOH-negative tumours. We decided to rely on the DNA ploidy data as a
marker for CIN, since ploidy status has been shown to reflect genome-wide instability.
tumours were MSI-stable). There was no association between radiotherapy or prognosis
and LOH-status.
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Table 2. Random patient group, n=81; 35 tumours analysed for ploidy.*
LOH-negative, n=19 LOH-positive, n=16
diploid aneuploid diploid aneuploid
MSI-stable without
tetranucleotide instability
8 (42) 6 (31) 1 (6) 10 (62)
MSI-stable with
tetranucleotide instability
2 (11) 2 (11) 2 (13) 3   (19)
MSI-high - 1 (5) - -
* Percentages have been calculated for the LOH-negative and LOH-positive group separately.
Immunohistochemical analysis of the diploid vs. aneuploid tumours
In order to further investigate tumours without gross genetic instability (diploid, MSI-
stable), we compared the diploid and aneuploid tumours for immunohistochemical expression
profiles (Table 3). There was only a significant difference in Ki-67 (lower in diploid tumours,
P=0.048) and p53 expression (lower in diploid tumours (<76-100%), P=0.026).
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Table 3. Immunohistochemical analyses of the random patient group;
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3   (9)
12 (35)
16 (47)
1   (8)
-
4   (31)
8   (62)
2   (10)
3   (14)
8   (38)





->10% positivity all over tumour
16 (48)
2   (6)
15 (45)
6   (46)
-
7   (54)
10 (50)
2   (10)





->10% positivity all over tumour
28 (82)
4   (12)
2   (6)
11 (85)
1   (8)
1   (8)
17 (81)
3   (14)





->10% positivity all over tumour
23 (68)
5   (15)
6   (18)
6   (46)
2   (15)
5   (38)
17 (81)
3   (14)







6   (17)
2   (6)
7   (20)
20 (57)
1   (8)
2   (15)
5   (38)
5   (38)
5   (23)
-










5   (15)
-
4   (31)
7   (54)
2   (15)
-
13 (65)
4   (20)













3   (27)
5   (45)











7   (58)
5   (42)

















3   (9)
31 (91)
-
2   (15
11 (82)
-
1   (5)
20 (95)
0.42
* Some numbers do not equal 35, since a few stainings were not successful.
† Because of rounding, percentages may not total be 100.
0.42
(8 )





p53 mutation and immunohistochemical analysis
Fresh frozen material was available of 5/13 tumours without evidence for genetic instability
(diploid, MSI-stable; of these tumours 4 did not show LOH (19, 54, 119, 157) and 1
tumour showed LOH in D8S1130 (126)). Two aneuploid tumours were studied in parallel.
In 2 of the 5 diploid, MSI-stable cases, p53 mutations were found in exon 5. Diploid
tumour 54 showed a mutation in codon 175, cgc to cac, and tumour 126 demonstrated a
mutation in codon 176, tgc to ttc. The two aneuploid tumours did not show a p53 mutation.
Immunohistochemical p53 investigation corresponded well with p53 mutation analysis;
p53 expression of 76-100% was associated with a p53 mutation and lower expression was
related to a wild type p53 status, also in irradiated tumours. In 5/13 diploid tumours high
p53 expression (76-100%) was present suggesting the presence of a p53 mutation.
Expression array analysis
For seven tumours, we analysed the expression of 1700 cancer-related genes using Affymetrix
G110 oligonucleotide arrays. The tumour set comprised five tumours without evidence for
genetic instability (diploid, MSI-stable), two of which carried a p53mutation, and the two
aneuploid tumours without a p53 mutation.
Two-way hierarchical clustering generated a tree with two subgroups, separating the
diploid p53 wild type tumours (19, 119, 157) from the diploid p53 mutant (54, 126) and the
aneuploid tumours (190, 258). However, no reliable clusters of consistently up or down
regulated genes could be found in these comparisons (data not shown). Next, we analysed
the diploid tumours for differential expression between p53 mutant vs. wild type status. We
selected genes with three methods: pairwise comparison, t-test and self-organising maps,
and found 16 upregulated and 3 downregulated genes in common (Table 4). The results
were confirmed by hierarchical clustering of the five diploid tumours, which resulted in
two subgroups, separating the diploid p53 wild type tumours (19, 119, 157) from the
diploid p53 mutant tumours (54, 126). Examples of clusters of up- and downregulated
genes are shown in Figure 1. The proliferation marker Ki-67 mRNA is upregulated in the
cluster analysis in the p53 mutated tumours, which was confirmed by immunohistochemistry
in these tumours using a anti-Ki-67 monoclonal antibody. Looking back at our
immunohistochemistry data of the 35 tumours from Table 3, is was found that tumours
with a high expression of p53 (76-100%, suggesting a p53 mutation), also showed a
significant higher expression of Ki-67 (26-75% or 76-100%, P=0.003) than tumours less
likely to carry a p53 mutation (<76-100% expression).
We also looked at the so-called “Presence Calls” in the Affymetrix expression array for
the presence or absence of mismatch repair gene transcripts (Table 5). The Presence Call
algorithm qualifies the signal as Present, Absent, or Marginal gene expression. A 29-year
old patient with a diploid tumour was identified with an Absent call for hMSH2/hMSH3
mRNA expression. Immunohistochemistry of hMLH1, hMSH2 and hMSH6 (Figure 2) in
this tumour confirmed the loss of hMSH2. In agreement with the expression array the
hMLH1 protein was present, whereas the hMSH6 protein showed loss
immunohistochemically. hMSH6 mRNA was scored positive in the expression array.
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Microsatellite analysis of this tumour however, did not show MSI using an expanded
international defined marker set. Analysis for hMSH2/hMSH6 mutations using tumour material
resulted negative.


































U73737 1017_at hMSH6 P P P P P P P
U03911 860_at hMSH2 P P P P A P P
U61981 1719_at hMSH3 P P P P A P P
U07418 1850_at hMLH1 P P P P P P P
AF001359 1944_f_at hMLH1
alternatively spliced
A A A A A A A
p53mt: p53 mutant
p53wt: p53 wild type





Gene Description Mean FC SD FC P-value Note
Increased in p53 mutated diploid rectal tumours
1616_at D14838 Fibroblast growth factor 9 (FGF-9) 4.9 1.1 0.001
904_s_at L47276 Alpha topoisomerase truncated-form 8.6 5.3 0.001
1973_s_at V00568 c-myc 2.7 0.4 0.002
1515_at Consensus HG4074-HT4344 Rad2 3.1 0.7 0.002
842_at U48251 Protein kinase C-binding protein RACK7 3.1 0.7 0.002 A in p53wt
282_at L16782 Putative M phase phosphoprotein 1 (MPP1) 5.1 1.5 0.006 A in p53wt
572_at M86699 Human kinase (TTK) 6.7 4.2 0.007
349_g_at D14678 Kinesin-related protein 4.8 1.6 0.009
893_at M91670 Ubiquitin carrier protein (E2-EPF) 3.1 1 0.013
1229_at U78556 Cisplatin resistance associated alpha protein 2.5 0.9 0.014
1592_at J04088 DNA topoisomerase II (top2) 2.3 0.5 0.015
1990_g_at U43746 Breast cancer susceptibility (BRCA2) 4.8 1.2 0.016 A in p53wt
2042_s_at M15024 c-myb 9.8 10.8 0.017
1721_g_at U65410 Mad2 (hsMAD2) 7.4 2.6 0.037
170_at U51096 Homeobox protein Cdx2 4.1 0.5 0.04
975_at Y13115 Serine/threonine protein kinase SAK 3.6 0.4 0.045 A in p53wt
Decreased in p53 mutated diploid rectal tumours
239_at M63138 Cathepsin D (catD) gene, exons 7, 8, and 9 1.7 0.2 0.007
608_at M12529 Apolipoprotein E mRNA 31.8 31.1 0.042 A in p53mt
767_at AF001548 Chromosome 16 BAC clone CIT987SK-A-815A9 4.1 2 0.044
Differentially expressed genes were selected by each of three analysis methods in the Affymetrix DataMiningTool: (1) Genes
that were consistently increased or decreased in all six pairwise comparisons between three p53wild type tumours and two
p53 mutant tumours. (2) T-test to identify up- and downregulated genes. (3) Self-organising map cluster of genes that were
upregulated in p53 mutant tumours. Abbreviations: FC, Fold change; A, absent.
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Figure 1. Gene expression patterns related to p53 mutation status of diploid rectal tumours.
Two-dimensional hierarchical clustering was applied to the expression data from 1700 Affymetrix probe sets
across five tumour samples. Two main branches are apparent in the dendrogram, separating the p53 mutant
(p53mt) from the p53 wild type (p53wt) tumours. Two subclusters of upregulated (A, red) and downregulated
(B, green) genes in p53 mutant tumours are shown. The colour in each cell of the tables reflects the mean-
























































Human ubiquitin carrier protein (E2-EPF) mRNA, complete cds
Human cdc25A mRNA, complete cds
HSREP10 Human beta-tubulin gene (5-beta) with ten Alu family members
Human replication factor C, 37-kDA subunit mRNA, complete cds
Human epidermal growth factor receptor (HER3) mRNA, complete cds
Homo sapiens p53 mRNA for regulatory subunit of cdk5 kinase
Homo sapiens replication protein A 14 kDa subunit (RPA) mRNA, complete cds
Homo Kruppel related zinc finger protein (HTF10) mRNA, complete cds
Homo sapiens replication protein A 14 kDa subunit (RPA) mRNA, complete cds
V182q03.r1 Homo sapiens cDNA clone 44708 5 similar to qb
Homo sapiens protein tyrosine phosphatase (CIP2)mRNA, complete cds
Human receptor tyrosine kinase (HEK) mRNA, complete cds
Focal Adhesion Kinase
Human protein kinase C-binding protein RACK7 mRNA, partial cds
Human protein phosphatase 2A B alphai regulatory subunit mRNA, complete cds
Human retinoic acid inducible factor (MK) gene, exons 1-5, complete cds
Human ubiquitin carrier protein (E2-EPF) mRNA, complete cds
Homo sapiens (cell line HL-60) alpha topoisomerase truncated-form MRNA, 3 UTR
Human homeobox protein Cdx2 mRNA, complete cds
Human putative M phase phosphoprotein 1 (MPP1) mRNA, partial cds
Human mRNA for FGF-9, complete cds
Homo sapiens Nedd-4-like ubiquitin-protein ligase WWP1 mRNA, partial cds
Human serine kinase mRNA, complete cds
Serine Hydroxymethyltransferase, Cytosolic, Alt. Splice 3
Human cisplatin resistant associated alpha protein (hCRA alpha) mRNA, complete cds
Human thymidylate kinase (CDC8) mRNA, complete cds
HSMYC1 Human mRNA encoding the c-myc oncogene
Human VHL binding protein-1 (VBP-1) mRNA, partial cds
HUMMDR1 Human P-glycoprotein (MDR1) mRNA, complete cds
Homo Kruppel related zinc finger protein (HTF10) mRNA, complete cds
HUMOP 18A Human oncoprotein 18 (Op18) gene, complete cds
Human transcriptional activation factor TAFII32 mRNA, complete cds
HUMPSC8 Human mRNA for proteasome subunit HC8
HSBRCA22 Homo sapiens BRCA2 gene, exon 2 (and joined coding region)
Human transcription factor E2F-5 mRNA, complete cds
Human cytochrome P450-IIB (hIIB1) mRNA, complete cds
Human mRNA for XPAC protein
Human cyclin mRNA
Human Jun activation domain binding protein mRNA, complete cds
Human non-histone chromosomal protein HMG-14 mRNA, complete cds
Homo sapiens mRNA for kinesin-like DNA binding protein, complete cds
Human TFIIA gamma subunit mRNA, complete cds
Human TATA-binding protein associated factor 30 kDa subunit (tafII30) mRNA, complete cds
Human c-myb mRNA, complete cds
Human TBP-associated factor (hTAFII130) mRNA, partial cds
Human MAP kinase MEK5c mRNA, complete cds
HUMNF 1AAA Human mRNA for NF1 N-isoform-exon 11, complete cds
Homo sapiens mRNA for ras-related GTP-binding protein, complete cds
Human protein-tyrosine phosphatase mRNA, complete cds
Human BRCA1-associated RING domain protein (BARD1) mRNA, complete cds
HUNPKSCD Human mRNA for protein kinase C delta-type
Human centromere protein-A (CENP-A) mRNA, complete cds
HUNPSH2 Human mRNA for proteasome subunit HsC7-I, complete cds
HUMEFL2 Homo sapiens EHK1 receptor tyrosine kinase ligand mRNA, complete cds
Human mRNA for proteasome subunit HsC10-II, complete cds
Human p21-activated protein kinase (Pak1) gene, complete cds
Human Bloom s syndrome protein (BLM) mRNA, complete cds
Nuclear Mitotic Apparatus Protein 1, Alt, Spice Form 2
Human protein-tyrosine phosphatase mRNA, complete cds
HSCYCHASS Homo sapiens mRNA for cycling H assembly factor
Human Mad2 (hsMAD2) mRNA, complete cds
Rad2
HSCSRCKIN Human mRNA for C-SRC-kinase
Homo sapiens mki67a mRNA (longtype) for antigen of monoclonal antibody Ki-67
Homo sapiens mRNA for serine/threonine protein kinase SAK
Homo sapiens mRNA for antizyme inhibitor, complete cds
Rad2
Human cyclin-selective ubiquitin carrier protein mRNA, complete cds
HUMLBR Human lamin B receptor (LBR) mRNA, complete cds
Human phosphotyrosyl-protein phosphatase (PTB-1B) mRNA, complete cds
HUMERKA Human mRNA for tyrosine kinase, complete cds
Human alkaline phosphatase (ALP-1) mRNA, complete cds
Oncogene Aml1-Evi-1, Fusion Activated
Human CLN3 mRNA, complete cds
Human mRNA for kinesin-related protein, partial cds
Human protein kinase (MLK-3) mRNA, complete cds
Human camptothecin resistant clone CEM/C2 DNA topoisomerase I mRNA, partial cds
Human mRNA for kinesin-related protein, partial cds
Human kinase (TTK) mRNA, complete cds
Human protein tyrosine kinase related, mRNA sequence
Human mRNA for Cdc7-related kinase, complete cds
HUMNFKB65A Human NF-kappa-B transcription factor p65 subunit mRNA, complete cds
Homo sapiens mRNA for serine/threonine protein kinase EMK
Antigen. Prostate Specific. Alt. Splice Form 2
Homo sapiens DNA polymerase alpha mRNA, complete cds
Human DNA topoisomerase II (top2) mRNA, complete cds
Human guanine nucleotide binding regulatory protein (G-y-alpha) mRNA, complete cds
Breast cancer 2, early onset
Human guanylate kinase associated protein (GKAP) mRNA, complete cds
Homo sapiens protein tyrosine phosphatase delta mRNA, complete cds
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Figure 2. Immunohistochemistry of hMLH1 (A), hMSH2 (B), hMSH6 (C) and p53 (D) in a 29-year
old patient (tumour 157) in whom a hMSH2/hMSH3 expression deficit was found with oligonucleotide
























































Human cathepsin D (catD) gene
P50-NF-kappa B homolog (Human peripheral blood T cells mRNA, 3113 nt)
Human hypoxia-inducible factor 1 alpha (HIF-1 alpha) mRNA, complete cds
Luteinizing Hormone, Beta Subunit
Human mRNA for Fas ligand, complete cds
Homo sapiens mRNA for protein kinase, Dyrk4, partial
Human breakpoint cluster region (BCR) gene, complete cds
Ovary- and prostate-specific exon 1 from Human cytochrome P-450 aromatase gene
Human RNA polymerase II subunit (hsRPB8) mRNA, complete cds
HUMMET Human metalloproteinase inhibitor mRNA, complete cds
Human damage-specific DNA binding protein p48 subunit (DDB2) mRNA, complete cds
Human interferon-induced cellular resistance mediator protein (MxB) mRNA, complete cds
Human APC gene mRNA, complete cds
Human mRNA for smooth muscle myosin heavy chain
Human small GTP-binding protein rab27b mRNA, complete cds
Endothelial Cell Growth Factor 1
Thyroid Hormone Receptor, Beta-2
Interferon
Homo sapiens crk-like gene CRKL
Human mRNA for cytochrome P-450IID (clone pMP33)
P97 Antigen. Melanoma-specific
Human seven transmembrane G-coupled receptor (GPR31) gene, complete cds
Human anaplastic lymphoma kinase receptor mRNA, complete cds
HUMTGFB3B Human transforming growth factor beta-3 gene, 5 end
Human mRNA for rasGTPase activating protein, partial cds
HUMPIM1 Human pim-1 oncogene mRNA, complete cds
HUMINTB 1A Human integrin beta-1 subunit mRNA, 3 end (cytoplasmic domain)
HUMRSPT Human homolog of yeast ribosomal protein S28, complete cds
HUMGPCR Human (clone L5) orphan G protein-coupled receptor mRNA, complete cds
Antigen. Prostate Specific. Alt. Splice Form 3
Human guanylate kinase (GUK1) mRNA, complet cds
HSIFR12 mRNA for human leucocyte (alpha) interferon
Homo sapiens bone morphogenetic protein 5 (BMP-5) mRNA, complete cds
Homo sapiens TAFII20 mRNA for transcription factor TFIID
Prostate-specific membrane antigen (alt. spliced) mRNA, partial
Homo sapiens mRNA for Fas/Apo-1 (clone pCRTM11-Fasdelta(4,7))
Human prostaglandin E2 receptor mRNA, complete cds
HUMCA13A Homo sapiens cadherin-13 mRNA, complete cds
HSCYCGI1 Homo sapiens mRNA for cyclin G1
Human interleukin-13 (IL-13) precursor gene, complete cds
Bone morphogenic protein-5 (BMP-5) promotor
Homo sapiens receptor protein-tyrosine kinase (TEK) mRNA, complete cds
Human mRNA for gliobastoma-derived T-cell suppressor factor G-TsF (TGF-beta2)
Human apolipoprotein E mRNA, complete cds
Human mRNA for c-myc binding protein, complete cds




We studied genetic instability in sporadic rectal cancers using MSI, LOH, ploidy,
immunohistochemical, p53 mutational and gene expression array analysis.
In our series of 81 rectal carcinomas, a MSI-high phenotype was observed in only one
tumour, indicating that this phenotype is rare in rectal cancer. Even when we separately
analysed specific subgroups previously reported to show higher incidences of MSI (young
patients and tumour multiplicity),39,40 we did not find more rectal tumours to be MSI-high.
Our results are in concordance with other studies, which showed low incidence of MSI in
distal tumours compared to proximal tumours.38
We identified replication errors in 11 tumours (14%) solely in tetranucleotide markers.
These tumours were classified as MSI-stable.23 One possible explanation for the instability
solely in tetranucleotide markers could be the proposed higher baseline mutation rate of
tetranucleotide repeats.41 One group of tetranucleotide alterations (AAAG)n seems to be
particularly susceptible to these alterations in non-HNPCC tumours of different types,
including lung, bladder and head and neck cancer.42 This different type of MSI has been
termed Elevated Microsatellite Alterations at Selected Tetranucleotide (EMAST) repeat
instability.23 In our series, 6 of the 11 tumours with tetranucleotide instability showed instability
in the EMAST repeats (D8S1130 and D15S1232). These alterations, however, do not seem
to have any biological relevance.38
In total, 74% of our tumours showed LOH with the highest frequencies for the markers
TP53 and D5S346 (APC), confirming previous reports11,43 and rendering selection bias in
our panel of rectal tumours unlikely. Not surprisingly, LOH-positive tumours (81%) more
frequently showed aneuploidy than LOH-negative tumours (47%, P=0.05). The discrepancy
that 47% of LOH negative tumours were aneuploid may be attributed to the limited number
of loci (n=12) investigated and to possible heterogeneity in tumours with regard to LOH and
ploidy status.44
We identified three distinct phenotypes in our rectal cancer series. The first phenotype
comprised the single MSI-high, aneuploid tumour (1/35). Cancers of the second phenotype
were MSI-stable and showed aneuploidy in 21/35 tumours investigated for ploidy. The
third phenotype combined a MSI-stable status with diploidy in 13/35 tumours. The existence
of this last group suggests that a substantial number of the rectal cancers were not driven
by the MSI or CIN pathway and that a third pathway might exist. Also other recent studies
of colorectal and rectal tumours showed subsets of MSI-stable carcinomas with diploid
DNA content or without LOH.45-48 The latter48 defined a subgroup of apparently stable near-
diploid chromosomes and stable microsatellites (Microsatellite And Chromosome Stable
(MACS)). These MACS tumours were often of early-onset with a high frequency of
chromosome 18q imbalances. Seventy-nine percent of these MACS tumours were located
in the distal colon. In our series of 13 diploid, MSI-stable tumours, the mean age was 56.3
years, which was nearly significantly different from the mean age in the total group of 81
tumours (mean age 62.5 years, P=0.07).
Further analysis of the diploid tumours without evidence of genetic instability (diploid,
MSI-stable) indicated that these tumours did not comprise a homogeneous group, but showed
different molecular phenotypes. Five out of 13 diploid tumours were likely to carry a p53
mutation. Our data and those of others indicate that mutation of p53 by itself may not be
sufficient for chromosomal instability.49 In concordance with our results, it has been
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demonstrated that p53 mutations occur in diploid MSI-positive tumours49 and that aneuploid
cell lines without p53 mutations exist.50 Other molecular mechanisms thought to be involved
in CIN are changes in mitotic checkpoint genes (Bub1),51 failure of DNA-damage checkpoints
(ATM)52 and the JC-virus.53 In addition, it was recently demonstrated that APC is related to
polarity, asymmetric division and aneuploidy and thus can cause CIN.54
Gene array expression analysis of five tumours without evidence for genetic instability
(diploid, MSI-stable) and two aneuploid also MSI-stable tumours showed heterogeneous
results. The most reliable expression differences were found between the p53 mutant and
wild-type diploid, MSI-stable tumours. Using four different methods of analysis a number
of differentially expressed genes were found in these two groups indicating the molecular
heterogeneity of these tumours. Gene products such as BRCA2 and the Cisplatin resistance
associated alpha protein, involved in tumourigenesis and therapy resistance respectively,
were differentially expressed. However, the impact of these data have to be confirmed in a
larger series of tumours. Differences in Ki-67 mRNA expression (a proliferation marker)
between p53 wild type and mutated diploid, MSI-stable tumours, identified by two-way
hierarchical clustering, were confirmed using immunohistochemistry. This observation might
also explain the relative higher expression of c-myc mRNA identified in the p53 mutated
tumours in view of its role in cell proliferation.55
A diploid tumour from a 29-year old patient showed a hMSH2/hMSH3 mRNA expression
deficit with loss of hMSH2 and hMSH6 at the protein level. The combination of retained
hMSH6 at the RNA-level, but loss at the protein-level when hMSH2 is lost, has been reported
before in mice.56 Also in endometrial tumours from HNPCC patients with hMSH2 mutations,
loss of the hMSH6 protein was seen.31 Microsatellite analysis and hMSH2/hMSH6 mutation
analysis of this tumour did not show MSI nor a mutation. Our results of loss of hMSH2/
hMSH3 both at the RNA and the former also at the protein level without MSI is hard to
explain, but might occur as a late effect during tumourigenesis. A hMSH3 germline mutation
being responsible for early onset of rectal cancer with concomitant loss of hMSH2 expression
seems unlikely in view of the redundant function of hMSH3.57
In conclusion, as others we identified a group of rectal tumours without evidence of
gross genetic instability by molecular analysis with microsatellite markers and flow cytometry.
Other authors subdivided these type of tumours already on basis of their age of onset or
chromosome 18q abnormalities. We show that tumour heterogeneity in this class of tumours
can also be defined by other molecular characteristics such as p53 mutation status and
differential expression profiles.
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The high local recurrence rate is a major problem in rectal cancer. Preoperative radiotherapy
(RT) has been shown to be useful in reducing the number of local recurrences.1 However,
a major disadvantage of preoperative RT is the over-treatment of a subset of patients.
Therefore prognostic markers for the tumour response to RT are needed. The tumour
suppressor gene p53 has been extensively studied for its prognostic value. In several studies,
overexpression of the p53 protein has been shown to correlate with patient survival,2-4 a
finding that has not been confirmed in other studies.5-8
One of the functions of p53 in normal cells is to respond to DNA damage by causing
either cell cycle arrest or by forcing damaged cells to go into apoptosis. Mutations in the
p53 gene lead to a functionally inactive protein. The p53 gene is one of the most commonly
inactivated genes in cancer9 and plays an important role in the multistage development of
colorectal cancer.10 The stability of the p53 protein is regulated by binding to MDM2, a
protein that degrades p53 and consequently inactivates the transcriptional function of p53.11-
12 Because of this regulation, wild type (wt) p53 is highly unstable, with a half-life of
minutes, and therefore hard to detect by immunohistochemistry (IHC). Mutations in p53
prevent degradation by MDM2, allowing stabilisation and detection of the protein by IHC.
Interpretation of IHC is complicated because other genetic alterations like frameshift mutations
or deletions can lead to truncation or complete loss of p53, which precludes detection with
IHC. Furthermore, MDM2 overexpression can prevent detection of wild type p53.
Therefore, negative staining for p53 indicates either wild type p53 or a non-functional gene.
After ionising irradiation the half-life of wt p53 increases significantly because of
phosphorylation of the protein, which inhibits degradation of the protein by MDM213 and
thus allows its detection by IHC. Accumulation of wt p53 normally leads to transcription of
several downstream target genes, such as p21waf1 and GADD45.14-15
The induction of the CDK inhibitor p21waf1 after ionising radiation leads to a G1 growth
arrest, thus allowing the cell to repair the damage.16 Apart from induction by wt p53,
activation of the p21waf1 gene can also occur through mechanisms independent of p53.17
TGF-β, the BRCA1 gene products and Nerve Growth Factor are examples of factors that
promote p21waf1 transcription by p53-independent mechanisms.18-20 In addition to a role in
the repair process, p21waf1 has an important function during differentiation of cells.21
In cell lines, the effects of ionising radiation on the expression of p53 and p21waf1 have
extensively been studied. After ionising radiation a rapid increase of wt p53 is observed,
normalising within 48-72 hours.22 A subsequent increase of p21waf1 expression is found in
cells with wt p53, however, this is not observed in cells with inactive p53.16 In normal
intestinal tissue of irradiated mice, a rapid increase of p53 as well as of p21waf1 positive cells
is reported.23 In p53-/- mice no increase in p21waf1 was observed after irradiation, indicating
that wt p53 is mandatory for upregulation of p21waf1.
Presence of wt p53, however, does not guarantee a functional intact pathway. Induction
of p53 after irradiation without upregulation of p21waf1 has been reported,24 suggesting
disruption of the pathway downstream of p53. Expression of p21waf1 after irradiation can
thus be used as an indicator of defects in the pathway downstream of p53.
The relationship between p53 and p21waf1 after irradiation has been investigated in the
normal intestinal mucosa of mice,23 but little is known about tumours in vivo. We therefore
evaluated the direct effect of ionising radiation on the expression of p53 and p21waf1 in
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normal mucosa and rectal carcinoma in vivo, by analysing a large number of tumours of
rectal cancer patients participating in a randomised trial. One half of the patients received
short-term preoperative RT within one week followed by surgery, and the other half
underwent surgery only. This trial disclosed a unique series of samples serving as an in
vivo model for the functional activity of the p53 protein.
By careful evaluation of expression patterns of both p53 and p21 we suggest new
criteria for determination of p53 mutations on IHC. Furthermore, we show that in tumours
with p53 wild type the downstream pathway is often disrupted.
METHODS
Patients and treatment
All tumours used for analysis were derived from rectal cancer patients, randomised in a
large multicenter trial in which the effect of short-term, preoperative RT (5x5 Gy) in
combination with total mesorectal excision (TME) surgery was investigated.25 They were
randomised to either RT followed by surgery or surgery alone. The patients assigned to
preoperative RT received a total dose of 25 Gy in 5 fractions during 5-7 days. Irradiated
patients in whom the interval between RT and operation exceeded 8 days were excluded
from analysis. Standardised routine pathologic examination was performed in the laboratories
of the referring hospitals as described by Quirke et al.26 Tumour staging was performed
using the Tumour-Node-Metastasis (TNM) classification.27
Tumours
The expression of p53 and p21waf1 was evaluated in tumour samples from the first 103
patients entered in the trial from the 12 hospitals contributing the most patients. Of these
patients, 51 received preoperative RT. To compare the expression of p53 before and after
RT in individual tumours, 32 pretreatment biopsies of irradiated patients were collected,
analysed for p53 expression and compared with the corresponding irradiated tumour
specimen. The other 19 biopsies were either not available or too small to analyse.
To evaluate the kinetics of p53 degradation after ionising radiation, we analysed p53
expression in tumour and normal tissue with varying intervals between the last fraction of
RT and surgery of 1, 3, 5 or 7 days. Because most patients underwent surgery after 3 days,
we additionally stained 53 samples to extend the different groups to 20 samples. Only 15
patients had an interval of 7 days in the trial, leading to 75 tumours in total. Both tumour and
normal tissue were stained for all samples.
Colorectal tumours are considered mucinous when mucin covers more than 50% of the
microscopically observed areas.28 From the literature, it is known that mucinous tumours
are more often  wild type p53.29 To evaluate the effect of RT on the expression of p53 in wt
tumours, we additionally analysed all tumours with 90-100% mucinous areas from patients
randomised in the trial.
Immunohistochemistry
Tissue samples of the primary tumours were fixed in 4% phosphate-buffered formalin,
dehydrated and embedded in paraffin. Tissue sections of 4 µm were cut and mounted onto
2% 3-aminopropyltriethoxysilane (APES) pre-coated slides. Serial sections were stained
with hematoxylin and eosin or processed for immunohistochemistry.
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p53 and p21waf1 expression were assessed by immunohistochemical investigation with
the following antibodies: anti-p53 (mAb NCL-p53-DO-7, Novocastra Laboratories Ltd.,
Newcastle, United Kingdom) and anti-p21 (WAF 1 (Ab-1), Oncogene Research Products,
Cambridge, Massachusetts). In brief, sections were deparaffinised in xylene and rehydrated.
Endogenous peroxidase activity was blocked by 1% hydrogen peroxide for 20 minutes. For
non-enzymatic epitope retrieval, 0.01 M citrate buffer (pH 6.0) was used. After overnight
incubation with the primary antibody (dilutions: p53 1/2000, p21 waf1 /250) in 1% phosphate-
buffered saline/bovine serum albumin (1% PBS-BSA), the secondary biotin-conjugated
antibody and a tertiary complex of streptavidin-avidin-biotin conjugated to 3-amino-9-ethyl-
carbazole (AEC) or 3',3'-diaminobenzidine (DAB) were applied. Finally, the sections were
counterstained with haematoxylin. Incubation with PBS instead of the primary antibody
served as a negative control.
Scoring
All slides were evaluated semi-quantitatively and independently by two investigators (CAMM
and EK). Sections that were categorised discrepantly were discussed together with an
independent investigator (JHJMvK). Nuclear p53 and p21waf1 staining were scored in tumour
tissue in the following categories: 0%, 1-5%, 5-15%, 16-25%, 26-75% and >75%. Normal
mucosal tissue was scored when present in the same block. p53 expression in normal
mucosa was scored in the same categories as the tumour tissue. For p21waf1, normal mucosal
tissue was scored as totally positive, apical cells positive or totally negative. Since some
mucinous tumours contain relatively few tumour cells, p53 was only scored in three categories
in these tumours: 0%, 1-25% and 26-100% positive cells.
In order to analyse the correlation between different variables, p21waf1 was regarded
positive if more than 5% of the tumour cells stained positive. p53 in tumours was divided in
three categories: 0% (negative), 1-25% (low) and >25% (positive) to evaluate the influence
of RT on the expression of p53.
Data collection and statistics
All data were entered in a database and analysed with Mann-Whitney tests to compare
quantitative and ordered variables and with Student’s t-tests to analyse differences in normally
distributed data between the two groups. Chi-square tests were used to compare proportions.
A two-sided P-value of 0.05 or less was considered statistically significant.
RESULTS
Patient characteristics
The mean age was 62 years in the irradiated group and 63 years in the unirradiated group.
Thirty-one percent of the irradiated patients had a TNM stage III tumour, vs. 40% of the
unirradiated patients. There was no difference in the distribution of gender, type of operation
or tumour type in both treatment arms.
p53
To assess the influence of RT on p53 expression in vivo, we examined 103 rectal tumours
and normal mucosa. Nuclear expression of p53 was observed in both irradiated and non-
irradiated tumours (Figure 1A). A complete absence of p53 after RT was observed in 8
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Table 1. Distribution of p53 expressing cells in normal mucosa of






p53 n % n %
0% 0 - 12 43 <0.001
1-5% 2 5 15 54
6-15% 7 18 - -
16-25% 2 5 - -
26-75% 26 68 1 3
76-100% 1 3 - -
tumours (Figure 1B), whereas irradiated normal mucosa as well as stromal tissue showed
widely distributed p53 staining (Figure 1C). p53 expression in tumour tissue in samples
from both treatment arms is displayed in Figure 2. In the non-irradiated group, slightly
more tumours were found with 1-5% or 6-15% of the cells expressing p53, while in the
irradiated group more tumours expressed p53 in 76-100% of the cells. These findings
suggest that tumours with low p53 expression (1-25%) might contain wt p53 that can be
upregulated by irradiation. When the whole group was evaluated this difference could no
longer be observed (P=0.39), because of the small numbers of tumours in these categories.
p53 expression in normal mucosa was determined when present, which was in 38
samples of the irradiated group and in 28 of the non-irradiated group. Only one non-irradiated
normal mucosa sample showed p53 expression in >5% of the cells, whereas this was
present in 36/38 (95%) of the irradiated normal mucosa samples (P<0.001, Table 1). This
clearly demonstrates upregulation of p53 in normal tissue after irradiation.
To evaluate the kinetics of p53 upregulation after RT in vivo, we selected tumours and
normal mucosa of 75 patients with an interval between RT and surgery of 1, 3, 5 or 7 days.
The percentage of p53-positive tumours ranged between 55% and 80% and did not vary
significantly between the different intervals.
In all normal mucosal tissue samples p53 expression was still observed up to 7 days
after the last fraction of RT. There was, however, a decrease in the percentage of positive
cells over time.
p53 in biopsies
Since the percentage of p53-positive tumour cells over the various categories in irradiated
tumours was not different from that for unirradiated tumour samples, we compared p53
expression before and after irradiation in individual tumours by evaluating the 32 available
preoperative biopsies. The distribution of the p53 expression in the biopsies as well as in the
corresponding irradiated tumours is given in Table 2. Five negative biopsies had corresponding
irradiated p53-negative tumours, indicating that these tumours represent non-functional
p53. Seven biopsies with negative or low p53 expression, showed upregulation of p53 in
the corresponding tumours after irradiation, suggesting the presence of wt p53. 19 biopsies
showed p53 expression in more than 25% of the cells. Since the patients had not been
irradiated at the time of biopsy, this is most likely due to mutant p53.
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Table 2. Relation between p53 expression in non-irradated biopsies
and corresponding irradiated tumours.*
Tumour
Biopsy 0% 1-25% 26-100%
0% 5 1 3
1-25% 0 0 4
26-100% 0 2 17
* Numbers in the cells represent numbers of tumours.
p53 in mucinous tumours
To evaluate the effect of RT on p53 expression in a group of tumours that most probably
contained wild type p53, we analysed p53 expression in all 100% mucinous tumours in the
trial. Results are depicted in Figure 3. In the non-irradiated group, 11 of 18 mucinous
tumours showed low p53 expression (1-25%) vs. 12 of 52 non-mucinous tumours (61%
vs. 23%), suggesting that wt p53 is frequently present in mucinous tumours. Eighteen of
the 24 irradiated mucinous tumours were more p53-positive compared to only 4 of 18 of
the non-irradiated mucinous tumours, suggesting upregulation of wt p53 after RT in this
group.
p21waf1
To evaluate the effect of radiotherapy on the expression of p21waf1 in rectal cancer in vivo
we compared irradiated and non-irradiated tumours and normal mucosa. Nuclear expression
of p21waf1 was observed in irradiated tumours and in non-irradiated tumours. p21waf1
expression in tumours in both treatment arms is displayed in Figure 4, demonstrating similar
p21waf1 expression in both treatment arms. Normal mucosa was present in 29 samples of
each treatment arm and showed widely distributed p21waf1 staining in 97% (28 of 29 of the
irradiated cases and was negative in 76% (22 of 29) of the unirradiated cases (P<0.001).
Occasionally, the unirradiated mucosa showed some p21waf1 positive cells in the upper part
of the crypts. This suggests that radiotherapy induces p21waf1 expression in normal cells,
but has no influence on the p21waf1 expression in rectal tumour cells.
Relationship between p53 and p21waf1
To investigate whether p21waf1 expression in vivo is dependent on the p53 status, we analysed
the relationship between p53 and p21waf1. This relationship for irradiated and non-irradiated
tumour tissue is represented in Table 3. In the irradiated group, none of the eight p53-
negative tumours showed p21waf1 expression, in line with the functional absence of p53. Of
the 36 irradiated tumours positive for p53, 9 (25%) were also positive for p21waf1. In the
unirradiated group 33 tumours were positive for p53, of which 6 (18%) were also positive
for p21waf1. These percentages for p21waf1 positivity in irradiated and unirradiated tumours
show that upregulation of p21waf1 by p53 after radiotherapy is not very common.
In normal mucosa, 28 samples in each group could be analysed for both p21 waf1 and p53
expression. Of the unirradiated samples, 20 of 28 were negative for p21waf1 and p53 expression,
however, of the irradiated samples 26 of 28 were positive for both p53 and p21waf1 expression.
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Table 3. Relationship between p53 and p21 expression in
irradiated and non-irradiated tumours.*
Irradiated tumours
p21 negative p21 positive
p53 negative 8 0
p53 low 3 2
p53 positive 27 9
Non-irradiated tumours
p21 negative p21 positive
p53 negative 6 1
p53 low 9 3
p53 positive 27 6
* Numbers represent numbers of tumours.
The status of p53 expression in untreated biopsies in relation to the corresponding irradiated
tumours is shown in Figure 5. In this figure, we included expression of p21waf1 as a marker
for the functionality of p53. Of the 7 tumours in Table 2 with probably wild-type p53, only
two tumours showed upregulation of p21waf1, and 5 were negative for p21waf1 (Figure 1D-
1F).
Of the 19 tumours with a p53-positive biopsy, 17 showed p53 positivity in the tumour,
indicating the presence of mutant p53. Three of these tumours showed p21waf1 expression
(Figure 1G-1I). Although the numbers were small, these results indicate that the presence
of wt p53 does not necessarily lead to upregulation of p21waf1, while the presence of mutant
p53 does not exclude p21waf1 overexpression.
DISCUSSION
This study was undertaken to evaluate the in vivo effect of radiotherapy on the expression
of p53 and p21waf1 in normal rectal mucosa and rectal carcinoma.
For the first time, we demonstrate that in normal cells p53 as well as p21waf1 are
upregulated in humans in vivo after short-term preoperative radiotherapy. In tumour cells
however, no difference in the expression of p53 or p21waf1 in rectal tumours could be
observed between the irradiated and non-irradiated groups. These results indicate that p53
protein in rectal tumours does not respond to irradiation, suggesting a very high frequency
of p53 abnormalities. We conclude that the p53-p21waf1 pathway is disrupted in nearly all
tumours, but that there are different underlying mechanisms.
p53 in normal mucosa
In normal cells, p53 can generally not be detected by immunohistochemistry, whereas
stabilised p53 can be detected. Stabilisation may occur either through mutation (in cancer)
or through phosphorylation of the protein (e.g. after radiotherapy). All irradiated normal
mucosa samples showed overexpression of p53, confirming that in vivowt p53 is upregulated
after irradiation. We detected p53 expression 7 days after the last fraction of radiotherapy,





Figure 1. Expression of p53 and p21 in tumour biopsies, tumours and normal mucosa.
A:  Non-irradiated sample, showing p53-positive tumour cells (), whereas normal mucosal cells (   ) are p53-
negative. B:  Irradiated sample, showing a tumour completely negative for p53 (    ), with p53-positive normal
mucosa cells (   ) and stromal cells. C: p53-positive normal mucosa after irradiation.
D, E, F: Samples from the same patient. D: Non-irradiated tumour biopsy with 1-25% of the cells p53 positive.
E: Corresponding irradiated tumour, showing >25% of the cells p53 positive, indicative for wild type p53. F:
Same tumour as E, showing no p21waf1 staining in tumour cells, indicative for a disrupted pathway. Stromal cells
are clearly positive.
G, H, I:  Samples from the same patient. G: Non-irradiated tumour biopsy with >25% of cells p53 positive,
indicative for mutant p53. H: Corresponding irradiated tumour, showing >25% of the cells p53 positive. I:  Same
tumour as H, showing p21waf1 positive cells throughout the tumour, indicating a p53 independent upregulation of
p21waf1. RT: irradiated, no RT: non-irradiated. (for full-colour figure, see page 181)
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Figure 2. Distribution of percentage of p53 expressing cells
over the treatment arms. No difference is observed (P=0.39).
RT+TME: radiotherapy followed by surgery, TME: surgery
only.
Figure 3. Distribution of p53 expression in non-mucinous,
mucinous and irradiated mucinous tumours. A shift from low
p53 expression in the mucinous tumours towards p53
positivity in the irradiated tumours is observed, indicative
for the upregulation of wild type p53 after irradiation.
Figure 4. Distribution of p21waf1 expressing cells over the
treatment arms. No difference is observed (P=0.36).
RT+TME: radiotherapy followed by surgery, TME:
surgery only.
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Figure 5. Flow chart demonstrating the relationship between
the p53 expression in untreated biopsies and the irradiated































































p21waf1 in normal mucosa
In unirradiated mucosa, we observed expression of p21waf1 in cells located in the upper part
of the crypts. This has been described before and this apical expression is thought to be
limited to differentiated and non-proliferating cells.21 After radiotherapy expression of p21waf1
in normal mucosa was upregulated throughout the crypt and demonstrates upregulation of
p21waf1 by wt p53 after ionising irradiation. These data confirm that in vivo a functional
p53-p21waf1 pathway can be demonstrated using IHC.
p53 in tumours
The clear upregulation of wt p53 in normal mucosa suggests that tumours in the irradiated
group completely negative for p53 do not represent tumours with functional p53. Because
no significant difference was found in the number of p53-negative tumours in both treatment
arms, we propose that all tumours completely devoid of p53-positive cells contain either a
frameshift or truncating p53 mutation or have MDM2 overexpression.
Previously we have shown that p53 positivity by immunohistochemistry in nonirradiated
carcinomas almost always represents mutated p53.30 In the irradiated group however, p53-
positive tumours can either have mutated or upregulated p53. Because the number of p53-
positive tumours was not significantly different between both treatment arms, it is likely
that in the irradiated group high p53 expression was in the great majority of cases caused by
mutation and not by radiation-induced upregulation of wt p53. The slight difference between
both treatment arms in the distribution of tumours with low p53 expression, suggests that
tumours expressing p53 in 1-25% of the cells might contain wt p53. In conclusion, we
propose that tumours completely negative for p53 or showing p53 overexpression represent
tumours with non-functional p53, and p53 expression in 1-25% of the cells is indicative for
wt p53. This means that in our study, in 84% of the tumours p53 was non-functional, a
higher percentage than usually reported for colorectal cancer (40-80%).4,31 The results of
p53 expression in mucinous tumours are in agreement with this hypothesis. The higher
number of unirradiated mucinous tumours with low p53 expression vs. the relatively low
frequency in the irradiated group, confirms the assumption that tumours with low p53
expression (1-25% of the cells positive) represent tumours with wild type protein, that
becomes upregulated after radiotherapy.
The observed upregulation after irradiation in p53 negative biopsies, seems in contrast
with the conclusion that p53-negative samples contain mutated p53. This might be explained
by the small size of these samples, preventing the detection of p53-positive cells in biopsies.
In a study with 5x5 Gy preoperative radiotherapy, the irradiated as well as the unirradiated
group showed p53 positivity in the tumours, while the biopsies were negative.4 This observed
increase in the non-irradiated tumours confirms that biopsies can be too small to reliably
indicate p53 status. Another study comparing nonirradiated biopsies with irradiated surgical
samples, showed no increase in the expression of p53 after radiotherapy.5 Apart from the
size of the biopsies, this might be explained by the fact that in this study the median interval
between radiotherapy and surgery was 14 days, allowing the degradation of radiation-
induced stabilised wt p53.
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In colorectal carcinoma there is an accumulation of genetic changes in a preferential order
in which specific oncogenes and tumour suppressor genes take part. In the initiation of
colorectal cancer, genomic instability plays an important role in the accumulation of these
genetic changes.
In the progression of colorectal tumours, microenvironmental interactions are important.
Loss of cell adhesion leads to a reorganisation of epithelial cells and enables invasion and
metastasis.1 In cell-cell adhesion, E-cadherin is associated with the actin cytoskeleton via
cytoplasmic proteins, including α-, β-, and γ-catenins, which together form the cadherin/
catenin complex.2 The epithelial cell adhesion molecule (EpCAM) has been shown to affect
in vitro expression of the intercellular adhesions mediated by cadherins.3 Furthermore,
angiogenesis has been described as vital for tumour growth and expansion; influx of new
blood vessels may facilitate dissemination to distant sites.4,5
Complete resection remains the best chance for cure in colorectal cancer. The results of
traditional rectal cancer surgery however, are discouraging with a high percentage of local
recurrence and large variability between surgeons.6,7 Two important factors that have been
reported to improve local control and survival are standardised Total Mesorectal Excision
(TME)-surgery8 and preoperative radiotherapy.9 Many studies have been performed to find
biological parameters that identify a higher degree of aggressiveness, independent of known
clinical and pathological features. Such parameters may have additional value to improve
treatment strategies.
In this study, the aim was to analyse the influence of irradiation on the expression of cell
adhesion molecules and microvessel count and to investigate the prognostic value of these
factors in rectal cancer. Rectal cancer cases were obtained from a large, prospective trial in
which the additional role of preoperative radiotherapy was investigated in combination with
TME-surgery. In this trial, radiotherapy, surgery and pathology were standardised and
provides optimal conditions for studying prognostic markers.10
METHODS
Patients
Ninety-seven rectal cancer patients who had undergone a macroscopically curative resection
with or without preoperative radiotherapy, were analysed. These patients were included in
a multicentre trial in which randomisation took place for preoperative radiotherapy of 5x5
Gy followed by standardised TME-surgery or TME-surgery alone. The 97 patients were
randomised in the trial during the first year; their samples were selected from the 12 largest
pathology laboratories to avoid too many different fixation methods.
Immunohistochemistry
From formalin-fixed, paraffin embedded tissue blocks 4 µm sections were cut and mounted
on 2% 3-aminopropyltriethoxysilane (APES) pre-coated slides. Sections were deparaffinised
in xylene and rehydrated. Endogenous peroxidase activity was blocked with 1% hydrogen
peroxide for 20 minutes. Immunohistochemical investigation was performed with the
following antibodies: E-cadherin (1:1000, Zymed Laboratories, San Francisco, CA, USA),
α-catenin (1:1000, Transduction laboratories, Lexington, KY, USA), β-catenin (1:20000,
Transduction laboratories, Lexington, KY, USA), γ-catenin (1:8000, Transduction
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laboratories, Lexington, KY, USA), EpCAM (1:2500, Centocor, Malvern, PA, USA) and
CD31 (1:400, Dako, Glostrup, Denmark). For E-cadherin, α-, β- and γ-catenin and CD31,
the sections were first boiled in citrate buffer (pH 6.0) for 25 minutes. For EpCAM the
sections were pretreated with trypsin (0.1% trypsin with 0.1% calcium chloride), pH 7.4 at
37 °C for 20 min. After overnight incubation with the primary antibody in 1% phosphate
buffered saline/bovine serum albumin (1% PBS-BSA), the secondary biotin-conjugated
antibody and a tertiary complex of streptavidin-avidin-biotin-conjugated to amino-9-ethyl-
carbazole (AEC) or 3’,3’-diaminobenzidine (DAB) were applied. Finally, the sections were
counterstained with hematoxylin. Incubation with PBS instead of the primary antibody
served as a negative control. Positive controls were included in each staining session. In
addition, in most slides normal colorectal tissue served as a positive internal control. The
same area of the tumour was used for the various stains, so there was no sampling problem
with respect to the comparison of staining patterns.
Analysis of staining patterns
The E-cadherin, α-catenin, β-catenin, γ-catenin and EpCAM slides were independently
assessed by two observers (EK and JHJMvK) and in case of discrepancy, discussed until
agreement was reached.
For each marker a scoring system was developed after initial screening of the variation
of expression of each marker and taking systems used in the literature into account.11,12
Membranous staining patterns of E-cadherin, α-catenin, γ-catenin and EpCAM, were scored
according to the following categories: severe loss (0-49% expression), moderate loss (50-
89% expression), loss only at the infiltrating front of the tumour (90-99% expression) and
no loss (100% expression). β-catenin was scored as membranous expression/no obvious
nuclear expression, nuclear expression in the infiltrating front of the tumour or nuclear
expression all over the tumour.
For microvessel count analysis (CD31), image analysis was performed using the Zeiss
vision KS400 image analysis system. Images were recorded by a three-chip CCD camera
(DXC-950P, Sony) mounted on top of a conventional light microscope (Axioskop, Zeiss).
Five hot spots were selected at x40 and/or x100 magnification by EK after consultation
with JHJMvK. Finally, the fields selected were scanned at x200 magnification. Microvessel
count was analysed by the computer and expressed as the amount of microvessel perimeter
per square millimetre. The mean value of the 5 measurements per sample was taken as
microvessel count for that sample.
To investigate the reproducibility of our staining technique and microvessel count analysis,
20 CD31 slides of our series were stained a second time using CD31 as antibody and
investigated with another computer-aided image system by BEvdW. There was a significant
correlation between the series of EK and BEvdW (Pearson correlation coefficient 0.5, P=0.04),
implying reasonably good reproducibility of the staining technique and microvessel count
analysis.
Statistics
Data were analysed using SPSS statistical software (version 9.0 for Windows, SPSS,
Chicago). Some clinicopathological variables were categorised in fewer categories to avoid
statistics with small numbers. Marker expression was dichotomised on the basis of frequency
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tables to achieve a 50%-50% distribution as close as possible; cases with an expression
below the cut-off were referred to as loss of expression, and above the cut-off as no loss
or preserved expression. For microvessel count, the mean was taken as cut-off for low-
vs. high-vascularisation. Chi-square tests were used to compare proportions. Comparison
of mean values between two groups were made using Student’s t-tests. Univariate recurrence
and survival analyses were carried out by using the Kaplan-Meier method and differences
between groups were compared by the log-rank test. The Cox proportional hazards model
was used for multivariate analysis; variables with a P-value of less than 0.1 in the univariate
analysis were included in the multivariate analysis. A P-value of 0.05 (two-sided) or less
was considered statistically significant.
RESULTS
Patients
The analysed series consisted of 46 irradiated and 51 non-irradiated patients, who underwent
a macroscopically curative resection. Clinical and pathological characteristics were equally
distributed among the randomisation groups, apart from more mucinous tumours (P=0.035)
and a worse differentiation grade in the irradiated group (P=0.02, Table 1). These differences
were also present in the whole trial population.13 Mean follow-up of patients still alive was
47 months (range 35-56 months). Of the 97 patients, 25 patients died. Five patients developed
local recurrences, all with distant recurrence at the time of presentation of local recurrence
or later in the follow-up. Eighteen patients developed distant recurrence alone.
Table 1. Clinical and histopathological data according to randomisation group, n (%).†
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† Because of rounding, percentages may not total 100.
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Randomisation group (Table 2)
Adhesion
The cut-off points for E-cadherin, α- and γ-catenin were determined at 0-89% vs. 90-
100% expression to obtain a 50%-50% distribution as close as possible. For EpCAM the
cut-off point was 90-99% vs. 100%. Irradiated tumours showed more nuclear β-catenin all
over the tumour as compared to non-irradiated tumours (P=0.007).
Microvessel count
We used mean microvessel count as cut-off; 41 tumours had a low microvessel count and




Loss of E-cadherin expression, was associated with the presence of a moderate/extensive
lymphoid reaction (P=0.046) and advanced TNM-stage (P=0.048). Furthermore, absence
of nuclear β-catenin expression was related to the mucinous phenotype (P=0.007). Tumours
with loss of EpCAM expression showed more often a growth pattern of diffuse tumour
infiltration (P=0.005).
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* There are missing cases, since some stainings were not successful.




A low microvessel count was associated with diffuse tumour infiltration (P=0.001) and the
presence of an extensive eosinophyl reaction (P=0.03).
Mutual associations between adhesion and microvessel count
Preserved E-cadherin expression was associated with nuclear expression of β-catenin either
at the invasive front or all over the tumour (P=0.05). Furthermore, preserved α-catenin
was associated with preserved γ-expression (P=0.004). No other mutual associations were
found between adhesion expression profiles and between adhesion and microvessel count.
Prognosis (Table 3)
Adhesion
Loss of EpCAM expression was significantly associated with local recurrence (loss: 12%
vs. preserved: 0%, P=0.015, Figure 1). No association was found between EpCAM expression
and distant recurrence (P=0.61). A minor effect of loss of EpCAM expression was seen on
overall survival (66% vs. 80%, P=0.08). Since the number of local recurrences was low
(n=5), we did not perform a multivariate Cox analysis for local recurrence risk.
Microvessel count
Low microvessel count was associated with an increased distant recurrence risk (low:
33% vs. high: 5%, P=0.04, Figure 2), and probably due to this, low microvessel count was
also associated with a lower survival rate (72% vs. 85%, P=0.02, Figure 3). No association
was found between microvessel count and local recurrence (P=0.73). For distant recurrence
risk, multivariate Cox regression showed that only TNM-stage (P=0.005) was an independent
predictor; microvessel count was not an independent predictor for distant recurrence when
corrected for TNM-stage (P=0.11). For overall survival, multivariate Cox regression showed
that TNM-stage (P<0.001) and gender (P=0.004) were independent predictors; microvessel
count was not significant in this analysis (P=0.21).
Remarkably, in Figure 2 showing distant recurrence risks of patients with low and high
microvessel count, the curves for low and high microvessel count diverge up to 36 months,
while after 36 months the curves converge. It seems that distant recurrences in the high
microvessel count group occurred later in the follow-up. However, we have to be careful
with this conclusion since the curves become less reliable after longer follow-up as lower
numbers of patients are at risk and the numbers of events are low. In addition, the difference
between low and high microvessel count was still significant for the whole period of follow-
up.
Separate analysis of irradiated vs. non-irradiated tumours revealed non-significant associations
between EpCAM-expression and local recurrence risk for irradiated tumours (P=0.16) and
non-irradiated tumours (P=0.27). Also, no significant association was found between
microvessel count and distant recurrence risk for irradiated tumours (P=0.12) and non-
irradiated tumours (P=0.065). These non-significant associations in our subgroup analysis
are probably due to the low numbers of events in the separate randomisation groups.
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Table 3. Results of univariate log rank analyses for the risk on local recurrence, distant























































































Figure 1. Local recurrence risk of 97
rectal cancer patients with loss vs.
preserved EpCAM expression (P=0.015).
Figure 2. Distant recurrence risk of 91
(out of 97) rectal cancer patients with low
vs. high microvessel count (P=0.04).
Figure 3. Overall survival of 91 (out of 97)
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affect components of the wnt/wingless signaling pathway which might lead to nuclear
localisation of β-catenin. We did not find an association between nuclear β-catenin and
prognosis. In concordance with our results, Gunther et al.15 did not detect an association
between nuclear β-catenin expression and the occurrence of distant metastases.
Our study did not show any association between expression of E-cadherin, α−, β− and
γ−catenin and prognosis. However, a relationship between E-cadherin expression and
metastasis has been suggested for colorectal tumours.16 Nevertheless, other studies did not
find an association between E-cadherin and metastasis; such studies have shown metastatic
tumour cells to be strongly E-cadherin positive.17,18 Associations between loss of α-catenin
and invasion, metastasis or poor prognosis have been reported in colorectal carcinomas.19,20
Another study found no association between loss of α-catenin expression and worse
prognosis.21 For γ-catenin, most studies showed no or few loss of expression in colorectal
cancers.16,22 One study however, showed decreased γ-catenin expression to be associated
with increasing severity of dysplasia in adenomas.23
EpCAM is an important component in cell-cell adhesion and seems to have a central role
in this process since it affects intercellular adhesions mediated by cadherins.3 In normal and
cancerous intestinal tissue, EpCAM is generally strongly expressed.24 W  found an association
between loss of EpCAM expression and local recurrence. The number of local recurrences
was only 5 in our series, representing a major decrease in local recurrence rate by the
introduction of TME-surgery in our multicentre trial.25 Although the number is low, we
consider our finding of EpCAM predicting local recurrence of substantial value, since all
the 5 primary tumours of patients with local recurrence showed loss of EpCAM expression.
In addition, when we compared the tumours of patients with a local recurrence vs. the
tumours with also loss of EpCAM expression (i.e. < 99% expression) but without local
recurrence, we found that in the local recurrence group 3/5 (60%) tumours showed severe/
moderate loss of EpCAM vs. 14/43 (33%) in the no local recurrence group with loss of
EpCAM.
Angiogenesis has been described as vital for tumour growth and expansion.4,5 We found
an association between irradiation and low microvessel count. Radiation therapy has been
shown to injure both endothelial cells and the basement membrane of microvessels, mainly
by increased permeability and fibrosis.26 On the other hand, the response of tumours to
DISCUSSION
In this study, we analysed the influence of irradiation on the expression of cell adhesion
molecules and microvessel count, and investigated the prognostic value of these aspects in
rectal cancer. Since cell adhesion and angiogenesis are important components in the process
of invasion and metastasis, we focussed on these two issues. Cases were obtained from a
randomised trial investigating the role of preoperative radiotherapy in combination with
standardised surgery. Standardisation of treatment is a prerequisite to optimally study aspects
of prognostic markers in rectal cancer, especially since the surgeon has been shown to be
an important factor for outcome.6,7
Nearly all components of the cadherin/catenin complex were investigated, which plays
an essential role in intercellular adhesions. We found an association between radiotherapy
and the presence of nuclear β-catenin. Nuclear localisation of β-catenin can be the result of
mutations in APC or β-catenin itself, and is an indication of a disruption of the wnt/wingless
signaling pathway.14 It is difficult to speculate on this finding, but perhaps irradiation can
EpCAM expression and microvessel count as prognostic factors
149
irradiation depends on the distribution of oxygen which is determined in part by the
architecture of the vascular network in tumours. Retrospective analysis of cervical and
nasopharyngeal carcinomas revealed that vascular density was related to results of
radiotherapy, larger vascular density being associated with prolonged survival.27,28 V scular
density determination can therefore be helpful in recognising the cases for which adjuvant
treatment may be useful. In our study we did not investigate expression profiles which
could predict the response to preoperative radiation since biopsies are not representative for
assessment of the microenvironment of tumours (i.e. the invasive front). Future research
of our group with preoperative biopsies will reveal which factors predict the response to
radiotherapy in rectal cancer.
We found low microvessel count to be associated with a higher distant recurrence risk
and worse overall survival for the total group of tumours, although it was not an independent
predictor for these outcomes and separate analysis in irradiated and non-irradiated tumours
did not reveal significant associations between microvessel count and distant recurrence.
Recently, we showed that preoperative radiotherapy significantly reduces local recurrence
risk when combined with total mesorectal excision, but does not have an effect on distant
recurrence risk.25 We cannot be absolutely sure whether the association between microvessel
count and distant recurrence for the total group of tumours has been influenced by the
effect of radiotherapy on microvessel count. However, this seems highly unlikely since we
found an association between low microvessel count (which can be induced by radiotherapy
as we show in this paper) and more distant recurrence; an outcome probably not influenced
by preoperative irradiation.
Several interacting factors control angiogenesis. The host defense, represented by e.g.
T lymphocytes, mononuclear phagocytes and natural-killer cells, is dependent on the tumour
blood supply,4 and tumour-associated macrophages have been shown to induce
neoangiogenesis.29 Our finding of high microvessel count being associated with less distant
recurrence and better overall survival, might be attributable to the fact that by increasing the
contact surface between circulating blood and the tumour (i.e. high microvessel density),
the opportunity for an immunological response becomes greater. We did not detect an
association between high microvessel count and extensive lymphoid or eosinophilic infiltration,
but other immune cells may have a more prominent role in the response against the tumour
and influence recurrence and survival rates, as has been shown in another paper of our
group.30
Our findings of microvessel count being a favourable prognostic factor are supported
by results of Lindmark et al.,31 who found that a high microvascular count predicted a
longer survival time in colorectal cancer. However, this study was criticised for its
methodology.31 Most other studies demonstrated that vessel count was associated with
metastasis or worse prognosis,32-35 although there were also studies in which no association
was found.36,37 The only prospective study of the effect of microvessel density by Vermeulen
et al.38 showed that high intratumoural microvessel density was significantly associated
with shorter survival and haematogenous metastasis.
Controversy concerning the role of microvessel count may arise from different
methodologies utilised in assessing microvessel counts.39 We defined microvessel count as
the total perimeter of all vessels in one microscopic field. Although we did not use Chalkley
counting,40 a method which suggests the validity for comparing angiogenesis for prognostic
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purposes between different centres, we think that we followed most guidelines of the
proposed standard method for intratumoural microvessel density as described by Vermeulen
et al.41 In addition, the most observer-dependent step still remains with Chalkley counting;
i.e. the selection of vascular hot spots. This was as much as possible ruled out by defining
the hot spots by two observers (EK and JHJMvK) for all tumours in our study. Furthermore,
our microvessel counts of 20 samples were reanalysed and confirmed by BEvdW, who
used a different image analysis system, indicating that our results are reliable. Our findings
and that of Lindmark et al. however, do need further investigation. We have already started
further investigations to analyse microvessel counts at the invasive front of rectal tumours.42
In conclusion, we demonstrate that molecules involved in adhesion and angiogenesis
provide prognostic information in a series of rectal cancer patients with well documented,
prospectively collected data from a randomised trial in which treatment was standardised.
Loss of EpCAM expression was associated with increased local recurrence risk and low
microvessel count with increased distant recurrence risk. Examining multiple mechanisms
in colorectal oncogenesis is a useful approach to dissect the complexity of genetic alterations
thereby uncovering the role, timing and prognostic value of such alterations. This provides
a better understanding of colorectal tumour behaviour and may contribute to improved
therapy.
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The general introduction in Chapter 1 presents clinical aspects and molecular backgrounds
of (colo)rectal cancer. In this thesis, we have focused on both of these aspects since
understanding of the molecular background of rectal cancer can provide useful information
for the determination of clinical strategies. The results are mainly obtained from a trial
performed by the Dutch ColoRectal Cancer Group “Total mesorectal excision with or without
preoperative radiotherapy in the treatment of primary rectal cancer” (TME-trial).
PART I: ADVANCES IN TREATMENT
Local recurrences (LR) have been a major problem in the treatment of rectal cancer. A high
incidence of local recurrence (15-45%) is associated with conventional, non-standardised
procedures, which consists of blunt dissection of the rectal fascia and often results in
incomplete removal of mesorectal tissue. Chapter 2 describes a population-based study of
local recurrence rates in curatively resected patients with rectal cancer, diagnosed between
1988 and 1992, in the west Netherlands. The first objective was to make an inventory of
the overall local recurrence rate after non-standardised conventional surgery, inter-institutional
local recurrence rate variability, and correlations between patient- and tumour-related factors
and local recurrence rate. A second objective was to investigate the compliance to guidelines
for postoperative radiotherapy. The overall local recurrence rate was 22.5% with a range of
9-36% between the 12 hospitals. These differences were not significant. Dukes’ Astler-
Coller stage, tumour location and residual tumour were significant independent prognostic
factors for the risk of local recurrence. Indications for postoperative radiotherapy were
Dukes’ Astler-Coller B2 and C tumours, positive surgical margins and tumour spill, but
compliance to these guidelines was only 50%. However, no significant difference in local
recurrence rate was found between patients treated according to the guidelines and those
not treated according to the guidelines. In conclusion, this study shows a high local recurrence
rate with conventional surgery and variability in local recurrence rate between the participating
hospitals. Furthermore, it confirms that the risk of local recurrence in primary rectal cancer
is dependent on Dukes’ Astler-Coller stage, tumour location and residual tumour. Lastly,
this study contributes to the discussion about the feasibility of guidelines for postoperative
radiotherapy.
To improve results of surgery, various additional treatments, such as radiotherapy,
chemotherapy and immunotherapy, have been applied. The Swedish Rectal Cancer Trial
(SRCT) was the first trial to show that better local control, achieved with preoperative
radiotherapy, resulted in improved survival. A major problem of published studies on adjuvant
therapy however, is that surgery has not been standardised. Furthermore, quality control of
the surgical technique by standardised pathological examination of the specimen is absent in
most studies. In Europe, TME has become the preferred standard of operative management
for rectal cancer. Adjuvant therapies should now be re-examined based upon a platform of
standardised, optimal surgery and pathology. In Chapter 3 we studied the current European
trials in which TME-surgery is intentionally performed. Most of these trials are still in
progress or have too short follow-up, so definitive results, apart from interim-analyses, are
not known yet. The TME-trial however, has already shown that performing a large, multicentre
trial with quality control of both surgery and pathology is feasible.
Reports on improved local control after short-term 5x5 Gy preoperative radiotherapy
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and TME-surgery have led to the conduction of the TME-trial, in which the effect of TME
surgery with or without short-term preoperative radiotherapy was evaluated. However, any
benefit regarding a reduced local recurrence rate and possible improved survival must be
weighed against potential adverse effects. The study in Chapter 4 was undertaken to
assess the acute side effects of short-term, preoperative radiotherapy in rectal cancer patients
undergoing TME and to study the influence of 5x5 Gy on surgical parameters, postoperative
morbidity and mortality. We analysed 1530 Dutch patients entered in the TME-trial of which
1414 were evaluable. Toxicity during radiotherapy hardly occurred. Irradiated patients had
100 ml more blood loss during the operation (P<0.001) and showed more perineal
complications (P=0.008) in case of an abdominoperineal resection. The total number of
complications was slightly increased in the irradiated group (P=0.008). No difference was
observed in postoperative mortality (4.0% vs. 3.3%) or in the number of reinterventions. In
conclusion, preoperative hypofractionated RT is a safe procedure in patients treated with
TME surgery, despite a slight increase in complications when compared to TME surgery
only.
Local control and survival of rectal cancer have been improved by the introduction of
the TME-technique. In addition to the surgical technique, hospital volume and specialisation
can be important prognostic factors. In Chapter 5 the effect of training in TME-surgery
was assessed on short- and long-term outcomes in rectal cancer in the TME-trial and
outcomes were compared with results from a former randomised trial (Cancer Recurrence
And Blood transfusion (CRAB) trial), in which conventional surgery was performed without
quality control. We analysed the eligible, preoperatively non-irradiated, curatively operated
patients. The influence of hospital volume was investigated in both trials, while the role of
hospital specialisation was analysed only in the TME-trial. We corrected for differences in
clinicopathological characteristics by means of multivariate analyses and to ensure valid
comparisons, only events occurring within 2 years of surgery were analysed for long-term
outcomes. Hospital volume was analysed as a continuous factor. Local recurrence rate
decreased from 16.3% in the CRAB-trial to 8.6% in the TME-trial, and type of surgery
(conventional (CRAB-trial) vs. TME (TME-trial)) was an independent predictor for local
recurrence (P=0.002). Type of surgery was also an independent predictor for overall survival
(P=0.019) with a higher survival rate in the TME-trial. Higher hospital volume was
significantly associated with lower distant recurrence (P=0.006) and higher overall survival
(P=0.011) in the CRAB-trial. However, in the TME-trial hospital volume and specialisation
were not of significant value for short- and long-term outcomes. In conclusion, training of
surgeons with TME-surgery, leads to improved long-term outcome of rectal cancer patients
without volume- or specialisation-related differences.
In Chapter 6, the outcome of the main objective of the TME-trial is reported: is
short-term preoperative radiotherapy still beneficial in rectal cancer patients undergoing
TME? The combination of these treatment modalities was never investigated. Between
January 1996 and December 2000, 1861 Dutch and foreign patients with resectable rectal
cancer were randomly assigned to preoperative radiotherapy of 5x5 Gy followed by TME
or to TME alone. Of the 1861 randomised patients, 1805 were eligible. The 2-year overall
survival rate for the 1805 eligible patients was 82.0% in the RT+TME group and 81.8% in
the TME group (P=0.84). For the 1748 patients who underwent a macroscopically local
complete resection, 2-year local recurrence rate was 5.3%. The 2-year local recurrence
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rates were 2.4% in the RT+TME group and 8.2% in the TME group (P<0.0001). In
conclusion, in a setting of standardised TME-surgery, short-term preoperative radiotherapy
still has a beneficial effect on local recurrence risk.
PART II: NEW INSIGHTS IN MOLECULAR BIOLOGY
Observations from other studies support the theory that development of left- and right-
sided colorectal cancers may involve different mechanisms. In this study, different genes
involved in tumourigenesis of colon vs. rectal cancers, were investigated, and their prognostic
value was analysed. Chapter 7 compares a series of colon cancers with standardised
treated rectal cancers obtained from the pilot-study of the TME-trial, with regard to different
genes involved in tumourigenesis of colorectal cancer. Mutation and expression profiles
were investigated and related to tumour site and prognosis. APC mutation analysis of the
mutation cluster region showed truncating mutations in 18 of 22 rectal tumours (82%), but
presence of an APC mutation was not related to nuclear β-catenin expression (P=0.75).
Rectal cancers showed significant more nuclear β-catenin than colon cancers (65% vs.
40%, P=0.04). p53 mutation analysis corresponded well with p53 immunohistochemistry
(P<0.001) and with this, rectal cancers showed significant more p53 expression than colon
cancers (64% vs. 29%, P=0.003). In rectal cancers a significant correlation was found
between positive p53 expression and worse disease-free survival (P=0.008), but not in
colon cancers. Cox regression showed that p53-expression (P=0.03) was an independent
predictor for disease-free survival in rectal cancers. This study shows that rectal cancers
may involve more nuclear β-catenin in the APC/β-catenin pathway than colon cancer and/
or nuclear β-catenin may have another role in rectal cancer independent of APC. The p53-
pathway seems to be more important in rectal cancer, in which p53 expression also has
independent prognostic value. When prognostic markers are investigated in larger series,
differences in biological behaviour between colon and rectal cancer should be considered.
In Chapter 8 we investigated molecular profiles of sporadic rectal cancers using 12
microsatellite markers and DNA ploidy analysis in order to classify tumours in terms of
genetic instability. Screening of 81 rectal cancers revealed one tumour with high frequency
of microsatellite instability (MSI). The majority of tumours (74%) showed loss of
heterozygosity (LOH) for at least one marker. Most of the LOH-positive tumours (81%)
and 47% of the LOH-negative tumours were aneuploid. The data indicate that chromosomal
instability (CIN) rather than microsatellite instability (MSI) plays a role in rectal cancers.
We found a subset of rectal tumours without hallmarks of gross genetic instability (n=13).
Five of these diploid, MSI-stable tumours, of which 4 did not show LOH, were further
characterised for p53 mutation status and expression of 1700 cancer-related genes, and
compared to two aneuploid tumours. Clustering of gene expression profiles revealed that
the p53 mutant diploid tumours seemed more similar to the p53 wild type aneuploid tumours
than to the p53 wild type diploid tumours. Within the diploid tumour subset, differential
gene expression patterns related to p53 mutation status were found. The expression analysis
also revealed a lack of mRNA expression of hMSH2 and hMSH3 in a diploid tumour originating
from a 29-year-old patient. In addition, hMSH2 and hMSH6 were lost at the protein level.
No mutation was detected in hMSH2 and hMSH6. Since this tumour was MSI-stable, the
loss of expression of these mismatch repair genes may be a late event. In conclusion, as
others we identified a group of rectal tumours without evidence of gross genetic instability
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by molecular analysis with microsatellite markers and flow cytometry. We show that tumour
heterogeneity in this class of tumours can be defined by molecular characteristics, such as
p53 mutation status and differential expression profiles.
In Chapter 9, the influence of radiotherapy on the expression of p53 and p21waf1 was
investigated in normal mucosa and rectal carcinomas in patients from the TME-trial. In
vitro, ionising radiation of epithelial cells leads to upregulation of wild type p53 and subsequent
induction of p21waf1. The effect of radiotherapy on the expression of these proteins in
patients is unknown. p53 and p21waf1 expression was determined in 51 irradiated and 52
non-irradiated patients using immunohistochemistry. In normal mucosa, both p53 and p21waf1
were strongly upregulated after radiotherapy, compared with the expression in unirradiated
normal tissue (P<0.001). In tumour cells, no significant difference in the expression of p53
or p21waf1 was found in the irradiated vs. the non-irradiated group. In the few rectal tumours
with wt p53, induction of p53 after radiotherapy did not necessarily lead to upregulation of
p21waf1. These findings demonstrate that in normal mucosa a functional p53-p21waf1 athway
is present, whereas in tumour cells it is defective in almost all cases due to either p53
mutation or down- or upstream disruption in tumours with wild type p53. Therefore, we
believe that the role of p53 expression as a single prognostic marker in rectal cancer needs
reconsideration.
In the process of invasion and metastasis, cell adhesion and angiogenesis are important.
In Chapter 10 we investigated 97 rectal tumours from the TME-trial to analyse the influence
of irradiation on the expression of cell adhesion molecules and microvessel count, and to
examine the prognostic value of these factors. Immunohistochemical expression of E-
cadherin, α-, β-, γ-catenin, EpCAM and CD31 were investigated in patients who had
undergone surgery with or without preoperative radiotherapy. Irradiated tumours showed
more nuclear β-catenin expression (P=0.004) and a lower microvessel count (P=0.03). No
other differences were found between irradiated and non-irradiated tumours. Loss of EpCAM
expression was significantly associated with local recurrence (P=0.015) for the total group
of tumours. Low microvessel count was associated with an increased distant recurrence
risk (P=0.04) and lower overall survival (P=0.02). The overall results of this study show
that loss of EpCAM expression is associated with increased local recurrence risk and low
microvessel count with increased distant recurrence risk in rectal cancer. Furthermore,
irradiation has an influence on nuclear β-catenin expression and microvessel count.
CONCLUSIVE REMARKS
In the last decades, major advances have been made in the treatment of rectal cancer by the
introduction of new surgical techniques and additional technical improvements (e.g. staplers).
During the last years, quality assurance of surgery has become an important topic in rectal
cancer treatment. Quality assurance is of major importance for standardisation of treatment
in (neo)adjuvant therapy studies and for improvement of outcomes.
The introduction of TME-surgery has led to a major reduction in local recurrence rates
and improved survival. We showed that short-term preoperative radiotherapy gives a further
reduction in local recurrence rate when standardised TME-surgery is used. TME-based
operations are now established as the standard of care for rectal cancer, and should form
the basis for trials concerning the role of (neo)adjuvant therapy.
In general, it is thought that high volume and specialist care produces superior results to
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low volume and non-specialist care, especially for those less frequent forms of cancer and
in technically difficult operations, like those for rectal cancer. However, limiting the
performance of rectal cancer surgery to surgeons who work in specialised centres or to
only those general surgeons who perform more than a certain volume is impractical in view
of the prevalence of rectal cancer. The concentration process can also take place within
one hospital surgical unit with 1-3 surgeons performing rectal cancer surgery. This has
been demonstrated in the TME-trial, in which training in TME-surgery to surgeons who are
dedicated to oncology, has led to improved outcome without volume- or specialisation-
related differences.
Quality assurance of the surgical technique requires besides training, adequate knowledge
of the anatomy of the organs and nerves in the pelvis and other related structures.
Furthermore, standardisation in the description of operations and reporting of pathology
specimens should be implemented as important features of quality control. In addition, a
multidisciplinary approach provides the best care for patients, since the access and use of
standardised and up-to-date therapy is better organised. Similarly, patients participating in
clinical trials generally experience a survival advantage over non-participating patients, which
is probably due to standardised treatment.
Within the TME-trial structuralisation and audit of rectal cancer treatment has led to
improvement of treatment results and this infrastructure provides optimal conditions for
conducting future rectal cancer trials. The successor trial of the TME-trial, the Preoperative
Radiotherapy and/Or adjuvant Chemotherapy combined with Tme surgery in Operable Rectal
cancer (PROCTOR)-trial, is currently investigating the role of postoperative chemotherapy
in TME-treated patients. However, it is of utmost importance that outside the setting of
trials, standardisation of treatment is also applied and sustained. Population-based cancer
registries, covering an increasing proportion of the world’s population, are an invaluable
source of data for this goal.
In addition to clinical improvements, the molecular biology of colorectal cancer will be
unravelled even more in the coming years. New techniques in cancer research comprise
genome-wide analysis techniques such as chromosome painting, comparative genomic
hybridisation, high-throughput analysis of LOH, serial analysis of gene expression (SAGE)
and expression microarray analysis. These techniques are now accelerating the high resolution
of aberrations in human tumours. By these new techniques identification of affected genes,
elucidation of their functions and associations of these genes with tumour progression will
be disentangled by which the tumourigenesis of colorectal cancer will be more fully
understood. Furthermore, these techniques can help to predict sensitivity or resistance of
individual patients to adjuvant therapy. Hereby, individual patients can be offered their own
most “suitable” therapy. This “tailor-made” therapy will emerge most likely in the next
decade for several diseases.
In the TME-trial, the criteria for analysis of individual risk factors as stated by R.A.E.M.
Tollenaar in his thesis were completely met.1 The criteria of uniform collection of clinical
findings according to strictly defined criteria, detailed documentation and standardisation of
therapeutic procedures, uniform collection of macroscopic and histological tumour
characteristics, standardised documentation of the course of the disease and lastly, evaluation
of the data using multivariate statistical methods, were all fulfilled. The TME-trial with its
unique and thorough setup, still offers a challenge to future investigators and will certainly
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provide more answers to questions concerning the molecular biology, prognostic factors
and the mechanisms of radiation-induced damage in tumour cells. In addition, more clinical
outcomes of the TME-trial will be known in the coming years, such as the long-term side-
effects of preoperative radiotherapy and the influence of irradiation on overall survival.
However, the most important objective of this trial has already been achieved; improvement
of the treatment for rectal cancer patients with much lower local recurrence rates as compared
to a decade ago when conventional surgical techniques were applied. This thesis has dealt
with clinical and molecular aspects of rectal cancer and shows that by investigating the
combination of these aspects in a large randomised multicentre trial, advances in treatment
and new insights in molecular biology have been obtained.
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De algemene introductie in Hoofdstuk 1 geeft een overzicht van de klinische en moleculaire
aspecten van (colo)rectale tumoren. In dit proefschrift is de aandacht gericht op beide
aspecten, omdat het onderzoeken van de moleculaire achtergrond van rectumkanker nut-
tige informatie kan verschaffen voor het bepalen van klinische strategieën. De resultaten in
dit proefschrift zijn met name gebaseerd op de data van een grote gerandomiseerde studie,
uitgevoerd door de Dutch ColoRectal Cancer Group: “Totale Mesorectale Excisie met of
zonder preoperatieve radiotherapie in de behandeling van het primair rectumcarcinoom”
(TME-studie).
DEEL I: VOORUITGANG IN DE BEHANDELING
Lokale recidieven zijn een groot probleem in de behandeling van het rectumcarcinoom om-
dat ze ernstig invaliderende symptomen veroorzaken en moeilijk te behandelen zijn. Con-
ventionele, niet-gestandaardiseerde chirurgische procedures zijn geassocieerd met een hoge
incidentie van lokaal recidieven (15-45%). Deze technieken bestaan uit stompe dissectie
van de rectale fascie met vaak een incomplete resectie van de tumor en het achterlaten van
mogelijk tumordragend weefsel. Hoofdstuk 2 beschrijft een populatie-studie in de IKW-
regio van lokaal recidiefpercentages in curatief geopereerde patiënten met een rectum-
carcinoom, gediagnosticeerd tussen 1988 en 1992. Het eerste doel van deze studie was het
inventariseren van het lokaal recidiefpercentage na niet-gestandaardiseerde conventionele
chirurgie. Tevens werd de variatie in interinstitutionele recidiefpercentages en correlaties
tussen patiënt- en tumorgerelateerde factoren en lokaal recidiefpercentage bestudeerd. Een
tweede doel was te onderzoeken wat de therapietrouw was met betrekking tot de richtlijnen
voor postoperatieve radiotherapie. Het totale lokaal recidiefpercentage was 22.5% met een
variatie van 9-36% tussen de 12 ziekenhuizen. De verschillen tussen de ziekenhuizen waren
statistisch niet significant. Dukes’ Astler-Coller stadium, tumorlocatie en de aanwezigheid
van tumorresidu waren significante onafhankelijke prognostische factoren voor het risico
op een lokaal recidief. De indicaties voor postoperatieve radiotherapie waren Dukes’ Astler-
Coller B2 en C tumoren, positieve chirurgische marges en tumor-”spill” tijdens de operatie.
Deze richtlijnen werden maar in 50% van de patiënten opgevolgd. Opvallend genoeg werd
er geen verschil in lokaal recidiefpercentage gevonden tussen patiënten die volgens de richt-
lijnen waren behandeld en patiënten die niet volgens de richtlijnen waren behandeld. Samen-
vattend toont deze studie een hoog lokaal recidiefpercentage met conventionele chirurgie en
variabiliteit in het lokaal recidiefpercentage tussen de participerende ziekenhuizen. Verder
wordt in deze studie bevestigd dat het risico op een lokaal recidief bij het primaire rectum-
carcinoom afhankelijk is van Dukes’ Astler-Coller stadium, tumorlocatie en de aanwezig-
heid van een tumorresidu. Tenslotte zet deze studie vraagtekens bij het opvolgen van richt-
lijnen voor postoperatieve radiotherapie.
Om de resultaten van chirurgie voor rectumkanker te verbeteren zijn verschillende
adjuvante therapieën toegepast, zoals radiotherapie, chemotherapie en immunotherapie. De
Swedish Rectal Cancer Trial (SRCT) was de eerste studie die liet zien dat een verbeterde
lokale controle, als gevolg van preoperatieve radiotherapie, resulteerde in een verbeterde
overleving. Een groot probleem van de tot nu toe uitgevoerde adjuvante therapie studies is
echter dat chirurgie niet gestandaardiseerd werd uitgevoerd. Verder is kwaliteitscontrole
van de chirurgische techniek door middel van een gestandaardiseerd pathologisch onder-
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zoek van het resectiepreparaat in de meeste studies niet verricht. In Europa is de TME-
techniek de standaard geworden voor de operatieve behandeling van het rectumcarcinoom.
Adjuvante therapie studies moeten nu herhaald worden tegen een achtergrond van gestand-
aardiseerde chirurgie en pathologie. In Hoofdstuk 3 hebben we de Europese studies, waarin
de intentie bestond om TME-chirurgie uit te voeren, onderzocht. De meeste van deze stu-
dies zijn nog steeds in de inclusiefase of hebben een te korte follow-up, waardoor defini-
tieve resultaten, uitgezonderd resultaten van interim-analyses, nog niet bekend zijn. De TME-
studie heeft echter al laten zien dat het uitvoeren van een grote, multicenter studie met
kwaliteitscontrole van zowel chirurgie als pathologie, mogelijk is.
Publicaties over verbeterde lokale controle na kortdurende 5x5 Gy preoperatieve radio-
therapie en TME-chirurgie hebben geleid tot het opzetten van de TME-studie. In deze trial
werd het effect van TME-chirurgie met of zonder kortdurende preoperatieve radiotherapie
geëvalueerd. Belangrijk bij het onderzoeken van dit effect is dat enig voordeel, dat wordt
bereikt met betrekking tot een reductie in lokaal recidiefpercentage en een mogelijke verbe-
tering in overleving, moet worden afgewogen tegen potentiële bijwerkingen. In Hoofdstuk
4 werden de acute bijwerkingen van kortdurende 5x5 Gy preoperatieve radiotherapie geë-
valueerd in rectumcarcinoom patiënten die een TME ondergingen. Tevens werd de invloed
van 5x5 Gy bestudeerd op chirurgische parameters, postoperatieve morbiditeit en mortali-
teit. We analyseerden 1530 Nederlandse patiënten uit de TME-studie; hiervan waren 1414
patiënten evalueerbaar. Het optreden van toxiciteit tijdens het toedienen van de radiotherapie
vond maar zelden plaats. Bestraalde patiënten hadden 100 ml meer bloedverlies tijdens de
operatie (P<0.001) en toonden meer perineale complicaties (P=0.008) als ze een
abdominoperineale resectie hadden ondergaan. Het totaal aantal complicaties was verhoogd
in de bestraalde groep (P=0.008). Er werd geen verschil gevonden in postoperatieve morta-
liteit (4.0% vs. 3.3%) en in het aantal reïnterventies. Preoperatieve, gehypofractioneerde
radiotherapie kan veilig gegeven worden bij patiënten die TME-chirurgie ondergaan, on-
danks een iets hoger complicatie percentage in bestraalde patiënten.
Lokale controle en overleving in rectumcarcinoom patiënten zijn verbeterd door de
introductie van de TME-techniek. Naast de chirurgische techniek kunnen ziekenhuisvolume-
en specialisatie ook belangrijke prognostische factoren zijn. In Hoofdstuk 5 werd het effect
van training in TME-chirurgie bestudeerd op korte en lange termijn uitkomsten in
rectumcarcinoom patiënten uit de TME-studie. De uitkomsten werden vergeleken met
resultaten van een eerdere gerandomiseerde studie (Cancer Recurrence And Blood transfusion
(CRAB)-studie), waarin patiënten conventionele chirurgie ondergingen zonder
kwaliteitscontrole. De invloed van het ziekenhuisvolume werd in beide studies onderzocht,
terwijl de rol van ziekenhuis specialisatie alleen werd onderzocht in de TME-studie. We
analyseerden uit beide studies de patiënten die aan de inclusiecriteria voldeden, die niet
voorbestraald waren en die een in opzet curatieve operatie hadden ondergaan. Er werd
gecorrigeerd voor verschillen in clinicopathologische karakteristieken door middel van
multivariate analyses. Voor de lange termijn uitkomsten werden alleen waarnemingen binnen
2 jaar na chirurgie geanalyseerd om een betrouwbare vergelijking te waarborgen. Het lokaal
recidiefpercentage daalde van 16.3% in de CRAB-studie naar 8.6% in de TME-studie, waarbij
het type chirurgie (conventioneel (CRAB-studie) vs. TME (TME-studie)) een onafhankelijke
voorspeller was voor het optreden van een lokaal recidief (P=0.002). Het type chirurgie
was ook een onafhankelijke voorspeller voor de totale overleving (P=0.019) met een langere
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overleving in de TME-studie. In de CRAB-studie was een groter ziekenhuisvolume significant
geassocieerd met een lager afstandsrecidief risico (P=0.006) en een langere totale overleving
(P=0.011). In de TME-studie waren ziekenhuisvolume- en specialisatie niet van significante
voorspellende waarde voor korte en/of lange termijn uitkomsten. Uit deze studie kan
geconcludeerd worden dat het trainen van chirurgen in de TME-techniek heeft geleid tot
verbeterde lange termijn uitkomsten van rectumcarcinoom patiënten zonder volume- of
specialisatiegerelateerde verschillen.
In Hoofdstuk 6 wordt een van de belangrijkste uitkomsten van de TME-studie beschre-
ven. Van zowel kortdurende preoperatieve radiotherapie van 5x5 Gy als TME was aange-
toond dat ze de lokale controle bij het resectabel rectumcarcinoom verbeteren. De combina-
tie van deze behandelingsmodaliteiten was echter nooit eerder onderzocht. In de TME-
studie werden tussen januari 1996 en december 1999 in totaal 1861 Nederlandse en buiten-
landse patiënten met een resectabel rectumcarcinoom gerandomiseerd tussen preoperatieve
radiotherapie van 5x5 Gy gevolgd door TME (n=924) of TME alleen (n=937). In de TME-
studie werden standaardisatie en kwaliteitscontrole van radiotherapie, chirurgie en patholo-
gie doorgevoerd. Van de 1861 gerandomiseerde patiënten voldeden er 1805 aan de
inclusiecriteria. De 2-jaars totale overleving voor de 1805 patiënten die aan de inclusiecriteria
voldeden, bedroeg 82.0% in de radiotherapie groep en 81.8% in de TME alleen groep (P=0.84).
Voor de 1748 patiënten die een macroscopisch lokale complete resectie hadden ondergaan,
bedroeg het 2-jaars lokaal recidiefpercentage 5.3%. De 2-jaars lokaal recidiefpercentages
waren 2.4% in de radiotherapie groep en 8.2% in de TME alleen groep (P<0.001). De
introductie van de TME-techniek in een grote multicenter studie heeft geleid tot een sub-
stantiële daling in het lokaal recidiefpercentage. In combinatie met gestandaardiseerde chi-
rurgie heeft kortdurende preoperatieve radiotherapie nog steeds een gunstig effect op het
lokaal recidief risico.
DEEL II: NIEUWE INZICHTEN IN MOLECULAIRE BIOLOGIE
Verscheidene studies hebben aangetoond dat bij de ontwikkeling van links- en rechtszijdige
colorectale tumoren verschillende mechanismen betrokken zijn. In hoofdstuk 7 werd een
serie colontumoren vergeleken met gestandaardiseerd behandelde rectumtumoren uit een
“pilot”-studie, die vooraf ging aan de TME-studie. De mutatie- en expressieprofielen van
verschillende genen werden onderzocht en gerelateerd aan de tumorlocatie en prognose.
APC mutatie analyse van de mutatie cluster regio liet truncerende mutaties in 18 van de 22
rectumtumoren (82%) zien. Het optreden van een APCmutatie was niet gerelateerd aan het
voorkomen van nucleair $-catenine expressie (P=0.75). Rectumtumoren lieten significant
vaker nucleair β-catenine zien dan colontumoren (65% vs. 40%, P=0.04). p53
immunohistochemie kwam goed overeen met p53 mutatie analyse (P<0.001) en was
significant vaker positief in rectumtumoren dan in colontumoren (64% vs. 29%, P=0.003).
In de rectumgroep werd een significante associatie gevonden tussen positieve p53 expressie
en een verminderde ziekte-vrije overleving (P=0.008), maar niet in de colongroep. p53-
expressie was een onafhankelijke voorspeller voor ziekte-vrije overleving in de rectumgroep
in de multivariate analyse (Cox regressie model, P=0.03). Concluderend blijkt uit deze studie
dat bij rectumtumoren mogelijk meer nucleair β-catenine in de APC/β-catenine route is
betrokken dan in colontumoren. Nucleair β-catenine heeft mogelijk ook een andere rol in
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rectumkanker onafhankelijk van APC. De p53-pathway lijkt een grotere rol te spelen in
rectumtumoren, waarbij p53 expressie ook een onafhankelijke prognostische waarde heeft.
Als prognostische markers worden onderzocht in grote patiëntenseries, moet men rekening
houden met verschillen in biologisch gedrag tussen colon- en rectumtumoren.
Hoofdstuk 8 beschrijft een studie waarin we moleculaire profielen van rectumtumoren
uit de TME-studie hebben onderzocht met behulp van microsatelliet analyse, flow cytometrie,
immunohistochemische, p53 mutatie en genexpressie analyses. Van de 81 rectumtumoren
was er slechts één tumor die een hoge frequentie van microsatelliet instabiliteit liet zien
(MSI-high, 1.2%). De meeste tumoren lieten verlies van heterozygositeit (LOH) zien van
tenminste één marker (74%). Flow-cytometrie toonde dat de meeste LOH-positieve tumoren
(81%) en 47% van de LOH-negatieve tumoren aneuploid waren. Deze data indiceren dat
chromosomale instabiliteit (CIN) belangrijker is in rectumcarcinomen dan microsatelliet
instabiliteit (MSI). We identificeerden een groep tumoren zonder tekenen van genetische
instabiliteit (n=13). Vijf van deze diploïde, MSI-negatieve tumoren, waarvan er 4 geen LOH
toonden, werden verder gekarakteriseerd voor p53 mutatie status en expressie van 1700
kankergerelateerde genen, en vergeleken met twee aneuploïde tumoren. Binnen de diploïde
tumor groep werden differentiële genexpressie patronen gevonden die gerelateerd waren
aan p53 mutatie status. De genexpressie analyse toonde tevens een gebrek aan mRNA
expressie van hMSH2 en hMSH3 in de diploïde tumor van een 29-jarige patiënt. Bovendien
werd in deze tumor verlies van hMSH2 en hMSH6 op eiwitniveau gezien. Er werden geen
mutaties gevonden in hMSH2 en hMSH6. Daar deze tumor MSI-stabiel was, is het verlies
van expressie van de mismatch repair genen mogelijk secundair opgetreden. Resumerend,
hebben wij met behulp van een moleculaire analyse met microsatelliet markers en flow
cytometrie, net als andere onderzoekers, een groep rectumtumoren geïdentificeerd zonder
aanwijzingen voor genetische instabiliteit. We tonen dat heterogeniteit in deze tumoren
gedefinieerd kan worden op basis van moleculaire karakteristieken, zoals p53 mutatie status
en differentiële expressie profielen.
In Hoofdstuk 9 werd de invloed van bestraling op de expressie van p53 en p21waf1
onderzocht in normale mucosa en tumorweefsel van patiënten uit de TME-studie. In vitro is
aangetoond dat ioniserende bestraling van epitheliale cellen tot opregulatie leidt van wild
type (wt) p53 en daardoor tot de inductie van p21waf1. Het effect van radiotherapie op de
expressie van deze eiwitten was niet eerder onderzocht in tumoren van patiënten (in vivo).
p53 en p21waf1 expressie werd in 51 bestraalde en 52 niet-bestraalde patiënten onderzocht
met behulp van immunohistochemie. Zowel p53 als p21waf1 waren sterk opgereguleerd in
bestraalde normale mucosa vergeleken met de expressie in niet-bestraald normaal weefsel
(P<0.001). In tumorcellen werden geen significante verschillen gevonden in de expressie
van p53 en p21waf1 tussen bestraalde en niet-bestraalde tumoren. In het lage aantal
rectumtumoren met wt p53 leidde de inductie van p53 na bestraling niet noodzakelijk tot
opregulatie van p21waf1. De resultaten in deze studie laten zien dat in normale mucosa een
functionele p53-p21waf1 route aanwezig is, terwijl in tumor cellen deze route defect is in bijna
alle patiënten ten gevolge van hetzij een p53 mutatie, hetzij een verstoring “downstream”
van p53 in tumoren met wild type p53. Op basis van deze resultaten concluderen wij dat de
rol van p53 expressie als enkelvoudige prognostische marker in rectumtumoren heroverwogen
moet worden.
Bij het proces van invasie en metastasering zijn de verstoring van celadhesie en het
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optreden van vaatnieuwvorming belangrijk. In Hoofdstuk 10 onderzochten we 97
rectumtumoren om de invloed van bestraling op de expressie van celadhesie moleculen en
de mate van microvascularisatie te analyseren. Tevens werd de prognostische waarde van
deze factoren bestudeerd. De immunohistochemische expressie van E-cadherine, α-, β-, γ-
catenine, EpCAM en CD31 werd onderzocht in patiënten die TME-chirurgie hadden
ondergaan met of zonder preoperatieve radiotherapie. In bestraalde tumoren werd meer
nucleair β-catenine (P=0.004) en een lagere mate van microvascularisatie (P=0.03) gezien
dan in niet-bestraalde tumoren. Er werden geen andere verschillen gevonden tussen bestraalde
en niet-bestraalde tumoren. Verlies van EpCAM expressie was significant geassocieerd met
het optreden van een lokaal recidief (P=0.015) voor de hele groep tumoren. Verder was een
lagere mate van microvascularisatie geassocieerd met een verhoogd risico op
afstandsrecidieven (P=0.04) en een lagere overleving (P=0.02). Concluderend laten de
resultaten van de bestraalde en niet-bestraalde patiënten samen zien dat verlies van EpCAM
expressie geassocieerd is met een grote kans op een lokaal recidief en dat een lagere mate
van microvascularisatie voorspellend is voor het optreden van afstandsrecidieven in
rectumkanker. Verder vonden we dat bestraling invloed heeft op de expressie van nucleair
β-catenine en de mate van microvascularisatie.
AFSLUITENDE OPMERKINGEN
In de afgelopen jaren is er een grote vooruitgang geboekt in de behandeling van het rectum-
carcinoom door de introductie van nieuwe chirurgische methodes. Kwaliteitscontrole van
chirurgie is een belangrijk onderwerp geworden in de behandeling van rectumtumoren.
Deze kwaliteitscontrole is van groot belang voor de standaardisatie van de behandeling in
(neo)adjuvante therapie studies en voor het verbeteren van de resultaten.
De introductie van de TME-techniek heeft geleid tot een grote reductie in het lokaal
recidiefpercentage en een verbeterde overleving. De TME-studie toonde dat kortdurende
preoperatieve radiotherapie een verdere reductie geeft in het lokaal recidiefpercentage bij
gestandaardiseerde TME-chirurgie. De TME-techniek wordt momenteel als de standaard
van zorg gezien voor het rectumcarcinoom en zou ook de standaard moeten zijn in studies
die de rol van (neo)adjuvante therapie onderzoeken.
Over het algemeen wordt gedacht dat een hoog volume aan procedures en gespeciali-
seerde zorg tot betere resultaten leiden dan een laag volume en niet-gespecialiseerde zorg,
met name wat betreft minder frequent voorkomende kankersoorten en technisch moeilijk
uit te voeren operaties, zoals die voor het rectumcarcinoom. Het beperken van chirurgie
voor rectumkanker tot gespecialiseerde chirurgen in een beperkt aantal centra of tot alge-
meen chirurgen die een bepaald volume aan procedures halen, is echter niet haalbaar met
het oog op de hoge prevalentie van rectumkanker. Het concentratieproces kan ook binnen
een ziekenhuis plaatsvinden waarbij 1-3 chirurgen rectumchirurgie uitvoeren. Goede resul-
taten met deze opzet zijn bereikt in de TME-studie, waarin training in de TME-techniek aan
chirurgen die geïnteresseerd zijn in de oncologie, heeft geleid tot verbeterde uitkomsten
zonder volume- of specialisatiegerelateerde verschillen.
Naast training is voor de kwaliteitsverbetering van de chirurgische techniek ook adequate
kennis van de anatomie van organen en zenuwen in het bekken vereist. Verder moet
standaardisatie in de beschrijving van operaties en pathologische beoordeling van het preparaat
geïmplementeerd worden als belangrijke onderdelen van de kwaliteitscontrole van de
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behandeling. Tevens levert een multidisciplinaire benadering de beste zorg op voor patiënten
doordat de toegang en het gebruik van gestandaardiseerde en “up-to-date” therapie beter
georganiseerd is. Ten slotte tonen patiënten die deelnemen aan klinische trials over het
algemeen een betere overleving in vergelijking met patiënten die buiten studieverband behandeld
worden, hetgeen waarschijnlijk het gevolg is van de gestandaardiseerde behandeling in trials.
Binnen de TME-studie heeft de structurering en toetsing van de behandeling van het
rectumcarcinoom geleid tot verbeterde uitkomsten. Deze infrastructuur verschaft optimale
condities voor het uitvoeren van toekomstige studies. De opvolger van de TME-studie, de
Preoperatieve Radiotherapie en/Of adjuvante Chemotherapie gecombineerd met Tme chirurgie
in Operabele Rectumkanker (PROCTOR)-studie, onderzoekt momenteel de rol van
postoperatieve chemotherapie in TME-behandelde patiënten. Het is echter van groot belang
dat ook buiten het verband van klinische trials, de standaardisatie van behandeling wordt
doorgevoerd. Kankerregistraties vormen een bron van grote waarde om dit te bereiken.
Naast de klinische verbeteringen, zal in de komende jaren de moleculaire biologie van
colorectale tumoren nog meer ontrafeld worden. Nieuwe technieken in het kankeronderzoek
bestaan uit analysetechnieken van het totale genoom, zoals chromosoom “painting”,
comparatieve genomische hybridisatie, seriële analyse van genexpressie (SAGE) en
“microarray” genexpressie analyse. Deze technieken versnellen momenteel het opsporen
van genetische afwijkingen in humane tumoren. Door deze nieuwe technieken zal ook de
identificatie van aangedane genen, alsmede de functie en associaties van deze genen met
tumorprogressie, nog meer ontward worden waardoor de tumorgenese beter begrepen
wordt. Verder kunnen deze technieken helpen bij het voorspellen of individuele patiënten
mogelijk sensitief of resistent zijn voor adjuvante therapieën. Hierdoor kan aan individuele
patiënten een eigen, passende therapie worden aangeboden. Deze “tailor-made” therapie
mogelijkheden zullen waarschijnlijk in de komende jaren beschikbaar komen voor verschillende
ziekten.
In de TME-studie werd aan alle criteria voldaan voor de analyse van individuele risico
factoren bij patiënten met kanker, zoals beschreven in het proefschrift van R.A.E.M.
Tollenaar.1 Het uniform verzamelen van klinische bevindingen volgens strikt gedefinieerde
criteria, gedetailleerde documentatie en standaardisatie van therapeutische procedures,
uniforme collectie van macroscopische en histologische tumorkarakteristieken,
gestandaardiseerde documentatie van het verloop van de ziekte en ten slotte, evaluatie van
de data met multivariate statistische methoden, werden alle doorgevoerd. De TME-studie
met zijn unieke en degelijke opzet, biedt ook in de toekomst nog veel uitdaging voor
onderzoekers en zal zeker nog meer antwoorden gaan geven op vragen met betrekking tot
de moleculaire biologie, prognostische factoren en mechanismen van stralingsgeïnduceerde
schade in tumorcellen. Tevens zullen er meer klinische uitkomsten van de TME-studie
bekend worden in de komende jaren, zoals de lange termijn bijwerkingen van preoperatieve
bestraling en de invloed van radiotherapie op de totale overleving. Een van de belangrijkste
doelen van de trial is echter reeds bereikt; de verbetering van de behandeling van
rectumcarcinoompatiënten door de invoering van de TME-techniek met significant lagere
lokaal recidiefpercentages vergeleken met een tiental jaar geleden. In dit proefschrift zijn de
klinische en moleculaire aspecten van het rectumcarcinoom onderzocht en wordt geïllustreerd
dat door het gecombineerd onderzoeken van deze aspecten in een grote gerandomiseerde
multicenter trial, vooruitgang in de behandeling en nieuwe inzichten in de moleculaire biologie
Chapter 12
168
van het rectumcarcinoom zijn verkregen.
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